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Controlling Tuberculosis in the United States
Recommendations from the American Thoracic Society, CDC,
and the Infectious Diseases Society of America
Summary
During 1993–2003, incidence of tuberculosis (TB) in the United States decreased 44% and is now occurring at a historic low
level (14,874 cases in 2003). The Advisory Council for the Elimination of Tuberculosis has called for a renewed commitment to
eliminating TB in the United States, and the Institute of Medicine has published a detailed plan for achieving that goal. In this
statement, the American Thoracic Society (ATS), CDC, and the Infectious Diseases Society of America (IDSA) propose recom-
mendations to improve the control and prevention of TB in the United States and to progress toward its elimination.
This statement is one in a series issued periodically by the sponsoring organizations to guide the diagnosis, treatment, control,
and prevention of TB. This statement supersedes the previous statement by ATS and CDC, which was also supported by IDSA
and the American Academy of Pediatrics (AAP). This statement was drafted, after an evidence-based review of the subject, by a
panel of representatives of the three sponsoring organizations. AAP, the National Tuberculosis Controllers Association, and the
Canadian Thoracic Society were also represented on the panel.
This statement integrates recent scientific advances with current epidemiologic data, other recent guidelines from this series, and
other sources into a coherent and practical approach to the control of TB in the United States. Although drafted to apply to TB
control activities in the United States, this statement might be of use in other countries in which persons with TB generally have
access to medical and public health services and resources necessary to make a precise diagnosis of the disease; achieve curative
medical treatment; and otherwise provide substantial science-based protection of the population against TB.
This statement is aimed at all persons who advocate, plan, and work at controlling and preventing TB in the United States,
including persons who formulate public health policy and make decisions about allocation of resources for disease control and
health maintenance and directors and staff members of state, county, and local public health agencies throughout the United
States charged with control of TB. The audience also includes the full range of medical practitioners, organizations, and institu-
tions involved in the health care of persons in the United States who are at risk for TB.
Introduction
During 1993–2003, incidence of tuberculosis (TB) in the
United States decreased 44% and is now occurring at a his-
toric low level (14,874 cases in 2003). The Advisory Council
for the Elimination of Tuberculosis (ACET) (1) has called for
a renewed commitment to eliminating TB in the United States,
and the Institute of Medicine (IOM) (2) has published a
detailed plan for achieving that goal. In this statement, the
American Thoracic Society (ATS), CDC, and the Infectious
Diseases Society of America (IDSA) propose recommenda-
tions to improve the control and prevention of TB in the
United States and to progress toward its elimination.
This statement is one in a series issued periodically by the
sponsoring organizations to guide the diagnosis, treatment,
control, and prevention of TB (3–5). This statement super-
sedes one published in 1992 by ATS and CDC, which also
was supported by IDSA and the American Academy of Pedi-
atrics (AAP) (6). This statement was drafted, after an evidence-
based review of the subject, by a panel of representatives of
the three sponsoring organizations. AAP, the National Tuber-
culosis Controllers Association (NTCA), and the Canadian
Thoracic Society were also represented on the panel. The rec-
ommendations contained in this statement (see Graded Rec-
ommendations for the Control and Prevention of Tuberculosis)
were rated for their strength by use of a letter grade and for
the quality of the evidence on which they were based by use of
a Roman numeral (Table 1) (7). No rating was assigned to
recommendations that are considered to be standard practice
(i.e., medical or administrative practices conducted routinely
by qualified persons who are experienced in their fields).
This statement integrates recent scientific advances with
current epidemiologic data, other recent guidelines from this
series (3–5), and other sources (2,8–10) into a coherent and
practical approach to the control of TB in the United States.
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Although drafted to apply to TB control activities in the United
States, this statement might be of use in other countries in
which persons with TB generally have access to medical and
public health services and resources necessary to make a pre-
cise diagnosis of the disease; achieve curative medical treat-
ment; and otherwise provide substantial science-based
protection of the population against TB.
This statement is aimed at all persons who advocate, plan,
and work at controlling and preventing TB in the United
States, including persons who formulate public health policy
and make decisions about allocation of resources for disease
control and health maintenance and directors and staff mem-
bers of state, county, and local public health agencies through-
out the United States charged with control of TB. The audience
also includes the full range of medical practitioners, organiza-
tions, and institutions involved in the health care of persons
in the United States who are at risk for TB.
Throughout this document, the terms latent TB infection
(LTBI), TB, TB disease, and infectious TB disease are used.
LTBI is used to designate a condition in which an individual
is infected with Mycobacterium tuberculosis but does not cur-
rently have active disease. Such patients are at risk for pro-
gressing to tuberculosis disease. Treatment of LTBI (previously
called preventive therapy or chemoprophylaxis) is indicated
for those at increased risk for progression as described in the
text. Persons with LTBI are asymptomatic and have a nega-
tive chest radiograph. TB, TB disease, and infectious TB indi-
cate that the disease caused by M. tuberculosis is clinically active;
patients with TB are generally symptomatic for disease. Posi-
tive culture results for M. tuberculosis complex are an indica-
tion of TB disease. Infectious TB refers to TB disease of the
lungs or larynx; persons with infectious TB have the potential
to transmit M. tuberculosis to other persons.
Progress Toward TB Elimination
A strategic plan for the elimination of TB in the United
States was published in 1989 (11), when the United States
was experiencing a resurgence of TB (Figure 1). The TB
resurgence was attributable to the expansion of HIV infec-
tion, nosocomial transmission of M. tuberculosis, multidrug-
resistant TB, and increasing immigration from counties with
a high incidence of TB. Decision makers also realized that the
U.S. infrastructure for TB control had deteriorated (12); this
problem was corrected by a substantial infusion of resources
at the national, state, and local levels (13). As a result, the
increasing incidence of TB was arrested; during 1993–2003,
an uninterrupted 44% decline in incidence occurred, and in
2003, TB incidence reached a historic low level. This success
in responding to the first resurgence of TB in decades indi-
cates that a coherent national strategy; coordination of local,
state, and federal action; and availability of adequate resources
can result in dramatic declines in TB incidence. This success
also raised again the possible elimination of TB, and in 1999,
ACET reaffirmed the goal of tuberculosis elimination in the
United States (1).
The prospect of eliminating tuberculosis was critically ana-
lyzed in an independent study published by IOM in 2000
(2). The IOM study concluded that TB could ultimately be
eliminated but that at the present rate of decline, elimination
would take >70 years. Calling for greater levels of effort and
resources than were then available, the IOM report proposed
a comprehensive plan to 1) adjust control measures to the
declining incidence of disease; 2) accelerate the decline in in-
cidence by increasing targeted testing and treatment of LTBI;
3) develop new tools for diagnosis, treatment, and preven-
tion; 4) increase U.S. involvement in global control of TB;
FIGURE 1. Number of reported cases of tuberculosis, by year












TABLE 1. Grading system for ranking recommendations in this
statement
Strength of
  recommendation Criteria
A Highly recommended in all circumstances
B Recommended; implementation might be
dependent on resource availability
C Might be considered under exceptional
circumstances
Quality of evidence
I Evidence from at least one randomized,
controlled trial
II Evidence from 1) at least one well-designed
clinical trial, without randomization; 2) cohort
or case-controlled analytic studies; 3) multiple
time-series; or 4) dramatic results from
uncontrolled experiments
III Evidence from opinions of respected authorities,
on the basis of cumulative public health
experience, descriptive studies, or reports of
expert committees
SOURCE: Kish MA. Guide to development of practice guidelines. Clin Infect
Dis 2001;32:851–4 (modified).
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and 5) mobilize and sustain public support for TB elimina-
tion. The report also noted the cyclical nature of the U.S.
response to TB and warned against allowing another “cycle of
neglect” to occur, similar to that which caused the 1985–1992
resurgence.
As noted, the 44% decrease in incidence of TB in the United
States during 1993–2003 (14,15) has been attributed to the
development of effective interventions enabled by increased
resources at the national, state, and local levels (1,2,16).
Whereas institutional resources targeted specific problems such
as transmission of TB in health-care facilities, public resources
were earmarked largely for public health agencies, which used
them to rebuild the TB-control infrastructure (13,17). A pri-
mary objective of these efforts was to increase the rate of
completion of therapy among persons with TB, which was
achieved by innovative case-management strategies, includ-
ing greater use of directly observed therapy (DOT). During
1993–2000, the percentage of persons with reported TB who
received DOT alone or in combination with self-supervised
treatment increased from 38% to 78%, and the proportion of
persons who completed therapy in <1 year after receiving a
diagnosis increased from 63% to 80% (14). Continued
progress in the control of TB in the United States will require
consolidation of the gains made through improved cure rates
and implementation of new strategies to further reduce inci-
dence of TB.
Challenges to Progress Toward
TB Elimination
The development of optimal strategies to guide continuing
efforts in TB control depends on understanding the challenges
confronting the effort. The five most important challenges to
successful control of TB in the United States are 1) prevalence
of TB among foreign-born persons residing in the United
States; 2) delays in detecting and reporting cases of pulmo-
nary TB; 3) deficiencies in protecting contacts of persons with
infectious TB and in preventing and responding to TB out-
breaks; 4) persistence of a substantial population of persons
living in the United States with LTBI who are at risk for pro-
gression to TB disease; and 5) maintaining clinical and public
health expertise in an era of declining TB incidence. These
five concerns (Box 1) serve as the focal point for the recom-
mendations made in this statement to control and prevent
TB in the United States.
Prevalence of TB Among Foreign-Born
Persons Residing in the United States
Once a disease that predominately affected U.S.-born per-
sons, TB now affects a comparable number of foreign-born
persons who reside in the United States permanently or
temporarily, although such persons make up only 11% of
the U.S. population (14). During 1993–2003, as TB inci-
dence in the United States declined sharply, incidence
among foreign-born persons changed little (14). Lack of
access to medical services because of cultural, linguistic,
financial, or legal barriers results in delays in diagnosis and
treatment of TB among foreign-born persons and in ongo-
ing transmission of the disease (18–21). Successful control
of TB in the United States and progress toward its elimina-
tion depend on the development of effective strategies to
control and prevent the disease among foreign-born persons.
Delays in Detection and Reporting of Cases
of Pulmonary TB
New cases of infectious TB should be diagnosed and
reported as early as possible in the course of the illness so
curative treatment can be initiated, transmission interrupted,
and public health responses (e.g., contact investigation and
case-management services) promptly arranged. However,
delays in case detection and reporting continue to occur; these
delays are attributed to medical errors (22–26) and to patient
factors (e.g., lack of understanding about TB, fear of the
authorities, and lack of access to medical services) (18–20). In
addition, genotyping studies have revealed evidence of persis-
tent transmission of M. tuberculosis in communities that have
implemented highly successful control measures (27–29), sug-
gesting that such transmission occurred before a diagnosis was
received. Improvements in the detection of TB cases, leading
to earlier diagnosis and treatment, would bring substantial
benefits to affected patients and their contacts, decrease TB
among children, and prevent outbreaks.
BOX 1. Major challenges to successful control of tuberculosis
(TB)
• Pravalence of TB among foreign-born persons residing
in the United States
• Delays in detecting and reporting cases of pulmonary TB
• Deficiencies in protecting contacts of persons with
infectious cases of TB and in preventing and respond-
ing to TB outbreaks
• Presence of a substantial population of persons living in
the United States with latent TB infection who are at
risk for progression to TB disease
• Maintaining clinical and public health expertise in an
era of declining TB incidence
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Deficiencies in Protecting Contacts of Person
with Infectious TB and in Preventing
and Responding to TB Outbreaks
Although following up contacts is among the highest pub-
lic health priorities in responding to a case of TB, problems in
conducting contact investigations have been reported (30–32).
Approaches to contact investigations vary widely from pro-
gram to program, and traditional investigative methods are
not well adapted to certain populations at high risk. Only
half of at-risk contacts complete a course of treatment for LTBI
(32). Reducing the risk of TB among contacts through the
development of better methods of identification, evaluation,
and management would lead to substantial personal and public
health benefits and facilitate progress toward eliminating TB
in the United States.
Delayed detection of TB cases and suboptimal contact
investigation can lead to TB outbreaks, which are increasingly
reported (26,33–38). Persistent social problems such as crowd-
ing in homeless shelters and detention facilities are contribut-
ing factors to the upsurge in TB outbreaks. The majority of
jurisdictions lack the expertise and resources needed to con-
duct surveillance for TB outbreaks and to respond effectively
when they occur. Outbreaks have become an important ele-
ment in the epidemiology of TB, and measures to detect,
manage, and prevent them are needed.
Persistence of a Substantial Population
of Persons Living in the United States with
LTBI Who Are at Risk for Progression
to TB Disease
An estimated 9.6–14.9 million persons residing in the
United States have LTBI (39). This pool of persons with
latent infection is continually supplemented by immigration
from areas of the world with a high incidence of TB and by
ongoing person-to-person transmission among certain popu-
lations at high risk. For TB disease to be prevented among
persons with LTBI, those at highest risk must be identified
and receive curative treatment (4). Progress toward the elimi-
nation of TB in the United States requires the development of
new cost-effective strategies for targeted testing and treatment
of persons with LTBI (17,40).
Maintaining Clinical and Public Health
Expertise in an Era of Declining TB Incidence
Detecting a TB case, curing a person with TB, and pro-
tecting contacts of such persons requires that clinicians and
the staff members of public health agencies responsible for
TB have specific expertise. However, as TB becomes less
common, maintaining such expertise throughout the loosely
coordinated TB-control system is challenging. As noted
previously, medical errors associated with the detection of
TB cases are common, and deficiencies exist in important
public health responsibilities such as contact investigations
and outbreak response. Errors in the treatment and man-
agement of TB patients continue to occur (41,42). Innova-
tive approaches to education of medical practitioners, new
models for organizing TB services (2), and a clear under-
standing and acceptance of roles and responsibilities by an
expanded group of participants in TB control will be needed
to ensure that the clinical and public health expertise




Further improvements in the control and prevention of TB
in the United States will require a continued strong public
health infrastructure and involvement of a range of health
professionals outside the public health sector. The traditional
model of TB control in the United States, in which planning
and execution reside almost exclusively with the public health
sector (17), is no longer the optimal approach during a sus-
tained drive toward the elimination of TB. This statement
emphasizes that success in controlling TB and progressing
toward its elimination in the United States will depend on the
integrated activities of professionals from different fields in
the health sciences. This statement proposes specific measures
to enhance TB control so as to meet the most important chal-
lenges; affirms the essential role of the public health sector in
planning, coordinating, and evaluating the effort (43); pro-
poses roles and responsibilities for the full range of partici-
pants; and introduces new approaches to the detection of TB
cases, contact investigations, and targeted testing and treat-
ment of persons with LTBI.
The plan to reduce the incidence of TB in the United States
must be viewed in the larger context of the global effort to
control TB. The global TB burden is substantial and increas-
ing. In 2000, an estimated 8.3 million (7.9–9.2 million) new
cases of TB occurred, and 1.84 million (1.59–2.22 million)
persons died from TB; during 1997–2000, the worldwide TB
case rate increased 1.8%/year (44). TB is increasing world-
wide as a result of inadequate local resources and the global
epidemic of HIV infection. In sub-Saharan Africa, the rate of
TB cases is increasing 6.4%/year (44). ACET (1), IOM (2),
and other public health authorities (45,46) have acknowledged
that TB will not be eliminated in the United States until the
global epidemic is brought under control, and they have called
for greater U.S. involvement in global control efforts. In
response, CDC and ATS have become active participants in a
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multinational partnership (Stop TB Partnership) that was
formed to guide the global efforts against TB. U.S. public
and private entities also have provided assistance to coun-
tries with a high burden of TB and funding for research to
develop new, improved tools for diagnosis, treatment, and
prevention, including an effective vaccine.
Despite the global TB epidemic, substantial gains can be
made toward elimination of TB in the United States by focus-
ing on improvements in existing clinical and public health
practices (47–49). However, the drive toward TB elimination
in the United States will be resource-intensive (1,12). Public
health agencies that plan and coordinate TB-control efforts
in states and communities need sufficient strength in terms of
personnel, facilities, and training to discharge their responsi-
bilities successfully, and the growing number of nonpublic
health contributors to TB control, all pursuing diverse indi-
vidual and institutional goals, should receive value for their con-
tributions. Continued progress toward TB elimination in the
United States will require strengthening the nation’s public health
infrastructure rather than reducing it (1,50).
Basic Principles of TB Control
in the United States
Four prioritized strategies exist to prevent and control TB
in the United States (17), as follows:
• The first strategy is to promptly detect and report per-
sons who have contracted TB. Because the majority of
persons with TB receive a diagnosis when they seek medi-
cal care for symptoms caused by progression of the dis-
ease, health-care providers, particularly those providing
primary health care to populations at high risk, are key
contributors to the detection of TB cases and to case
reporting to the jurisdictional public health agency for
surveillance purposes and for facilitating a treatment plan
and case-management services.
• The second strategy is to protect close contacts of
patients with contagious TB from contracting TB infec-
tion and disease. Contact evaluation not only identifies
persons in the early stages of LTBI, when the risk for dis-
ease is greatest (30–32), but is also an important tool to
detect further cases of TB disease.
• The third strategy is to take concerted action to pre-
vent TB among the substantial population of U.S. resi-
dents with LTBI. This is accomplished by identifying
those at highest risk for progression from latent infec-
tion to active TB through targeted testing and admin-
istration of a curative course of treatment (4). Two
approaches exist for increasing targeted testing and treat-
ment of LTBI. The first approach is to encourage clinic-
based testing of persons who are under a clinician’s care
for a medical condition, such as human immunodefi-
ciency virus (HIV) infection or diabetes mellitus, who
are at risk for progressing from LTBI to active TB (4).
The second approach is to establish specific programs
to reach persons who have an increased prevalence of
LTBI, an increased risk for developing active disease if
LTBI is present, or both (51).
• The fourth strategy is to reduce the rising burden of TB
from recent transmission of M. tuberculosis by identifying
settings at high risk for transmission and applying effective
infection-control measures to reduce the risk. This strategy
was used during the 1985–1992 TB resurgence, when dis-
ease attributable to recent transmission was an important
component of the increase in TB incidence (52–54). TB
morbidity attributable to recent spread of M. tuberculosis
continues to be a prominent part of the epidemiology of
the disease in the United States. Data collected by CDC’s
National Tuberculosis Genotyping and Surveillance Net-
work at seven sentinel surveillance sites indicate that 44%
of M. tuberculosis isolates from persons with newly diag-
nosed cases of TB were clustered with at least one other
intrasite isolate, often representing TB disease associated
with recent spread of M. tuberculosis (55). TB outbreaks
are also being reported with greater frequency in correc-
tional facilities (37), homeless shelters (33), bars (27), and
newly recognized social settings (e.g., among persons in an
East Coast network of gay, transvestite, and transsexual HIV-
infected men [34]; persons frequenting an abandoned
junkyard building used for illicit drug use and prostitution
[26]; and dancers in adult entertainment clubs and their
contacts, including children [38]).
Institutional infection-control measures developed in
the 1990s in response to the 1985–1992 resurgence in
transmission of M. tuberculosis in the United States (10)
have been highly successful in health-care facilities (56).
However, newly recognized high-risk environments
(26,27,33,34,37,38) present challenges to the implemen-
tation of effective infection-control measures. Further
attention is required to control the transmission of
M. tuberculosis in these environments.
Structure of this Statement
This statement provides comprehensive guidelines for the
full spectrum of activities involved in controlling and pre-
venting TB in the United States. The remainder of this state-
ment is structured in eight sections, as follows:
• Scientific Basis of TB Control. This section reviews the
base of knowledge of how TB is transmitted and how
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the disease is distributed in the U.S. population,
including new information based on genotyping
studies. It provides basic background information as a
review for current workers in the field and orients health-
care professionals who become new participants in
TB-control efforts.
• Principles and Practice of TB Control. This section
makes the transition from the scientific knowledge base
to clinical and public health practice by discussing the
goal of TB control in the United States, which is to
reduce the morbidity and mortality caused by TB by pre-
venting transmission of M. tuberculosis from persons with
contagious forms of the disease to uninfected persons and
preventing progression from LTBI to TB disease among
persons who have contracted M. tuberculosis infection.
This section also provides basic background information
as a review for current workers in the field and serves as
an orientation for health-care professionals who become
new participants in TB-control efforts.
• Recommended Roles and Responsibilities for TB
Control. This section outlines roles and responsibilities
for the spectrum of participants in the diverse clinical and
public health activities that lead to the control and pre-
vention of TB. The paramount role of the public health
sector is reviewed, followed by proposed responsibilities
for nine prominent nonpublic health partners in tuber-
culosis control: medical practitioners, civil surgeons, com-
munity health centers, hospitals, academic institutions,
medical professional organizations, community-based
organizations, correctional facilities and the pharmaceu-
tical and biotechnology industries. Because responsibili-
ties for the nonpublic health sector have not been
specified previously, this information also should be
useful to policy makers and advocates for strengthened
TB control.
• Essential Components of TB Control in the United
States. This section gives detailed recommendations for
enhancing the core elements of TB control: case detec-
tion and management, contact investigations, and targeted
testing and treatment of LTBI. Recommendations are
provided for targeted public education to neutralize the
stigma of TB and facilitate earlier care-seeking behavior
among patients and for education of health-care profes-
sionals from whom patients with TB seek care. A set of
five clinical scenarios is presented in which a diagnosis of
TB should be undertaken in primary medical practice,
and guidelines are presented for activities among certain
populations to detect TB among persons who have not
sought medical care. Guidelines are provided for a con-
ducting a systematic, step-by-step contact investigation.
All jurisdictional TB-control programs are urged to
develop written policies and procedures on the basis of
these guidelines. Recommended procedures are also out-
lined for conducting surveillance for TB outbreaks and
for developing an outbreak response plan. In addition, a
framework is presented for identifying and prioritizing
subpopulations and settings within a community that are
at high risk for TB and that should receive targeted test-
ing and treatment for LTBI. Priorities for high-risk popu-
lations should be established on the basis of the expected
impact and efficacy of the intervention. Persons who are
readily accessible and have preexisting access to health-
care services (e.g., prisoners, patients receiving ongoing
clinic-based care for HIV infection, and immigrants and
refugees with abnormalities on preimmigration chest
radiographs) should receive the highest priority. An
approach is also presented to reach members of new
immigrant and refugee communities, who often exist on
the margin of U.S. society.
• Control of TB Among Populations at High Risk. On
the basis of the epidemiology of TB in the United States,
this section provides specific recommendations for control-
ling and preventing TB among five populations: 1) chil-
dren; 2) foreign-born persons; 3) HIV-infected persons;
4) homeless persons; and 5) detainees and prisoners in cor-
rectional facilities. Each population is readily identifiable
and has been demonstrated to be at risk for TB exposure or
progression from exposure to disease, or both. Surveillance
and surveys from throughout the United States indicate
that certain epidemiologic patterns of TB are consistently
observed among these populations, suggesting that the
recommended control measures are generalizable.
• Control of TB in Health-Care Facilities and Other
High-Risk Environments. This section recommends
infection-control measures to prevent the transmission of
M. tuberculosis in high-risk settings. The approach to con-
trol of TB that was developed for health-care facilities
continues to be the most successful model and is discussed
in detail. The recommendations in this section have been
updated with respect to the assessment of institutional
risk for TB. Three levels of risk (low, medium, and poten-
tial ongoing transmission) are outlined on the basis of
community and institutional experience with TB. An
associated recommendation is that the frequency of test-
ing of employees for LTBI should be based on the
institution’s risk category. Recommendations also are pro-
vided for control of transmission of M. tuberculosis in cor-
rectional facilities, homeless shelters, and other newly
identified high-risk environments.
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• Research Needs To Enhance TB Control. This section
defines gaps in knowledge and deficiencies in technol-
ogy that limit current efforts to control and prevent
TB. Additional research is needed in these areas to pro-
duce the evidence base and the tools for optimal diag-
nosis, treatment, and prevention of TB. This section
should be useful to persons who formulate U.S. public
health policy and research priorities and members of
academic professions interested in contributing to
enhanced TB control, both in the United States and
throughout the world.
• Graded Recommendations for Control and Preven-
tion of TB. This section groups detailed graded rec-
ommendations for each area discussed in this report.
Scientific Basis of TB Control
Transmission of TB
M. tuberculosis is nearly always transmitted through an
airborne route, with the infecting organisms being carried
in droplets of secretions (droplet nuclei) that are expelled
into the surrounding air when a person with pulmonary
TB coughs, talks, sings, or sneezes. Person-to-person trans-
mission of M. tuberculosis is determined by certain charac-
teristics of the source-case and of the person exposed to the
source-person and by the environment in which the expo-
sure takes place (Box 2). The virulence of the infecting strain
of M. tuberculosis might also be a determining factor for
transmission.
Characteristics of the Source-Case
By the time persons with pulmonary TB come to medi-
cal attention, 30%–40% of persons identified as their close
personal contacts have evidence of LTBI (30). The highest
rate of infection among contacts follows intense exposure
to patients whose sputum smears are positive for acid-fast
bacilli (AFB) (31,57–59) (Figure 2). Because patients with
cavitary pulmonary TB are more likely than those without
pulmonary cavities to be sputum AFB smear-positive (60),
patients with cavitary pulmonary disease have greater
potential to transmit TB. Such persons also have a greater
frequency of cough, so the triad of cavitary pulmonary dis-
ease, sputum AFB smear-positivity, and frequency of cough
are likely related causal factors for infectivity. AFB smear-
negative TB patients also transmit TB, but with lower
potential than smear-positive patients. Patients with
sputum AFB smear-negative pulmonary TB account for
approximately 17% of TB transmission (61).
Characteristics of the Exposed Person
A study of elderly nursing home residents indicated that
persons with initially positive tuberculin skin test results dur-
ing periods of endemic exposure to TB had a much lower risk
for TB than those whose skin test results were initially nega-
tive (62,63). This finding suggests that preexisting LTBI con-
fers protection against becoming infected upon subsequent
exposure and progression to active disease. Similarly, having
prior disease caused by M. tuberculosis had been assumed to
confer protection against reinfection with a new strain of
M. tuberculosis. However, molecular typing of paired iso-
lates of M. tuberculosis from patients with recurrent episodes
of TB disease has demonstrated that reinfection does occur
among immunocompetent and immunocompromised
persons (64,65).
SOURCE: Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active
pulmonary tuberculosis. Bull Int Union Tuberc 1975;50:90–106.
FIGURE 2. Percentage of persons infected with Mycobacterium
tuberculosis, by bacteriologic status of and proximity to the















BOX 2. Factors determining transmission of Mycobacterium
tuberculosis
Characteristics of the source case
• Concentration of organisms in sputum
• Presence of cavitary disease on chest radiograph
• Frequency and strength of cough
Characteristics of the exposed person
• Previous M. tuberculosis infection
• Innate resistance to M. tuberculosis infection
• Genetic susceptibility to M. tuberculosis infection
or disease or both
Characteristics of the exposure
• Frequency and duration of exposure
• Dilution effect (i.e., the volume of air containing
infectious droplet nuclei)
• Ventilation (i.e., the turnover of air in a space)
• Exposure to ultraviolet light, including sunlight
Virulence of the infecting strain of M. tuberculosis
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The classic means of protecting persons exposed to infec-
tious diseases is vaccination. Because of its proven efficacy in
protecting infants and young children from meningeal and
miliary TB (66), vaccination against TB with Mycobacterium
bovis bacillus Calmette-Guerín (BCG) is used worldwide
(although not in the United States). This protective effect
against the disseminated forms of TB in infants and chil-
dren is likely based on the ability of BCG to prevent pro-
gression of the primary infection when administered at that
stage of life (67). Epidemiologic evidence suggests that BCG
immunization does not protect against the development of
infection with M. tuberculosis upon exposure (68), and use
of BCG has not had an impact on the global epidemiology
of TB.  One recent retrospective study found that BCG
protective efficacy can persist for 50–60 years, indicating
that a single dose might have a long duration of effect (69).
A meta-analysis indicated that overall BCG reduced the
risk for TB 50% (66); however, another meta-analysis that
examined protection over time demonstrated a decrease in
efficacy of 5%–14% in seven randomized controlled trials
and an increase of 18% in three others (70). An effective
vaccine against M. tuberculosis is needed for global TB
control to be achieved.
Because only 30%–40% of persons with close exposure to a
patient with pulmonary TB become infected (30,31), innate
immunity might protect certain persons from infection (71).
The innate mechanisms that protect against the development
of infection are largely uncharacterized (71). Although
immunocompromised persons (e.g., those with HIV infec-
tion) are at increased risk for progression to TB disease after
infection with M. tuberculosis, no definitive evidence exists that
immunocompromised persons, including those with HIV
infection, have increased susceptibility to infection upon exposure.
Observational studies suggest that population-based vari-
ability in susceptibility to TB might be related to the length
of time a population has lived in the presence of M. tuberculosis
and has thus developed resistance to infection through natu-
ral selection (72–74). However, the genetic basis for suscepti-
bility or resistance to TB is not well understood (72,75).
Characteristics of the Exposure
Studies that have stratified contacts of persons with pulmo-
nary TB according to time spent with the infected person
indicate that the risk for becoming infected with M. tuberculosis
is in part determined by the frequency and duration of expo-
sure (60). In a given environment shared by a patient with
pulmonary TB and a contact, the risk for transmitting the
infection varies with the density of infectious droplet nuclei
in the air and how long the air is inhaled. Indoors, tubercle
bacilli are expelled into a finite volume of air, and, unless
effective ventilation exists, droplet nuclei containing
M. tuberculosis might remain suspended in ambient air (76).
Exposures in confined air systems with little or no ventila-
tion pose a major risk for transmission of TB; this has been
demonstrated in homes, ships, trains, office buildings, and
health-care institutions (77–80). When contact occurs
outdoors, TB bacilli expelled from the respiratory tract of
an infectious person are rapidly dispersed and are quickly
rendered nonviable by sunlight (77). The risk for trans-
mission during such encounters is very limited.
Considerable attention has been given to transmission of
M. tuberculosis during air travel. Investigations have dem-
onstrated that the risk for transmission from an infectious
person to others on an airplane is greater on long flights
(>8 hours) and that the risk for contracting M. tuberculosis
infection is highest for passengers and flight crew members
sitting or working near an infectious person (81,82). How-
ever, the overall public health importance of such events is
negligible (77,81).
Virulence of the Infecting Strain
of M. tuberculosis
Although much is known about factors that contribute to
the risk for transmission of M. tuberculosis from person to per-
son, the role of the organism itself is only beginning to be
understood (83). Genetic variability is believed to affect the
capability of M. tuberculosis strains to be transmitted or to cause
disease once transmitted, or both. The M. tuberculosis W-strain
family, a member of the globally spread Beijing family (84), is
a group of clonally related multidrug-resistant organisms of
M. tuberculosis that caused nosocomial outbreaks involving HIV-
infected persons in New York City (NYC) during 1991–1994
(85,86). W-family organisms, which have also been associ-
ated with TB outbreaks worldwide, are believed to have evolved
from a single strain of M. tuberculosis that developed resistance-
conferring mutations in multiple genes. The growth of
W-family organisms in human macrophages is four- to eight-
fold higher than that of strains that cause few or no secondary
cases of TB; this enhanced ability to replicate in human
macrophages might contribute to the organism’s potential for
enhanced transmission (87).
Whether M. tuberculosis loses pathogenicity as it acquires
resistance to drugs is not known. Isoniazid-resistant
M. tuberculosis strains are less virulent than drug-susceptible
isolates in guinea pigs (88), and genotyping studies from San
Francisco, California, and from the Netherlands indicated that
isoniazid-resistant strains are much less likely to be associated
with clusters of TB cases than drug-susceptible strains (89,90).
Nevertheless, because person-to-person spread has been dem-
onstrated repeatedly, persons with TB with drug-resistant
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isolates should receive the same public health attention at
the programmatic level as those with drug-susceptible
isolates (91,92).
Effect of Chemotherapy on Infectiousness
Patients with drug-susceptible pulmonary and other forms
of infectious TB rapidly become noninfectious after insti-
tution of effective multiple-drug chemotherapy. This prin-
ciple has been established by studies demonstrating that
household contacts of persons with infectious pulmonary
TB who were treated at home after a brief period of hospi-
talization for institution of therapy developed LTBI at a
frequency no greater than that of persons with pulmonary
TB who were hospitalized for 1 year (93) or until sputum
cultures became negative (94). This potent effect of che-
motherapy on infectiousness is likely attributable, at least
in part, to the rapid elimination of viable M. tuberculosis
from sputum (95) and to reduction in cough frequency
(96). The ability of chemotherapy to eliminate infectivity is
one reason why detecting infectious cases and promptly
instituting multiple-drug therapy is the primary means of
interrupting the spread of TB in the United States.
The effect of chemotherapy to eliminate infectiousness was
once thought to occur rapidly, and patients on chemotherapy
were thought not to be infectious (97,98). However, no ideal
test exists to assess the infective potential of a TB patient on
treatment, and infectivity is unlikely to disappear immedi-
ately after multidrug therapy is started. Quantitative bacte-
riologic studies indicate that the concentration of viable
M. tuberculosis in sputum of persons with cavitary sputum
AFB smear-positive pulmonary TB at the time of diagnosis,
which averaged 106–107 organisms/ml, decreased >90%
(10-fold) during the first 2 days of treatment, an effect attrib-
utable primarily to administration of isoniazid (99), and >99%
(100-fold) by day 14–21, an effect attributable primarily to
administration of rifampin and pyrazinamide (100). Thus, if
no factor other than the elimination of viable M. tuberculosis
from sputum were to account for the loss of infectivity during
treatment, the majority of patients (at least those with infec-
tion attributable to isolates susceptible to isoniazid) who have
received treatment for as few as 2 days with the standard regi-
men (i.e., isoniazid, rifampin, ethambutol, and pyrazinamide)
could be assumed to have an infective potential that averages
10% of that at the time of diagnosis. After 14–21 days of
treatment, infectiousness averages <1% of the pretreatment
level.
This statement presents general guidelines on elimina-
tion of infectivity with treatment (Box 3). However, deci-
sions about infectiousness of a person on treatment for TB
should always be individualized on the basis of 1) the
extent of illness; 2) the presence of cavitary pulmonary
disease; 3) the degree of positivity of sputum AFB smear
results; 4) the frequency and strength of cough; 5) the like-
lihood of infection with multidrug-resistant organisms; and
6) the nature and circumstances of the contact between
the infected person and exposed contacts (101). Patients
who remain in hospitals or reside either temporarily or per-
manently in congregate settings (e.g., shelters and correc-
tional facilities) are subject to different criteria for
infectiousness. In such congregate settings, identification
and protection of close contacts is not possible during the
BOX 3. Criteria for determining when during therapy a patient
with pulmonary tuberculosis (TB) has become noninfectious*
• Patient has negligible likelihood of multidrug-
resistant TB (no known exposure to multidrug-
resistant tuberculosis and no history of prior episodes
of TB with poor compliance during treatment).
• Patient has received standard multidrug anti-TB therapy
for 2–3 weeks. (For patients with sputum acid-fast
bacilli [AFB] smear results that are negative or rarely
positive, threshold for treatment is 5–7 days.)
• Patient has demonstrated complete adherence to treat-
ment (e.g., is receiving directly observed therapy).
• Patient has demonstrated evidence of clinical improve-
ment (e.g., reduction in the frequency of cough or
reduction of the grade of the sputum AFB smear
result).
• All close contacts of patients have been identified, evalu-
ated, advised, and, if indicated, started on treatment for
latent TB infection. This criterion is critical, especially
for children aged <4 years and persons of any age with
immunocompromising health conditions (e.g., HIV
infection).
• While in hospital for any reason, patients with pulmo-
nary TB should remain in airborne infection isolation
until they 1) are receiving standard multidrug anti-TB
therapy; 2) have demonstrated clinical improvement;
and 3) have had three consecutive AFB-negative smear
results of sputum specimens collected 8–24 hours apart,
with at least one being an early morning specimen. Hos-
pitalized patients returning to a congregate setting (e.g.,
a homeless shelter or detention facility) should have three
consecutive AFB-negative smear results of sputum speci-
mens collected >8 hours apart before being considered
noninfectious.
* These criteria for absence of infectivity with treatment should be
considered general guidelines. Decisions about infectivity of a person
on treatment for TB should depend on the extent of illness and the
specific nature and circumstances of the contact between the patient
and exposed persons.
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early phase of treatment, and more stringent criteria for
determining absence of infectivity (i.e., three consecutive
AFB-negative sputum smears) should be followed (10). All
patients with suspected or proven multidrug resistant TB
should be subjected to these more stringent criteria for
absence of infectivity (10).
Progression from LTBI
to TB Disease
Although the human immune response is highly effective
in controlling primary infection resulting from exposure to
M. tuberculosis among the majority of immunocompetent
persons, all viable organisms might not be eliminated.
M. tuberculosis is thus able to establish latency, a period dur-
ing which the infected person is asymptomatic but harbors
M. tuberculosis organisms that might cause disease later (4,71).
The mechanisms involved in latency and persistence are not
completely understood (71,72).
For the majority of persons, the only evidence of LTBI is an
immune response against mycobacterial antigens, which is
demonstrated by a positive test result, either a tuberculin
skin test (3) or, in certain circumstances, a whole blood
antigen-stimulated interferon-γ release assay result (e.g.,
QuantiFERON®-TB Gold test [QFT-G] [Cellestis Lim-
ited, Carnegie, Victoria, Australia]). The tuberculin skin
test measures delayed-type hypersensitivity; QFT-G, an ex
vivo test for detecting latent M. tuberculosis infection, mea-
sures a component of cell-mediated immune response
(102). QFT-G is approved by the Food and Drug Admin-
istration (FDA), and CDC will publish guidelines on its
use. CDC had previously published guidelines for use of
QuantiFERON®-TB, an earlier version of the test that is
no longer available (103). T SPOT-TB,® an enzyme-linked
immunospot assay for IFN-γ, is marketed in Europe along
with QFT-G but is not FDA-approved for use in the United
States. Although approved by FDA, the Tine Test® is not
recommended for the diagnosis of M. tuberculosis infection.
Tests available in other countries to diagnose M. tuberculosis
infection (e.g., T SPOT-TB and Heaf test) are not recom-
mended for clinical use in the United States.
Once a person has contracted LTBI, the risk for progres-
sion to TB disease varies. The greatest risk for progression to
disease occurs within the first 2 years after infection, when
approximately half of the 5%–10% lifetime risk occurs
(4,104). Multiple clinical conditions also are associated with
increased risk for progression from LTBI to TB disease. HIV
infection is the strongest known risk factor (4). Other key risk
factors because of their prevalence in the U.S. population are
diabetes mellitus (105), acquisition of LTBI in infancy or early
childhood, and apical fibro-nodular changes on chest
radiograph (106).
A recent addition to the known risk factors for progres-
sion from LTBI to TB disease is the use of therapeutic agents
that antagonize the effect of cytokine tumor necrosis factor
alpha (TNF-α) and have been proven to be highly effective
treating autoimmune-related conditions (e.g., Crohn’s dis-
ease and rheumatoid arthritis) (107). Cases of TB have been
reported among patients receiving all three licensed TNF-
α antagonists (i.e., infliximab, etanercept, and adalimimab)
(108). CDC has published interim guidelines for prevent-
ing TB when these agents are used (109).
Epidemiology of TB in the United States
Surveillance (i.e., the systematic collection, analysis, and
dissemination of data) is a critical component of successful
TB control, providing essential information needed to
1) determine patterns and trends of the disease; 2) identify
populations and settings at high risk; and 3) establish priori-
ties for control and prevention activities. Surveillance is also
essential for quality-assurance purposes, program evaluation,
and measurement of progress toward TB elimination. In
addition to providing the epidemiologic profile of TB in a
given jurisdiction, state and local surveillance are essential to
national TB surveillance.
CDC’s national TB surveillance system publishes epidemio-
logic analyses of reported TB cases in the United States (110).
Data for the national TB surveillance system are reported by
state health departments in accordance with standard TB case-
definition and case-report formats (110,111). The system
tracked the reversal of the declining trend in TB incidence in
the United States in the mid-1980s, the peak of the resur-
gence in 1992 (with a 20% increase in cases reported during
1985–1992), and the subsequent 44% decline to an all-time
low number (14,871) and rate (5.1 cases/100,000 popula-
tion) of TB cases in 2003 (14,15) (Figure 1).
Geographic Distribution of TB
Wide disparities exist in the geographic distribution of TB
cases in the United States. In 2003, six states (California,
Florida, Georgia, Illinois, New York, and Texas) each reported
>500 cases and accounted for 57% of the national total (14).
These states along with New Jersey accounted for approxi-
mately 75% of the overall decrease in cases since 1992. The
highest rates and numbers of TB cases are reported from
urban areas; >75% of cases reported in 2003 were from areas
with >500,000 population (14). In 2003, a total of 24 states
(48%) had incidence of <3.5 cases of TB/100,000 popula-
tion, the rate established as the year 2000 interim target for
the United States in the 1989 strategic plan for eliminat-
ing TB (11).
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Demographic Distribution of TB
In 2003, adults aged 15–64 years accounted for 73.6%
of reported TB cases. Incidence of TB was highest (8.4 cases/
100,000 population) among adults aged >65 years, who
accounted for 20.2% of cases. Children aged <14 years
accounted for 6.2% of reported cases and had the lowest
incidence of TB; 61.3% of reported cases occurred among
men, and case rates among men were at least double those
of women in mid- and older-adult age groups. In 2003,
the white, non-Hispanic population accounted for only 19%
of reported cases of TB, and TB incidence among the four
other racial/ethnic populations for which data were avail-
able was 5.7–21.0 times that of non-Hispanic whites
(Table 2). Foreign-born persons accounted for 94% of TB
cases among Asians and 74% of cases among Hispanics,
whereas 74% of cases among non-Hispanic blacks occurred
among persons born in the United States (15).
Distribution of TB by Socioeconomic
and Employment Status
Socioeconomic status (SES). Low SES is associated with
an increased risk for TB. An analysis of national surveil-
lance data that assigned socioeconomic indicator values on
the basis of residence zip code indicated that the risk for
TB increased with lower SES for six indicators (crowding,
education, income, poverty, public assistance, and unem-
ployment), with crowding having the greatest impact (112).
Risk for TB increased uniformly between socioeconomic
quartile for each indicator, similar to other socioeconomic
health gradients for other chronic diseases, except for crowd-
ing, for which risk was concentrated in the lowest quartile.
Adjusting for SES accounted for approximately half of the
increased risk for TB associated with race/ethnicity among
U.S.-born blacks, Hispanics, and American Indians (112).
Occupation. Increased incidence of TB among persons
with certain occupations is attributable to exposure in the
work environment and to an increased likelihood that work-
ers will have other risk factors unrelated to occupation, such
as foreign birth. A 29-state study of patients with clini-
cally active TB reported during 1984–1985 indicated that
increased incidence was independent of occupation. An
association between general SES groupings of occupations
and risk for TB also was demonstrated in that study (113).
Chronically unemployed persons had high incidence of TB;
this finding is consistent with surveillance data indicating
that >50% of TB patients were unemployed during the 2 years
before diagnosis (14).
TB among health-care workers (HCWs). Because trans-
mission of M. tuberculosis in health-care institutions was a con-
tributing factor to the resurgence of TB during 1985–1992,
recommendations were developed to prevent transmission in
these settings (10). In 2003, persons reported to have been
HCWs in the 2 years before receiving their diagnoses
accounted for 3.1% of reported TB cases nationwide (14).
However, the elevated risk among HCWs might be attribut-
able to other factors (e.g., birth in a country with a high inci-
dence of TB) (114). A multistate occupational survey
indicated that the majority of HCWs did not have a higher
risk for TB than the general population; respiratory thera-
pists, however, did appear to be at greater risk (113).
Identification of Populations at High Risk
for TB
Contacts of infectious persons. A high prevalence of TB
disease and LTBI has been documented among close contacts
of persons with infectious pulmonary TB (31). A study of
approximately 1,000 persons from urban sites with pulmo-
nary AFB sputum smear-positive TB indicated that more than
one third of their contacts had positive tuberculin skin tests
and that 2% of all close contacts had active TB. Contacts
identified with TB disease were more likely to be household
members or children aged <6 years (31).
Foreign-born persons. The proportion of TB cases in the
United States occurring among foreign-born persons
increased progressively during the 1990s; in 2003,
persons born outside the United States accounted for 53%
of reported cases (14) (Figure 3). Although foreign-born
persons who received a diagnosis of TB in 2002 were born
in >150 countries worldwide, as in each of the 6 previous
years, five countries of origin accounted for the greatest
number of foreign-born persons with TB: China (5%),
India (8%), Mexico (26%), the Philippines (12%), and
Vietnam (8%). During 1992–2003, the number of states
in which >50% of the total reported cases occurred among
foreign-born persons increased from four (8%) in 1992 to
24 (48%) in 2003 (15). Among states and cities, however,
this profile can change rapidly, reflecting changes in
patterns of immigration and refugee settlement (21).
TABLE 2. Tuberculosis (TB) incidence* among five racial/ethnic
populations — United States, 2003
Race/Ethnicity                                           Rate†
White, non-Hispanic 1.4
American Indian/Alaska Native 8.0 (5.7)
Hispanic 10.5 (7.5)
Black, non-Hispanic 11.5 (8.2)
Asian/Pacific Islander 29.4 (21.0)
SOURCE: CDC. Trends in tuberculosis—United States, 1998–2003. MMWR
2004;53:209–14.
* Per 100,000 population.
†Numbers in parentheses represent risk for TB compared with white
non-Hispanics.
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Surveillance data indicate that incidence of TB among
foreign-born persons is approximately 23 cases/100,000
population (14). Incidence varied by county of origin,
appearing to reflect incidence of TB in the country of birth
(21,115,116). In 2003, approximately 47% of foreign-
born persons with TB received their diagnoses within 5
years of their arrival in the United States, and 19% received
their diagnoses within 1 year of arrival. Among foreign-
born persons, TB case rates decreased with longer duration
of residence in the United States. TB rates were nearly four
times higher among persons residing in the United States
for <5 years than in those who were residents for >5 years
(115,116).
HIV-infected persons. Because reporting of HIV infec-
tion among persons with TB is not complete, the exact
prevalence of HIV infection among such persons is
unknown. During 1993–2001, the prevalence of reported
HIV infection occurring among persons also reported with
TB decreased from 15% to 8% (14); this decrease has been
attributed, in part, to reduced transmission of TB among
HIV-infected persons (16). According to a recent world-
wide epidemiologic assessment, however, 26% of adult TB
cases in the United States are attributable to HIV infection (44).
Homeless persons. In 2003, persons known to have been
homeless in the year before receiving a diagnosis accounted
for 6.3% of cases of TB nationwide. On the basis of avail-
able population estimates (117), incidence of TB among
homeless persons is approximately 30–40/100,000 popu-
lation, more than five times the national case rate. How-
ever, a prospective study of a cohort of approximately 3,000
homeless persons in San Francisco documented an annual
incidence of >250 cases/100,000 population (118). In
addition, outbreaks of TB linked to overnight shelters con-
tinue to occur among homeless persons and likely contrib-
ute to the increased incidence of TB among that population
(119,120).
Other populations at high risk. In 2003, persons known
to have injected drugs in the year before receiving a
diagnosis accounted for 2.2% of reported cases of TB, and
noninjection drug use was reported by 7.3% of persons
with TB. In certain U.S. communities, injection drug use
is sufficiently prevalent so as to constitute a high risk for
epidemiologic importance rather than simply an individual
risk factor, especially when overlap exists between injection
drug use and HIV infection (121,122).
TB Among Detainees and Prisoners
in Correctional Facilities
The proportion of cases of TB occurring among inmates
of prisons and jails has remained stable at approximately
3%–4% since data began to be collected in 1993; it was
3.2% in 2003 (14). Inmates also have high incidence of
TB, with rates often >200/100,000 population (123), and
they have a disproportionately greater number of risk fac-
tors for TB (e.g., low SES, HIV infection, and substance
abuse) compared with the general population (124,125).
TB transmission in correctional facilities contributes to the
greater risk among those populations, presumably because
of the difficulties in detecting cases of infectious TB and in
identifying, evaluating, and treating contacts in these set-
tings (37,126).
TB outbreaks occur in both prison and jail settings. Dedi-
cated housing units for prison inmates with HIV infection
were sites of transmission in California in 1995 (126) and
South Carolina in 1999 and in South Carolina in 1999 (37).
In the South Carolina outbreak, delayed diagnosis and isola-
tion of an inmate who apparently had active TB after enter-
ing the facility led to >15 outbreak cases. Transmission
leading to TB infection in the community also was docu-
mented in an outbreak that occurred in a jail in Tennessee
during 1995–1997 (127,128) that involved approximately
40 inmates; contact investigations were incomplete because
of brief jail terms and frequent movement of inmates. Dur-
ing the same period, 43% of patients with TB in the sur-
rounding community had previously been incarcerated in
that jail (127), and, after 2 years, the jail outbreak strain
was more prevalent in the community than it was during
the jail outbreak. Genotyping studies indicated that the
outbreak strain accounted for approximately 25% of TB
cases in the community, including those among patients
with no history of incarceration (128).
Contributions of Genotyping
of M. tuberculosis
M. tuberculosis genotyping refers to procedures developed
to identify M. tuberculosis isolates that are identical in spe-
cific parts of the genome (83). To date, M. tuberculosis
FIGURE 3. Number and percentage of cases of tuberculosis






















Vol. 54 / RR-12 Recommendations and Reports 13
genotyping has been based on polymorphisms in the num-
ber and genomic location of mycobacterial repetitive ele-
ments. The most widely used genotyping test for
M. tuberculosis is restriction fragment length polymorphism
(RFLP) analysis of the distribution of the insertion sequence
IS6110 (129). However, genotyping tests based on poly-
morphisms in three additional mycobacterial repetitive
elements (i.e., polymorphic guanine cytosine–rich repeti-
tive sequences, direct repeats [e.g., spoligotyping], and
mycobacterial interspersed repetitive units [MIRU]) have
also been developed (83). M. tuberculosis isolates with iden-
tical DNA patterns in an established genotyping test
often have been linked through recent transmission among
the persons from whom they were isolated.
When coupled with traditional epidemiologic investiga-
tions, analyses of the genotype of M. tuberculosis strains have
confirmed suspected transmission and identified unsus-
pected transmission of M. tuberculosis. These analyses have
also identified risk factors for recent infection with rapid
progression to disease, demonstrated exogenous reinfection
with different strains, identified weaknesses in conventional
contact investigations, and documented the existence of
laboratory cross-contamination. Genotyping has become
an increasingly useful tool for studying the pathogenesis,
epidemiology, and transmission of TB.
Epidemiology of TB Among Contacts
in Outbreak Settings
Conventional contact investigations have used the concen-
tric circles approach to collect information and screen house-
hold contacts, coworkers, and increasingly distant contacts
for TB infection and disease (17). The concentric circles model
has been described previously (130). However, this method
might not always be adequate in out-of-household settings.
In community-based studies from San Francisco (131), Zurich
(132), and Amsterdam (133), only 5%–10% of persons with
clustered IS6110-based genotyping patterns were identified
as contacts by the source-person in the cluster. This finding
indicates that either 1) transmission of M. tuberculosis might
occur more commonly than suspected and is not easily
detected by conventional contact tracing investigations or
2) genotype clustering does not necessarily represent recent
transmission (55). Because genotyping studies discover only
missed or mismanaged contacts (i.e., those that subsequently
receive a diagnosis of TB), such studies cannot explain the
successes of the process or the number of cases that were
prevented.
Certain populations (e.g., the urban homeless) present spe-
cific challenges to conducting conventional contact investiga-
tions. Genotyping studies have provided information about
chains of transmission in these populations (118,119). In
a prospective study of TB transmission in Los Angeles,
the degree of homelessness and use of daytime services at
three shelters were factors that were independently associ-
ated with genotype clustering (119). Additional studies
support the idea that specific locations can be associated
with recent or ongoing transmission of M. tuberculosis among
homeless persons. Two studies among predominantly HIV-
infected men have demonstrated evidence of transmission
at specific bars in the community (134,135).
Genotyping techniques have confirmed TB transmission
in HIV residential facilities (136), crack houses (i.e., set-
tings in which crack cocaine is sold or used) (137), hospi-
tals and clinics (54), and prisons (138,139). TB
transmission also has been demonstrated among church
choirs (140) and renal transplant patients (141) and in
association with processing of contaminated medical waste
(142) and with bronchoscopy (143,144).
Communitywide Epidemiology of TB
TB might arise because of rapid progression from a
recently acquired M. tuberculosis infection, from progres-
sion of LTBI to TB disease, or occasionally from exogenous
reinfection (145). The majority of genotyping studies have
assumed that clustered isolates in a population-based sur-
vey reflect recent transmission of M. tuberculosis. Certain
studies have identified epidemiologic links between clus-
tered TB cases, inferring that the clustered cases are part of
a chain of transmission from a single common source or
from multiple common sources (131,146).
The number and proportion of population-based cases of
TB that occur in clusters representing recent or ongoing trans-
mission of M. tuberculosis have varied from study to study;
frequency of clustering has varied from 17%–18% (in
Vancouver, Canada) to 30%–40% (in U.S. urban areas)
(131,147,148). Youth, being a member of a racial or ethnic
minority population, homelessness, substance abuse, and HIV
infection have been associated with clustering (131,133,
148,149).
The increasing incidence of TB among foreign-born per-
sons underscores the need to understand transmission dynam-
ics among this population. In San Francisco, two parallel TB
epidemics have been described (150,151), one among foreign-
born persons that was characterized by a low rate of genotype
clustering and the other among U.S-born persons that was
characterized by a high rate of genotype clustering. In a
recent study from NYC, being born outside the United
States, being aged >60 years, and receiving a diagnosis
after 1993 were factors independently associated with
being infected with a strain not matched with any other,
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whereas homelessness was associated with genotype clus-
tering and recent transmission (152). Among foreign-born
persons, clustered strains were more likely to be found
among patients with HIV infection (152).
Other Contributions of Genotyping
Genotyping can determine whether a patient with a
recurrent episode of TB has relapsed with the original strain
of M. tuberculosis or has developed exogenous reinfection
with a new strain (64,153). In Cape Town, South Africa,
where incidence of TB is high and considerable ongoing
transmission exists, 16 (2.3%) of 698 patients had more
than one episode of TB disease. In 12 (75%) of the 16
recurrent cases, the pairs of M. tuberculosis isolates had dif-
ferent IS6110-based genotyping patterns, indicating
exogenous reinfection (154). However, in areas with a low
incidence of TB, episodes of exogenous reinfection are
uncommon (153). Because TB incidence in the majority
of areas of the United States is low and decreasing, reinfec-
tion is unlikely to be a major cause of TB recurrence.
Genotyping has greatly facilitated the identification of
false-positive cultures for M. tuberculosis resulting from labo-
ratory cross-contamination of specimens. Previously, false-
positive cultures (which might lead to unnecessary
treatment for patients, unnecessary work for public health
programs in investigating cases and pseudo-outbreaks, and
unnecessary costs to the health-care system) were difficult
to substantiate (155). Because of its capability to deter-
mine clonality among M. tuberculosis strains, genotyping
has been applied extensively to verify suspected false-
positive cultures (156–158) and to study the causes and
prevalence of laboratory cross-contamination (159,160).
The Role of Genotyping of M. tuberculosis
in TB-Control Programs
In 2004, CDC established the Tuberculosis Genotyping
Program (TBGP) to enable rapid genotyping of isolates from
every patient in the United States with culture-positive TB
(161). State TB programs may submit one M. tuberculosis iso-
late from each culture-positive case within their jurisdictions
to a contracted genotyping laboratory. A detailed manual
describing this program, including information on how to
interpret genotyping test results and how to integrate genotyping
into TB-control activities, has been published (162).
Genotyping information is essential to optimal TB con-
trol in two settings. First, genotyping is integral to the
detection and control of TB outbreaks, including ruling a
suspected outbreak in or out and pinpointing involved cases
and the site or sites of transmission (54,136–144). Second,
genotyping is essential to detect errors in handling and
processing of M. tuberculosis isolates (including laboratory
cross-contamination) that lead to reports of false-positive
cultures for M. tuberculosis (156,158–160,163).
More extensive use of M. tuberculosis genotyping for TB
control depends on the availability of sufficient program
resources to compare results with information from tradi-
tional epidemiologic investigative techniques. Time-framed
genotyping surveys and good fieldwork can unravel uncer-
tainties in the epidemiology of TB in problematic popula-
tions at high risk (150–152,164). Genotyping surveys and
epidemiologic investigations also can be used as a program
monitoring tool to determine the adequacy of contact
investigations (29,119,132–134,164–166) and evaluate
the success of control measures designed to interrupt trans-
mission of M. tuberculosis among certain populations or
settings (167).
Programs that use genotyping for surveillance of all of the
jurisdiction’s M. tuberculosis isolates should work closely on
an ongoing basis with the genotyping laboratory and commit
sufficient resources to compare genotyping results with those
of traditional epidemiologic investigations. Information from
both sources is needed for optimum interpretation of the com-
plex epidemiologic patterns of TB in the United States
(84,168).
Principles and Practice of TB Control
Basic Principles of TB Control
The goal of TB control in the United States is to reduce
morbidity and mortality caused by TB by 1) preventing trans-
mission of M. tuberculosis from persons with contagious forms
of the disease to uninfected persons and 2) preventing pro-
gression from LTBI to TB disease among persons who have
contracted M. tuberculosis infection. Four fundamental strat-
egies are used to achieve this goal (Box 4) (17,169), as
follows:
• Early and accurate detection, diagnosis, and report-
ing of TB cases leading to initiation and completion
of treatment. Detecting and reporting suspected cases
of TB is the key step in stopping transmission of
M. tuberculosis because it leads to prompt initiation of
effective multiple-drug treatment, which rapidly reduces
infectiousness (Box 3). Completion of a full course of
standard therapy is essential to prevent treatment failure,
relapse, and the acquisition of drug resistance (5). TB
is commonly diagnosed when a person seeks medical
attention for symptoms caused by the disease or a con-
comitant medical condition. Thus, health-care provid-
ers, particularly those providing primary health-care
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to populations at high risk, are key contributors to TB
case detection. A suspected or confirmed case of TB
should be reported immediately to the jurisdictional
public health agency. Reporting of new cases is essen-
tial to initiate public health responses, including insti-
tution of a treatment plan, case-management services,
and evaluation of contacts, and for surveillance pur-
poses. This statement contains detailed recommenda-
tions for improving detection of TB cases. Treatment of
TB is the subject of another statement in this series
from ATS, CDC, and IDSA (5).
• Identification of contacts of patients with infectious
TB and treatment of those at risk with an effective
drug regimen. The evaluation of contacts of cases of
infectious TB is one of the most productive methods of
identifying adults and children with LTBI at high risk for
progression to TB disease and persons in the early stages
of TB disease (30,31). Contact investigations therefore
serve as an important means of detecting tuberculosis cases
and at the same time identify persons in the early stage of
LTBI, when the risk for progression to TB disease is high
and the benefit of treatment is greatest (4).
• Identification of other persons with LTBI at risk for
progression to TB disease and treatment of those per-
sons with an effective drug regimen. Targeted testing
is intended to identify persons other than TB contacts
who have an increased risk for acquiring TB and to
offer such persons diagnostic testing for M. tuberculosis
infection and treatment, if indicated, to prevent subse-
quent progression to TB disease (4). This approach is
critical to the eventual elimination of TB in the United
States, because it is the only means of preventing TB in
the substantial pool of persons with LTBI at high risk
for progression to TB disease. Targeted testing and treat-
ment of LTBI is also a primary means of controlling
TB among foreign-born persons at high risk residing
in the United States because genotyping surveys have
consistently demonstrated that the majority of TB cases
in that population are attributable to progression from
LTBI (150–152). Targeted testing and treatment of
LTBI is best accomplished through cost-effective pro-
grams aimed at patients and populations identified on
the basis of local surveillance data as being at increased
risk for TB (51). Guidelines for this activity have been
published (4). This statement includes recommenda-
tions for organizing and conducting programs for tar-
geted testing and treatment of LTBI.
• Identification of settings in which a high risk exists
for transmission of M. tuberculosis and application of
effective infection-control measures. For the rising bur-
den of TB from recent transmission of M. tuberculosis to
be reduced, settings at high risk for transmission should
be identified, and effective infection-control measures
should be taken to reduce the risk. In the 1980s, the
majority of cases of TB in the United States were
believed to arise through activation of LTBI, and few
cases were believed to occur as a consequence of recent
transmission of M. tuberculosis (6). During the 1985–
1992 TB resurgence, however, disease caused by
recent transmission was a critical component of the in-
crease in TB incidence. TB outbreaks associated with
person-to-person spread occurred in different venues,
most prominently in health-care facilities (52–54,170).
TB morbidity caused by recent spread of M. tuberculosis
has continued to be a prominent part of the epidemi-
ology of the disease in the United States. During 1996–
2000, when incidence of TB was in constant decline, a
survey involving 10,883 M. tuberculosis isolates collected
from persons with newly diagnosed cases from seven
NTGSN sentinel surveillance sites indicated that 52%
were clustered with at least one other isolate (average
genotype cluster size: six isolates), frequently represent-
ing cases of TB disease associated with recent spread of
M. tuberculosis (171). Outbreaks of TB are also being
reported with greater frequency (33,34,172,173).
Institutional infection-control measures have been
highly successful in health-care facilities (56), but other
high-risk settings (e.g., correctional facilities [37],
homeless shelters [33], bars [27]), and social settings
that extend beyond single venues [26,34,38,172])
present challenges to effective infection control (172).
Vaccination with BCG is not recommended as a means
to control TB in the United States because of the unproved
efficacy of the vaccine in the U.S. population (174,175),
its effect of confounding the results of tuberculin skin
BOX 4. Strategies to achieve the goal of reduction of tuber-
culosis (TB) morbidity and mortality
• Early and accurate detection, diagnosis, and reporting
of TB cases leading to initiation and completion of treat-
ment
• Identification of contacts of patients with infectious TB
and treatment of those at risk with an effective drug
regimen
• Identification of other persons with latent TB infection
at risk for progression to TB disease and treatment of
those persons with an effective drug regimen
• Identification of settings in which a high risk exists for
transmission of Mycobacterium tuberculosis and applica-
tion of effective infection-control measures
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testing (176) and the success of other measures in reduc-
ing incidence of TB (16). During the 1985–1992 TB
resurgence, the documented spread of TB, including
multidrug-resistant TB, in health-care institutions and in
the community (52–54,177,178) stimulated interest in
the potential use of BCG to protect HCWs and others from
exposure to M. tuberculosis. In 1996, a statement from
ACET and the Advisory Committee on Immunization Prac-
tices (179) recommended vaccination with BCG for 1)
infants and children with exposure to M. tuberculosis in set-
tings in which other protective measures are either inacces-
sible or proven to be ineffective and 2) HCWs when
likelihood of exposure to multidrug-resistant TB is high
and recommended control measures have not been success-
ful. With improved TB control in the United States and
the decline of multidrug-resistant TB (13), use of BCG for
protection against TB has declined. An improved vaccine,
particularly one that protects adults with LTBI against
acquiring TB disease, would accelerate progress toward TB
elimination in the United States (180).
Deficiencies in TB Control
Because TB control is a complex undertaking that
involves multiple participants and processes, mistakes
often occur, with adverse consequences. Common errors
include 1) delays among persons with active TB obtaining
health care; 2) delayed detection and diagnosis of active
TB; 3) failed or delayed reporting of TB; 4) failure to com-
plete an effective course of treatment for TB; 5) missed
opportunities to prevent TB among children; and 6) defi-
ciencies in conducting contact investigations and in
recognizing and responding to outbreaks.
Delays in Obtaining Health Care
Homeless patients with TB symptoms often delay seek-
ing care or experience delays in gaining access to care (181),
and fear of immigration authorities has been associated
with patient delay among foreign-born persons (19).
Patients who speak languages other than English or who
are aged 55–64 years are more likely than others to delay
seeking care (20).
Cultural factors that might affect health-seeking behavior
by foreign-born persons include misinterpretation or mini-
mization of symptoms, self-care by using over-the-counter or
folk medicines, and the social stigma associated with TB (18).
In certain societies, women with TB are less likely to take
advantage of health-care services, perhaps because of stigma
associated with the diagnosis, including a lower likelihood of
marriage (182,183). Even in areas with open access to public
health clinical services, persons at risk for TB might not
seek evaluation and treatment because they are not aware
that these resources are available for persons with limited
financial means (118,184–186).
Delayed Detection and Diagnosis
of Active TB
Delayed detection of a case of TB and resulting delays in
initiation of treatment can occur if the clinician does not sus-
pect the diagnosis. A survey conducted in NYC in 1994 found
that the median delay within the health-care system (defined
as the time from first contact to initiation of treatment for
active TB) was 15 days (range: 0–430 days) (20). Asians
and homeless persons were more likely to encounter delays
in receiving a diagnosis than non-Asians and persons with
stable housing. Persons without cough who had AFB smear-
negative TB or who did not have a chest radiograph at their
initial visit also experienced delays. In London, England,
delays in diagnosis occurred among whites and among women
of all racial/ethnic populations (187).
Regardless of the reason, the consequences of delays in
diagnosis and initiation of effective therapy can be serious. In
Maine, a shipyard worker aged 32 years who was a TB con-
tact and who was untreated despite having symptoms of
active TB, repeated medical visits, and a chest radiograph con-
sistent with active TB did not receive a diagnosis of TB until
8 months after he became ill (188), and 21 additional cases of
TB occurred among his contacts. Of 9,898 persons who were
investigated as contacts, 697 (7.0%) persons received
diagnoses of new LTBIs. A high school student in California
was symptomatic for >1 year before TB was diagnosed
(177). Subsequently, 12 additional TB cases among fellow
students were linked to the source-case, and 292 (23%) of
1,263 students tested had positive tuberculin skin tests.
Other instances of delayed or missed diagnoses of TB
have been reported that have resulted in extended periods
of infectiousness and deaths (22,24,178). These problems
reflect the increasing difficulty in maintaining clinical
expertise in the recognition of TB in the face of declining
disease incidence (41). Recognition of TB among patients
with AFB-negative sputum smear results is a challenge for
practitioners and has been associated with delays in report-
ing and treatment (22,189,190).
Delayed Reporting of TB
Failure to promptly report a new TB case delays public
health responses (e.g., institution of a treatment plan, case-
management services, and protection of contacts). Although
TB cases in the United States rarely remain unreported,
timeliness of reporting varies (median: 7–38 days) (190).
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Failure to Receive and Complete a Standard
Course of Treatment for Active TB
Failure to receive and complete a standard course of treat-
ment for TB has adverse consequences, including treatment
failure, relapse, increased TB transmission, and the emer-
gence of drug-resistant TB (191–193). At least two rea-
sons exist for failure to complete standard treatment. Patients
frequently fail to adhere to the lengthy course of treatment
(188). Poor adherence to treatment regimens might result
from difficulties with access to the health-care system, cul-
tural factors, homelessness, substance abuse, lack of social
support, rapid clearing of symptoms, or forgetfulness
(18,194). Also, as TB has become less common, clinicians
might fail to use current treatment regimens (48). These
adverse outcomes are preventable by case-management
strategies provided by TB-control programs, including use
of DOT (13,195,196).
Missed Opportunities To Prevent
TB Among Children
The absence of TB infection and disease among children is
a key indicator of a community’s success in interrupting the
transmission of TB (197). The 1985–1992 TB resurgence
included a reversal of the long-term decline in the incidence
of TB among children, which indicated a failure of the public
health system to prevent disease transmission (197). A study
of 165 children reported with TB in California in 1994 found
that for 59 (37%), an adult source-case was identified (198).
Factors that contributed to transmission to children included
delayed reporting, delayed initiation of contact investiga-
tions, and poor management of adult source-cases. Improve-
ments in contact investigations might have prevented 17
(10%) of those cases (198).
Deficiencies in Conducting Contact
Investigations and in Recognizing
and Responding to Outbreaks
Deficiencies in contact investigations and failure to recog-
nize and respond to TB outbreaks are among the most impor-
tant challenges to optimal control of TB in the United States.
These topics are discussed in detail in this statement along
with the other essential components of TB control.
Importance of TB Training
and Education
The 1985–1992 TB resurgence led ACET to call for a
renewed focus on training and education as an integral part
of strategies for TB control, prevention, and elimination (1).
Factors indicating a need for this focus include the following:
• Deficiencies in clinical knowledge and practice.
Errors have been documented on the part of medical prac-
titioners and TB-control staff in the diagnosis, reporting,
treatment, and follow-up of TB cases. These deficiencies
indicate a broad need for training and education through-
out the TB-control system, among both public health and
nonpublic health participants.
• Staffing and workforce concerns. Ongoing education
and training within TB-control programs are required to
inform staff members about programmatic and patient
management issues. For example, implementation of
DOT for treatment of TB disease or LTBI or the inte-
gration of a new category of HCWs (e.g., outreach
workers) might have substantial training requirements.
Changes in the state or local epidemiology of TB and
the emergence of new populations or settings of high
risk also might necessitate additional training or
retraining of staff members.
• New guidelines and recommendations. TB guidelines
and recommendations are regularly published and updated
(3–5). However, the promulgation of guidelines alone does
not necessarily improve provider practices (42,199).
Guidelines are more effective when supplemented with
targeted education (42).
• Education of new contributors to TB control. TB
elimination will require that new categories of health
professionals, not previously identified as contributors
to TB control in the community, take on expanded
responsibilities. Education strategies for these new part-
ners will be needed. For example, clinicians should
understand the local epidemiology of TB sufficiently
to know if their practice includes patients at high risk.
They should know how to identify and treat patients
at high risk who have LTBI. They should be able to
recognize the signs and symptoms of TB disease and
understand how to evaluate and treat persons with sus-
pected cases. They should understand the public health
aspects of TB, including the need for prompt report-
ing and the facilitating role of the jurisdictional health
agency in case management. In particular, strategies
are needed to maintain TB knowledge and expertise
among clinicians in areas of low TB incidence (48).
• Diminished teaching about TB in medical and
nursing schools. As TB case rates declined in the United
States, schools of medicine and nursing gradually reduced
their emphasis on TB education. With the resurgence of
TB in the United States during 1985–1992 and recogni-
tion of the extent of the global epidemic, clinicians and
public health programs have been faced with the chal-
lenges of learning to diagnose, manage, and control TB
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as if it were a new disease (42,200,201). Education is
essential to the future control of TB in the United States
and globally (2), and creating interest in TB among stu-
dents of the health professions is critical to generating the
competent workforce needed to eliminate TB in the
United States and contribute human resources to
fighting the global TB epidemic.
Educating Patients and Communities
at High Risk
Education of patients by clinicians, TB program staff,
and trusted community members promotes acceptance
and adherence to authoritative advice about controlling and
preventing TB. Such education can influence patients’
decision-making about whether to accept and complete
treatment for LTBI (202).
Because cultural and health beliefs might act as barriers to
effective control of TB (18,19), an increasing need exists for
education targeted at populations at high risk (19).
TB-control programs should enlist community-based orga-
nizations and other key informants to discover the health
beliefs, norms, and values of communities at high risk in their
jurisdictions (202,203). Professional associations and academic
institutions (including schools of medicine, public health, and
nursing) will be valuable partners in developing an under-
standing of the health perceptions of these populations.
Education materials should be developed with input from
the target audience to ensure that they are culturally and
linguistically appropriate (203,204).
The Strategic Plan for TB Training
and Education
In 1997, CDC funded a project to develop a Strategic
Plan for Tuberculosis Training and Education (the Strate-
gic Plan) that provided guidance to agencies and organiza-
tions in the United States that offer TB training and
education for public- and private-sector providers. The Stra-
tegic Plan specified critical areas requiring attention,
including 1) the need for culturally competent programs
and materials, 2) effective methods and technologies, 3)
collaboration and cooperation among training and educa-
tion partners outside TB-control programs, and 4) adequate
funding for training and education efforts.
Other Resources for TB Training
and Education
Substantial progress has been made in developing and
disseminating resources for TB training and education. CDC
and national TB centers, NTCA, regional controllers associa-
tions (e.g., the Northeast Tuberculosis Training Consortium),
state and local health departments, and the National Labo-
ratory Training Network have all conducted education pro-
grams or developed training and education materials. In
2001, as stipulated by the Strategic Plan, the Tuberculosis
Education and Training Network was established. The net-
work is coordinated by CDC and includes educators in
local, state, and territorial health agencies. CDC has also
developed the Tuberculosis Information CD-ROM,
Version 3, and the Tuberculosis Education and Training
Resource Guide; these products are designed to enhance
awareness and accessibility of resources (available at
http://www.cdc.gov/nchstp/tb/default.htm) for TB educa-
tion and training. The establishment in 2004 of the
National Tuberculosis Curriculum Coordinating Center at
the University of California at San Diego by the National
Heart Lung and Blood Institute signals a commitment by
the National Institutes of Health (NIH) to provide basic
TB education for health-care students and providers.
Professional societies and specialty boards are means for
reaching private medical providers. Including TB as a sub-
ject in state medical society programs, hospital grand rounds,
and medical specialty board examinations would be a valu-
able resource for providers serving populations at low risk.
New linkages should be established to reach providers
serving populations at high risk (e.g., foreign-born, home-
less, and HIV-infected persons). For example, the AIDS Edu-
cation and Training Centers funded by the Health Resources
and Services Administration are a resource for reaching HIV/
AIDS providers, and foreign physicians’ associations and
community-based organizations are potential partners for
reaching international medical graduates and health-care
providers of foreign-born persons.
Laboratory Services for Optimal
TB Control
The diagnosis of TB, management of patients with the
disease, and public health control services rely on accurate
laboratory tests. Laboratory services are an essential com-
ponent of effective TB control, providing key information
to clinicians (for patient care) and public health agencies
(for control services).
Up to 80% of all initial TB-related laboratory work (e.g.,
smear and culture inoculation) is performed in hospitals, clin-
ics, and independent laboratories outside the public health
system, whereas >50% of species identification and drug sus-
ceptibility testing is performed in public health laboratories
(205). Thus, effective TB control requires a network of public
and private laboratories to optimize laboratory testing and
the flow of information. Public health laboratorians, as a
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component of the public health sector with a mandate for
TB control, should take a leadership role in developing labo-
ratory networks and in facilitating communication among
laboratorians, clinicians, and TB controllers.
Role of Public Health Laboratories
Public health laboratories should ensure that clinicians
and public health agencies within their jurisdictions have
ready access to reliable laboratory tests for diagnosis and
treatment of TB (206). Specific tasks to ensure the avail-
ability, accessibility, and quality of essential laboratory ser-
vices are 1) assessment of the cost and availability of TB
laboratory services and 2) development of strategic plans
to implement and maintain a systems approach to TB test-
ing (207). In this process, public health laboratories should
assess and monitor the competence of laboratories that per-
form any testing related to the diagnosis, management, and
control of TB within their jurisdictions; develop guidelines
for reporting and tracking of laboratory results; and edu-
cate laboratory staff members, health-care providers, and
public health officials about available laboratory tests, new
technologies, and indications for their use. For example,
public health laboratories should lead the discussion on
the costs, logistics requirements (e.g., collection and trans-
port of clinical specimens within the required time), and
quality assurance issues associated with the use of QFT-G,
the new test for latent M. tuberculosis infection (103). The
process of coordinating TB laboratory services is usually
best organized at the state level (208), and the Association
of Public Health Laboratories has compiled descriptions
of successful organizational models for integrated labora-
tory services (207).
Role of Clinical Laboratories
Because the majority of initial TB laboratory work
related to diagnosis of TB is conducted in hospitals, clin-
ics, and independent laboratories (205), clinicians and
public health agencies are increasingly dependent on the
laboratory sector for the confirmation of reported cases, and
public health laboratories are similarly dependent for
referral of specimens for confirmatory testing and archiving.
However, as a result of laboratory consolidation at the
regional or national level (206), private laboratories are
experiencing more difficulties in fulfilling this function. In
certain instances, consolidation has resulted in poor com-
munication among laboratory personnel, clinicians, and
public health agencies (206,209). Problems also have been
identified in specimen transport, test result reporting, and
quality control (206,209,210). In response, certain states
(e.g., Wisconsin*) have adopted laws and regulations that
mandate essential clinical laboratory services for TB con-
trol (e.g., drug susceptibility testing and reporting of the
first M. tuberculosis isolate from each patient and submis-
sion of isolates to the state public health laboratory).
The clinical laboratory sector should accept the respon-
sibilities that accompany its emergence as a provider of
essential TB testing (209). This statement provides rec-
ommendations to guide turnaround times for essential tests,
reporting to clinicians and jurisdictional public health agen-
cies, and referral of specimens to public health laboratories
or their designees.
Essential Laboratory Tests
Six tests performed in clinical microbiologic laboratories
are recommended for optimal TB control services (Table 3).
These laboratory tests should be available to every clini-
cian involved in TB diagnosis and management and to
jurisdictional public health agencies charged with TB con-
trol. In addition, other tests that are useful in the diagnosis
and management of selected patients and for specific TB
control activities include M. tuberculosis genotyping, serum
drug levels, tests used for monitoring for drug toxicity, and
QFT-G for diagnosis of latent M. tuberculosis infection
(5,103,162). Access to these specialized tests should be
provided as needed.
For suspected cases of pulmonary TB, sputum smears for
AFB provide a reliable indication of potential infectiousness;
and for AFB smear-positive pulmonary cases, a nucleic acid
amplification assay (NAA) provides rapid confirmation that
the infecting mycobacteria are from the M. tuberculosis
TABLE 3. Essential laboratory tests for tuberculosis control
Test Maximum turnaround time
Microscopy for acid-fast <24 hours from specimen collection or,
bacilli if test is performed offsite, <24 hours from
receipt in laboratory; if latter, time from
specimen collection to laboratory receipt
should be <24 hours
Nucleic acid amplification <48 hours from date of specimen
assay collection
Mycobacterial growth <14 days from date of specimen collection
detection by culture
Identification of cultured <21 days from date of specimen collection
mycobacteria
Drug susceptibility testing <30 days from date of specimen collection
Drug susceptibility testing <4 weeks from date of request
of second-line drugs
* Wisconsin Department of Health and Family Services. HFS 145. Control
of Communicable Diseases. Available at http://www.legis.state.wi.us/rsb/
code/hfs/hfs145.pdf.
20 MMWR November 4, 2005
complex. These two tests, which should be available with
rapid turnaround times from specimen collection, facili-
tate decisions about initiating treatment for TB or a non-
TB pulmonary infection, and, if TB is diagnosed, for
reporting the case and establishing priority to the contact
investigation.
Growth detection and identification of M. tuberculosis by
culture of sputum and other affected tissue is essential for
confirmation of the identity of the organism and for subse-
quent drug susceptibility testing, which is recommended
on all initial isolates for each patient. Cultures also remain
the cornerstone for the diagnosis of TB in smear-negative
pulmonary and extrapulmonary cases and, along with spu-
tum smears for AFB, provide the basis for monitoring a
patient’s response to treatment, for release from isolation,
and for diagnosing treatment failure and relapse (5). The
use of liquid media systems, which can provide informa-
tion in less time than solid media (in certain cases, 7 days),
should be available in all laboratories that perform culture
for mycobacteria. Detailed descriptions of these recom-
mended laboratory tests; recommendations for their cor-
rect use; and methods for collecting, handling, and
transporting specimens have been published (3,211).
Recommended Roles
and Responsibilities for TB Control
This section delineates organizational and operational
responsibilities of the public health sector that are essential to
achieve the goals of TB control in the United States. How-
ever, a central premise of this statement is that continuing
progress toward elimination of TB in the United States will
require the collaborative efforts of a broad range of persons,
organizations, and institutions in addition to the public health
sector, which has responsibility for the enterprise. For example,
clinicians who provide primary health care and other special-
ized health services to patients at high risk for TB, academic
medical centers that educate and train them, hospitals in
which they practice, and professional organizations that
serve their interests can all make meaningful contributions
to improve the detection of TB cases, one of the most
important obstacles to continuing progress (Box 1). Simi-
larly, important roles exist for such entities as community-
based organizations representing populations at risk for TB
and the pharmaceutical industry, which takes academic
advances and develops the tools for diagnosis, treatment,
and prevention of TB. This section discusses the impor-
tance to the TB elimination effort of participants outside
the public health sector and proposes specific roles and
responsibilities that each could fulfill toward that goal. The
sponsoring organizations intend for these proposals to serve
as the basis for discussion and consensus building on the
important roles and responsibilities of the nonpublic health
sector in continuing progress toward the elimination of TB
in the United States.
Public Health Sector
The infrastructure for TB control has been discussed
extensively in recent years. An analysis of contributing fac-
tors to the rise in the number of TB cases during 1985–
1992 concluded that the resurgence never would have
occurred had the public health infrastructure been left in
place and supported appropriately (212). The need to
maintain the TB-control infrastructure has been expressed
repeatedly (1,2,13,213,214).
Public health activities have been described as consisting
of four interrelated components: mission/purpose, struc-
tural capacity, processes, and outcomes (215). Among these
four components, structural capacity (i.e., persons who do
the work of public health, their skills and capacities, the
places where they work, the way they are organized, the
equipment and systems available to them, and the fiscal
resources they command) represents the public health
infrastructure for TB control.
The responsibility for TB control and prevention in the
United States rests with the public health system through
federal, state, county, and local public health agencies. Pro-
grams conducted by these agencies were critical to the
progress that has been made in TB control, and the dete-
rioration of those programs following the loss of categoric
federal funding contributed to the resurgence of TB in the
United States during 1985–1992 (1,2,13,212–214). Since
1992, as a result of increased funding for TB-control pro-
grams, national incidence of TB disease has declined. In
2004, $147 million in federal funds were dedicated to
domestic TB control, compared with $6.6 million in 1989,
during the resurgence. These funds have been used to
rebuild public health–based TB-control systems, and the
success achieved highlights the critical role of the public
health system in TB control.
TB control in the United States has traditionally been
conducted through categoric programs established to
address the medical aspects of the disease and the specific
interventions required for its successful prevention and
management (17,216). CDC’s Division of TB Elimination,
in partnership with other CDC entities that conduct TB-
related work, provides guidance and oversight to state and
local jurisdictions by conducting nationwide surveillance;
developing national policies, priorities, and guidelines; and
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providing funding, direct assistance, education, and pro-
gram evaluation. Setting the national agenda for support
of basic and clinical research is also a critical function of
federal health agencies, including NIH and CDC, with
support from nongovernment organizations such as ATS
and IDSA.
To meet the priorities of basic TB control (Box 4), state and
local public health agencies with responsibility for TB control
should provide or ensure the provision of a core group of func-
tions (Box 5). Jurisdictional public health agencies should
ensure that competent services providing these core elements
function adequately within their jurisdictions and are
available with minimal barriers to all residents.
How the core components of TB control are organized
differs among jurisdictions, depending on the local burden
of disease, the overall approach to public health services
within the jurisdiction, budgetary considerations, the avail-
ability of services within and outside the public health sec-
tor, and the relationships among potential participants.
Certain jurisdictions provide core program components
themselves, whereas other jurisdictions contract with oth-
ers to provide them. In the majority of cases, the organiza-
tion includes a mix in which the public health agency
provides certain services, contracts for others, and works
collaboratively with partners and stakeholders to accom-
plish the remainder (48). Sharing of direct services, includ-
ing patient management, increases the importance of the
public health sector, which retains responsibility for suc-
cess of the process. This evolving role of the public health
sector in TB control is consistent with the widely accepted
concept of the three core functions of public health that




The Health Insurance Portability and Accountability Act
(HIPAA) of 1996 included provisions to protect the privacy
of individually identifiable health information. To imple-
ment these privacy protections, the U.S. Department of
Health and Human Services has issued a ruling on how
health-care providers may use and disclose personally iden-
tifiable health information about their patients; these regu-
lations provide the first national standards for requirements
regarding the privacy of health information (217).
HIPAA also recognizes the legitimate need for public health
authorities and others responsible for ensuring the public’s
health and safety to have access to personal health informa-
tion to conduct their missions and the importance of pub-
lic health disease reporting by health-care providers. HIPAA
permits disclosure of personal health information to public
health authorities legally authorized to collect and receive
the information for specified public health purposes. Such
information may be disclosed without written authoriza-
tion from the patient. Disclosures required by state and
local public health or other laws are also permitted. Thus,
HIPAA should not be a barrier to the reporting of suspected
and verified TB cases by health-care providers, including
health-care institutions. Additional information about
HIPAA is available at http://www.hhs.gov/ocr/hipaa.
Roles and Responsibilities of Federal Public
Health Agencies
• Establishment of standards and guidelines. Federal
agencies should take a leadership role in developing and
promulgating standards of public health and clinical prac-
tice for TB, in collaboration with professional medical
societies, state and local TB-control programs, and other
organizations. These partnerships have served the medical
and public health communities and should be continued
and strengthened.
• Financial and technical support for TB control and
elimination. Federal agencies should continue to provide
financial and technical support for TB control and elimi-
nation within their own institutions and jurisdictions
and provide direct support to state and local
TB-control programs through CDC cooperative agree-
ments. In addition, CDC should continue to provide
technical assistance through the assignment of medical
and administrative staff to state and local TB-control
programs and by responding to requests for assistance
with TB outbreaks. In relation to these responsibili-
ties, CDC should determine the level of necessary
BOX 5. Core responsibilities for control of tuberculosis (TB)
by a jurisdictional public health agency
• Assessment of the extent and characteristics of TB in
the jurisdiction through collection and analysis of epi-
demiologic and other data
• Development of policies and procedures and of a plan
for controlling TB, on the basis of the assessment of the
problem
• Assurance of diagnostic, clinical, and preventive ser-
vices needed to implement the plan for controlling TB
• Monitoring and evaluating the effectiveness of the plan
for controlling TB
• Providing information and education to policy makers,
health-care professionals, and the public regarding con-
trol of TB in the jurisdiction
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financial support from the federal government needed
to control and prevent TB in the United States.
• National reporting, surveillance, and analysis. Fed-
eral agencies should continue to support the collec-
tion, aggregation, and distribution of national
surveillance data through cooperative agreements with
state and local TB programs. Consultation and techni-
cal support from federal resources are also essential to
maintain the state and local network of surveillance
throughout the United States.
• Program oversight and monitoring. Federal agencies
should facilitate development of quality improvement
programs and establishment of quality indicators for state
and local TB-control programs.
• Education and training. Although multiple partici-
pants in TB control are responsible for education and
training of patients and health-care providers, federal
agencies should take the lead in developing training
and education materials to facilitate TB control at the
state and local levels.
• Public health research. Federal agencies should plan, con-
duct, and support basic, clinical, and public health
research leading to improvements in TB diagnosis, treat-
ment, and prevention.
• Evaluation of immigrants and refugees outside the
United States. Federal agencies are responsible for ensur-
ing that legal immigrants and refugees are evaluated
appropriately for TB before their arrival in the United
States and for notifying state and local TB-control pro-
grams of the arrival in their jurisdictions of immigrants
and refugees with suspected TB. Agencies involved in
evaluating and reporting arriving immigrants and refu-
gees should ensure the quality and timeliness of those
processes.
• Coordination of interstate TB-control efforts. Federal
agencies should take the lead in resolving interstate
TB-control issues, including movement of TB patients
across state lines and multistate TB outbreaks.
Roles and Responsibilities of Jurisdictional
Public Health Agencies
Planning and policy development. The blueprint for TB
control for a given area is a responsibility of the jurisdictional
public health agency. Policies and plans should be based
on a thorough understanding of local epidemiologic data
and on the capabilities and capacities of clinical and sup-
port services for clients, the fiscal resources available for TB
control, and ongoing indicators of program performance.
Open collaboration is essential among public health offi-
cials and community stakeholders, experts in medical and
nonmedical TB management, laboratory directors, and pro-
fessional organizations, all of whom provide practical per-
spectives to the content of state and local TB-control policy.
Policies and procedures should reflect national and local
standards of care and should offer guidance in the manage-
ment of TB disease and LTBI.
A written TB control plan that is updated regularly should
be distributed widely to all interested and involved parties.
The plan should assign specific roles and responsibilities;
define essential pathways of communication between provid-
ers, laboratories, and the public health system; and assign suf-
ficient resources, both human and financial, to ensure its
implementation, including a responsible case manager for each
suspected and verified case of TB. The plan should include
the provision of expert consultation and oversight for
TB-related matters to clinicians, institutions, and commu-
nities. It should provide special guidance to local laborato-
ries that process TB-related samples, assist local authorities
in conducting contact or outbreak investigations and DOT,
and provide culturally appropriate information to the com-
munity. Systems to minimize or eliminate financial and
cultural barriers to TB control should be integral to the
plan, and persons with TB and persons at high risk with
TB infection should receive culturally appropriate educa-
tion about TB and clinical services, including treatment,
with no consideration for their ability to pay. Finally, the
plan should be consistent with current legal statutes
related to TB control. Relevant laws and regulations should
be reviewed periodically and updated as necessary to
ensure consistency with currently recommended clinical
and public health practice (e.g., mandatory reporting laws,
institutional infection-control procedures, hospital and
correctional system discharge planning, and involuntary
confinement laws) (218).
Collection and analysis of epidemiologic and other data.
The development of policies and plans for the control of TB
within a jurisdiction requires a detailed understanding of the
epidemiology of TB within the jurisdiction. Mandatory and
timely case reporting from community sources (e.g., provid-
ers, laboratories, hospitals, and pharmacies) should be enforced
and evaluated regularly. To facilitate the reporting process and
data analyses, jurisdictions should modify systems as neces-
sary to accommodate local needs and evolving technologies.
State and local TB-control programs should have the capa-
bility to monitor trends in TB disease and LTBI in popula-
tions at high risk and to detect new patterns of disease and
possible outbreaks. Populations at high risk should be iden-
tified and targeted for active surveillance and prevention,
including targeted testing and treatment of LTBI (4).
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Timely and accurate reporting of suspected and confirmed
TB cases is essential for public health planning and assess-
ment at all levels. Analyses of these data should be performed
at least annually to determine morbidity, demographic char-
acteristics, and trends so that opportunities for targeted
screening for disease or infection can be identified. Regular
reviews of clinical data (e.g., collaborative formal case pre-
sentations and cohort analyses of treatment outcomes; com-
pleteness, timeliness and effectiveness of contact
investigations; and treatment of LTBI) may be used as
indicators of program performance.
Data should be collected and maintained in a secure, com-
puterized data system that contains up-to-date clinical infor-
mation on persons with suspected and confirmed cases and
on other persons at high risk. Each case should be reviewed at
least once monthly by the case manager and by field or
outreach staff to identify problems that require attention.
The TB-case registry should ensure that laboratory data,
including data on sputum culture conversion and drug sus-
ceptibility testing of clinical isolates, are promptly reported,
if applicable, to the health-care provider so any needed
modifications in management can be made. This requires a
communications protocol for case managers, providers, and
the public health and private laboratory systems that will
transmit information in a timely fashion. Aggregate pro-
gram data should be available to the health-care commu-
nity and to community groups and organizations with
specific interests in public health to support education and
advocacy and to facilitate their collaboration in the plan-
ning process.
Clinical and diagnostic services for patients with TB and
their contacts. TB-control programs should ensure that
patients with suspected or confirmed TB have ready access to
diagnostic and treatment services that meet national standards
(3,5). These services are often provided by state- or city-
supported TB specialty clinics and staffed by health depart-
ment personnel or by contracted service providers; however,
persons may seek medical care for TB infection or disease in
the private medical sector. Regardless of where a person
receives medical care, the primary responsibility for ensuring
the quality and completeness of all TB-related services rests
with the jurisdictional health agency, and health departments
should develop and maintain close working relations with
local laboratories, pharmacies, and health-care providers to
ensure that standards of care, including those for report-
ing, are met.
Clinical services provided by the health department, con-
tracted vendors, or private clinicians should be competent,
accessible, and acceptable to members of the community served
by the jurisdiction. Hours of clinic operation should be
convenient, and waiting intervals between referral and
appointments should be kept to a minimum. Persons with
symptoms of TB should be accommodated immediately
(i.e., on a walk-in basis). Staff, including providers, should
reflect the cultural and ethnic composition of the commu-
nity to the extent that this is possible, and competent clinical
interpreter services should be available to those patients
who do not speak English. All clinical services, including
diagnostic evaluation, medications, clinical monitoring, and
transportation, should be available without consideration
of the patient’s ability to pay and without placing undue
stress on the patient that might impair completion of
treatment.
Clinical facilities should provide diagnostic, monitoring,
and screening tests, including radiology services. Health-
care providers, including nurses, clinicians, pharmacists,
laboratory staff members, and public health officials, should
be educated about the use and interpretation of diagnostic
tests for TB infection and disease. Clinics and providers
should monitor patients receiving TB medications at least
monthly for drug toxicity and for treatment response,
according to prevailing standards of care (5). Counseling
and voluntary testing for HIV infection should be offered
to all persons with suspected and proven TB and to certain
persons with LTBI, with referral for HIV treatment ser-
vices when necessary. A case manager, usually a health
department employee, should be assigned to each patient
suspected or proven to have TB to ensure that adequate
education is provided about TB and its management, stan-
dard therapy is administered continuously, and identified
contacts are evaluated for infection and disease.
A treatment plan for persons with TB should be developed
immediately on report of the case. This plan should be
reviewed periodically by the case manager and the treating
clinician and modified as necessary as new data become avail-
able (219). The treatment plan should include details about
the medical regimen used, how and where treatment is to be
administered, monitoring of adherence, drug toxicity, and
clinical and bacteriologic responses. Social and behavioral
factors that might interfere with successful completion of
treatment also should be addressed.
Patient-specific strategies for promoting adherence to
treatment should take into account each patient’s clinical
and social circumstances and needs (5). Such strategies
might include the provision of incentives or enablers (e.g.,
monetary payment, public transportation passes, food,
housing, child care, or transportation to the clinic for vis-
its). Whether the patient’s care is managed by a public
health clinic or in the private sector, the initial strategy
used should emphasize direct observation of medication
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ingestion by an HCW. Patient input into this process (e.g.,
regarding medications to be taken or the location of DOT)
is often useful as it can minimize the burden of treatment
and provide the patient a degree of control over an antici-
pated lengthy course of therapy.
Expert medical consultation in TB should be available to
the health-care community, especially for patients who have
drug-resistant disease or medical diagnoses that might affect
the course or the outcome of treatment. Consultants may be
employees of the health department or clinicians with exper-
tise who are under contract with the health department.
Inpatient care should be available to all persons with sus-
pected or proven TB, regardless of the person’s ability to pay.
Hospitalized patients with suspected proven TB should have
access to expert medical and nursing care, essential diagnostic
services, medications, and clinical monitoring to ensure that
diagnostic and treatment standards are met. Inpatient facili-
ties that manage persons who are at risk for TB should have
infection-control policies and procedures in place to mini-
mize the risk for nosocomial spread of infection. Facilities
should report persons with suspected or confirmed TB to the
health department and arrange for discharge planning as
required by statute.
Public health agencies should have legal authority and
adequate facilities to ensure that patients with infectious TB
are isolated from the community until they are no longer
infectious. This authority should include the ability to
enforce legal confinement of patients who are unwilling or
unable to adhere to medical advice (218,220). This
authority also should apply to nonadherent patients who
no longer are infectious but who are at risk for becoming
infectious again or becoming drug resistant.
TB-control programs should serve as sources of informa-
tion and expert consultation to the health-care community
regarding airborne infection and appropriate infection-
control practice. A TB program’s presence raises overall pro-
vider awareness of TB and facilitates timely diagnosis, report-
ing, and treatment. Collaboration with local health-care
facilities to design and assist in periodic staff education and
screening is often a health department function. Expertise in
airborne infections by TB-control personnel may be shared
with biologic terrorism programs to assist in the design and
implementation of local protocols.
Contact investigation, including education and evalua-
tion of contacts of persons with infectious TB, is a key com-
ponent of the public health mandate for TB control. Often
the primary responsibility of the case manager, contact
investigation should proceed as quickly and as thoroughly
as indicated by the characteristics of the specific case and
by those of the exposed contact (e.g., young children or
immunocompromised persons). This statement includes
recommendations on organizing and conducting contact
investigations. TB-control programs that are prepared to
implement enhanced TB-control strategies should initiate
or facilitate implementation by other medical providers of
programs for targeted testing and treatment of persons with
LTBI on the basis of local epidemiologic data that identify
populations at high risk. A public health approach to this
activity is presented in this statement (see Essential
Components of TB Control in the United States).
Liaison with communities at high risk is critical to the
success of TB control in any jurisdiction. TB-control pro-
grams should develop strong lines of communication with
local community groups and organizations and their health-
care providers to understand local priorities and beliefs
about TB. Trusted community members can facilitate the
design and implementation of strategies to improve TB
diagnosis and prevention. Community-based clinical ser-
vices that use local providers who are educated in TB treat-
ment and prevention and who have a connection with the
TB-control program can improve community acceptance
of prevention and treatment of TB (221).
Training and education. TB-control programs should pro-
vide education and training in the clinical and public health
aspects of TB to all program staff. Staff members should
receive appropriate education at regular intervals on the basis
of their particular responsibilities in the program and should
demonstrate proficiency in those areas when tested. Public
health TB programs also should educate health-care provid-
ers (both public and private), community members, public
health officials, and policy makers on the basis of local epide-
miology and needs. To ensure the availability of a competent
workforce for TB that understands and meets the needs of its
community, state TB programs should use resources from
CDC-funded national TB centers, NIH-supported TB cur-
riculum centers, NTCA, and other national and local agen-
cies to create and implement education activities in
coordination with schools of medicine, nursing, pharmacy,
dentistry, and public health; community-based organizations
and their constituents; local health-care providers; and health-
care institutions (222). A Strategic Plan for Public Health Work
Force Development (223) and a Strategic Plan for Tuberculosis
Training and Education have been developed.
Information management. Information-management
systems are key factors in medical safety and quality
improvement (224,225) and should be prioritized by all
TB-control programs. Information technology can improve
care of patients with TB through standardized collection of
data; tracking of test results and details of treatment,
including administration of DOT; and prediction of
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interactions among medications. Information technology
can also facilitate analysis and rapid distribution of epide-
miologic data and the management of individualized treat-
ment plans (5) and support ongoing program performance
analyses. Barriers to successful implementation of informa-
tion technology include costs and resistance to change.
Monitoring and evaluation. The systematic monitoring
and analysis of program activities is a critical factor in
enhancing program performance. Evaluation techniques
provide TB programs with an evidence-based approach to
assess and improve their TB-control strategies by under-
standing what causes good or bad program performance.
Evaluation can also be used for program advocacy, assess-
ing staffing needs, training and capacity building, direct-
ing limited resources to the most productive activities,
accounting for available resources, generating additional
resources, and recognizing achievement (226).
Each public health agency should develop its own pri-
orities for program evaluation on the basis of the nature
and dimensions of the TB problem in its jurisdiction and
the way that services are organized. In general, the first
priority for evaluation efforts should be to focus on those
activities and outcomes that relate most directly to the key
strategies of TB control: detecting patients with infectious
TB and administering a complete course of treatment; find-
ing contacts and other persons at high risk with LTBI and
treating them; and interrupting transmission of
M. tuberculosis in high-risk settings (Box 4).
Targets for program performance have been established
by CDC (227) to assist public health agencies in treating
TB patients, protecting their contacts, and improving the
quality of case reporting for national surveillance (Table 4).
These national objectives for program performance provide
a starting point for state and local TB-control programs to
use for program evaluation, but each TB-control program
should establish methods to evaluate its performance.
TB case management has typically been evaluated by
reviewing individual charts and case conferences. However,
cohort analysis, a systematic evaluation of the treatment out-
comes of all TB cases during a stipulated period of time, is the
preferred means of determining the number and percentage
of cases that complete a course of treatment in <12 months.
Cohort analyses should be a cornerstone of evaluation by all
TB-control programs. A guide to cohort analysis and other
evaluation tools has been published (228). National
objectives have been set for completing treatment for LTBI
among contacts of infectious cases of TB (Table 4). Other
program areas that should be monitored through formal
evaluation methods include timeliness and completeness
of reporting of TB cases and suspected cases, frequency of
use of a recommended treatment regimen for patients with
TB and LTBI, and quality of the program’s databases for
surveillance and case management.
To respond to the need for improved and standardized pro-
gram evaluation activities, CDC and six state TB-control pro-
grams have established an Evaluation Working Group whose
goal is to improve the capacity of TB-control programs to
routinely conduct self-evaluations and use the findings to
improve and enhance their programs. The group is develop-
ing indicators for program performance and an inventory of
evaluation tools, including data collection instruments, data
analysis methods, and evaluation training materials. During
the next 2 years, a draft set of these materials will be tested in
three TB-control programs for utility, feasibility, and accu-
racy. Ultimately, this package of evaluation materials and
resources will be made available to all TB-control programs.
Public Health Workforce
No single model exists for staffing public health
TB-control programs. Approaches to TB control should be
flexible and adaptable to local needs and circumstances. Two
components of the public health workforce, public health
nurses and community outreach workers, merit specific
attention.
Public health nurses. Public health nurses are registered
nurses with a Bachelor of Science degree who are employed or
whose services are contracted for by health departments.
Certain states require certification for additional compe-
tencies before being hired as a public health nurse. Public
TABLE 4. National performance measures and objectives for
tuberculosis (TB) control
Objective Performance
Performance measure (2005)  (yr*)
Increase the percentage of TB patients 90% 80% 2000
who complete a course of curative
TB treatment in <12 months after initiation
of treatment (certain patients require
>12 months)
Increase the percentage of TB patients 95% 93% 2002
with initial cultures who also have drug
susceptibility results
Increase the percentage of contacts 61% 57% 2000
of persons with infectious (acid-fast
bacilli sputum smear-positive) TB who
are placed on treatment for latent
TB infection and complete a treatment
regimen
For TB case reports sent to CDC from 95% 73% 2002
states, increase the percentage in
which >90% of core data items are
complete
SOURCE: CDC. Final FY 2005 performance plan. Atlanta, GA: US
Department of Health and Human Services, CDC; 2005. Available at
http://www.cdc.gov/od/perfplan/index.htm.
* Most recent year for which data to determine performance are available.
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health nurses traditionally have played a prominent role in
TB control in the United States. Their training, including
that in nonmedical aspects of disease, has provided nurses
with the special skills needed to manage or coordinate the
medical and the social-behavioral concerns associated with
the prevention and treatment of TB (229). Their training
includes 1) designing contact and source-case investigations;
2) educating patients, contacts, and families; 3) identify-
ing ineffective drug therapy regimens and drug toxicities;
4) recognizing patient behaviors that might lead to poor
adherence; and 5) developing strategies to encourage
completion of therapy. As health departments adapt to
changing health-care environments, the role of public health
nurses working to control TB also is evolving to accommo-
date the varied mechanisms by which services are deliv-
ered. Standards of practice for TB nursing are being
updated by the National Tuberculosis Nurse Consultant
Coalition, a section of NTCA, to guide jurisdictions in cre-
ating and maintaining a specialized nursing resource for
TB control and prevention.
Community outreach workers. Community outreach
workers are staff members who provide services, such as DOT,
to patients outside of the clinic. They may also be classified as
disease investigation specialists or community health educa-
tors. Because TB has become concentrated in specific popula-
tions (e.g., foreign-born and homeless persons) in the United
States, outreach workers have assumed a key role in TB con-
trol. Often members of the communities they serve, outreach
workers connect the health-care system with populations at
high risk, ensuring that the principles and processes of TB
control are communicated to and understood by those popu-
lations. Outreach workers’ functions include facilitating treat-
ment for patients and contacts; providing DOT; educating
patients, their families, workplace personnel, and communi-
ties; and participating in contact investigations. In each case,
outreach workers form a bridge between patients and health-
care providers to achieve common understandings and accep-
tance of plans for diagnoses and treatment. Clinicians with
specialized expertise, including nurse-case managers, should
supervise outreach workers.
Clinicians
Clinicians in medical practice in the nonpublic health
sector play a vital role in TB control throughout the United
States. Hospital- or clinic-based medical practitioners,
including those working in emergency departments (EDs),
are usually the first source of medical care for persons with
TB (230–232); they also may provide ongoing manage-
ment for TB patients (48). The role of medical practitio-
ners in TB control will increase as TB morbidity in the
United States decreases and jurisdictions reduce or even
eliminate public health clinical services for TB.
Medical practitioners are often not sufficiently knowl-
edgeable about TB (233), and clinicians in private practice
frequently do not follow recommended guidelines and make
errors in prescribing anti-TB therapy (231,234,235). The fail-
ure of public health and private practitioners to interact effec-
tively is a weak link in global TB control (236). Successful
models exist for acknowledging and facilitating the work of
private medical practitioners in the complex process of diag-
nosing and treating persons with TB. For example, for each
reported TB case in New Mexico, a collaborative case-
management strategy is used that includes treating clinicians
and pharmacists from the private sector in addition to public
health case managers (48). Another model of effective private-
public partnerships was employed in NYC during the
1985–1992 TB resurgence, with health department case
management and DOT for patients under private care (13).
As TB elimination efforts continue, the role of medical prac-
titioners will further expand because they provide access to
populations that have been targeted for testing and treatment
of LTBI. Greater participation by the nonpublic health sector
in preventive intervention has been advocated (2,51), and clini-
cal standards have been published to guide medical practitio-
ners in managing patients with TB disease and LTBI (8).
Roles and Responsibilities of Clinicians
• Private medical practitioners should
— understand prevalent medical conditions, including
those with public health implications, of populations
within their practice;
— understand applicable state laws and regulations for
reporting diseases and the need to report cases;
— understand the range of responsibilities, statutory and
otherwise, that arise when TB is suspected in a patient
under medical evaluation, including 1) the need for
prompt establishment of diagnosis; 2) use of consult-
ants and hospitalization if indicated; 3) reporting the
suspected case to the jurisdictional public health agency
and cooperating with subsequent public health activi-
ties; and 4) developing, in partnership with the public
health agency, a treatment plan that optimizes the like-
lihood that the patient will complete the recommended
course of therapy;
— incorporate current recommendations for diagnosis
(3), standard treatment of TB (5), and targeted testing
and treatment of LTBI (4); and
— be able to place and read tuberculin skin tests, rule
out suspected TB disease (by clinical examination,
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history, and chest radiograph), and treat and moni-
tor treatment for LTBI.
• Providers of medical care for children and adolescents
should also
— use a questionnaire to screen all new patients for risk
factors for LTBI and give those with risk factors a
tuberculin skin test to be interpreted by a trained
health-care provider (237), and
— place and interpret tuberculin skin tests of family mem-
bers of children with LTBI when this service is not
otherwise accessible.
• Clinicians who administer treatment that can suppress
the immune system should administer a questionnaire
about risk factors for TB. If risk factors are present, a
tuberculin skin test should be administered and the result
obtained before or commensurate with starting
immunosuppressive therapy.
Civil Surgeons
Civil surgeons are licensed physicians who are certified
by the U.S. Citizenship and Immigration Service (CIS) to
conduct a required health screening examination, includ-
ing testing for LTBI and active TB disease, on foreign-born
persons living in the United States who apply for perma-
nent residency. In 2002, approximately 679,000 foreign-
born persons applied for permanent residency and were
screened by civil surgeons, compared with 245,000 such
persons in 1995 (238). CDC has responsibility for provid-
ing guidance on screening and treatment but has no regu-
latory role in monitoring the quality or outcomes of these
examinations.
Because of their access to foreign-born persons at high risk,
civil surgeons are a critical component of TB control.
U.S.-based immigration screening can identify foreign-born
persons with LTBI for whom treatment is indicated (239).
Although civil surgeons receive immigration-focused train-
ing, little information is available on the knowledge, attitudes,
and practices of civil surgeons. A recent survey indicated that
among 491 physicians serving as civil surgeons in California,
Massachusetts, and New York, the majority were graduates of
U.S. medical schools; 75% were primary care practitioners;
and 47% were board certified in their specialty. Among 5,739
foreign-born applicants examined by these civil surgeons,
1,449 (25%) received nonstandard screening (240). As a
result of these findings, efforts are under way to develop guid-
ance documents and training materials for physicians who
screen immigrants for TB infection and disease.
Roles and Responsibilities of Civil Surgeons
• Civil surgeons should
— understand current guidelines for the diagnosis (3)
and treatment of TB (5) and LTBI (4),
— establish a working relationship with the jurisdictional
health agency and report suspected and confirmed cases
of TB, and
— develop a referral mechanism for evaluation for TB
disease and LTBI of persons seeking adjustment of
immigration status.
Community Health Centers
Community health centers typically provide primary health-
care services to populations that encounter barriers to receiv-
ing those services at other sites in the health-care system, such
as low-income working persons and their families, immigrants
and refugees, uninsured persons, homeless persons, the frail
elderly, and poor women and children. Patients at high risk
for TB often receive primary and emergency health care in
community health centers (51). For example, community
health centers in certain inner-city areas might serve pri-
marily a clientele of homeless persons, whereas centers in
neighborhoods in which certain racial and ethnic popula-
tions are concentrated might become predominant health-
care providers for immigrants and refugees. Newly arriving
refugee families are frequently directed to community health
centers to receive federally supported health-screening ser-
vices, which might include targeted testing and treatment
for LTBI. Persons with symptoms of TB might go first for
evaluation and care to a community health center. For these
reasons, community health centers are a critical part of
efforts to control and prevent TB.
Roles and Responsibilities of Community
Health Centers
• Community health centers should
— provide their medical staff with the skills and knowl-
edge needed to conduct a TB risk assessment of their
clients, diagnose and initiate treatment for TB disease,
and diagnose and treat LTBI (241);
— develop close working relationships with consultant
physicians, hospitals, and clinical laboratories and with
the public health agency that serves their jurisdiction;
— arrange for reporting patients with suspected TB,
ensuring availability of diagnostic services (e.g., spu-
tum smears for AFB, cultures for M. tuberculosis, and
chest radiographs), and providing consultation and
referral of patients for diagnosis, treatment, and hospi-
talization, as indicated);
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— understand federal and state programs that support
screening, diagnostic, and treatment services for
patients at high risk and make prevention, diagno-
sis, and treatment of TB a high priority;
— work with public health agencies to educate patients
about the personal and public health implications of
TB and LTBI and motivate them to accept prevention
services; and
— establish recommended infection-control practices (10)
to protect patients and staff.
Hospitals
Hospitals provide multiple services that are instrumental to
the diagnosis, treatment, and control of TB. Hospitals with
active outpatient and EDs often serve as sites of acute and
primary medical care for homeless persons, inner-city resi-
dents, immigrants and refugees, and other persons at high
risk for TB. Also, hospital staff members often provide medi-
cal consultation services for the diagnosis and management of
TB by public health and community clinicians. Labora-
tory services provided by hospitals for community-based
medical care providers might include key diagnostic tests
for TB.
TB cases often are detected during hospitalization at acute-
care hospitals (230,242). In a prospective cohort study at
10 sites in the United States, 678 (45%) of 1,493 patients
reported with TB received their diagnosis during hospitaliza-
tion (230). Hospital-based health professionals evaluate
patients for TB, establish the diagnosis, and initiate treatment
regimens and reporting of cases to public health departments.
Instances of delayed recognition, diagnosis, and treatment for
TB among hospitalized patients subsequently found to have
TB have been reported (24,178), indicating a need for more
effective training and education of hospital medical staff
members.
Because 25%–45% of patients with TB receive their diag-
nostic evaluation while in a hospital (230,242), hospitals have
an opportunity to provide patient-based teaching on TB for
their own staff members and for health professionals from the
community served by the hospital. Venues such as staff con-
ferences and medical grand rounds, conducted regularly by
hospitals, can be sources of training and education on clini-
cal, laboratory, and public health concerns that arise during
evaluation and initial medical management of hospitalized
patients with TB.
Hospitals should protect their patients, staff, and visitors
from exposure to M. tuberculosis. The importance of effective
TB infection control was emphasized during the 1985–1992
TB resurgence in the United States, when hospitals were iden-
tified as sites of transmission of multidrug-resistant TB
(243). Implementation of effective infection-control guide-
lines has been effective in reducing transmission of TB in
hospitals (56,244,245).
Roles and Responsibilities of Hospitals
• Hospitals that deliver inpatient care for TB should
develop policies that ensure that patients suspected to have
contagious forms of the disease are isolated and that
effective infection-control measures are implemented.
Such hospitals should provide recommended TB-related
diagnostic testing and should ensure that patients receive
a standard treatment regimen (245).
• Hospitals should promptly report any patient with a sus-
pected or confirmed diagnosis of TB to the jurisdictional
public health agency. A written policy for discharging
patients with TB, developed in collaboration with the
public health agency, should be prepared. Certain states
have regulations stipulating that the jurisdictional public
health agency should approve discharge from hospital of
patients with TB. Patients with TB should be discharged
on a standard anti-TB regimen, and advance arrange-
ments should be made to ensure follow-up after dis-
charge. Close coordination between the hospital and
the jurisdictional public health agency can enhance
patient follow-up after discharge (5,56).
• Hospitals should develop a written policy and plan for
prevention of the nosocomial transmission of TB. Rec-
ommendations have been published to guide the devel-
opment of an infection-control plan (10) and are reviewed
in this statement. New guidelines for prevention of trans-
mission of M. tuberculosis in health-care settings will be
published by CDC in 2005.
• Hospitals should take responsibility for the training and
ongoing medical education of their medical and house
staff in the prevailing diseases of the populations to which
they provide care. When appropriate, education should
include the local epidemiologic profile of TB, the best
current diagnostic tests and recommended treatment regi-
mens, appropriate infection-control measures, and case
management responsibilities (i.e., reporting, protection
of contacts, importance of treatment until cure, and the
concept of public health case management).
Academic Institutions
Academic institutions (including schools of medicine,
public health, and nursing) have an opportunity to con-
tribute to TB control in the United States and worldwide.
Students from diverse disciplines, including the clinical and
laboratory sciences, nursing, epidemiology, and health ser-
vices should be introduced to applicable concepts of
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public health in general and, because TB is a major cause
of preventable illness and death in developing countries
(44), to TB in particular. During the resurgence of TB in
the United States during 1985–1992, expertise in TB was
limited. Federal funding for programs (e.g., the NIH
National Heart Lung Blood Institute’s Tuberculosis Aca-
demic Award program) helped provide funding to incor-
porate teaching of TB more fully into medical school
curricula. Researchers at academic institutions are critical
to efforts to improve the prevention, management, and con-
trol of TB because of their efforts to develop new tools,
including new diagnostic tests, new drugs, better means of
identifying and treating LTBI, and basic research to create
a vaccine for TB (180,246,247).
As with hospitals, academic institutions can provide ben-
efits to other participants in TB control. Conferences, grand
rounds, and other presentations are a source of continuing
education for private medical practitioners and other
community-based HCWs. As well-trained specialists,
researchers at academic institutions can provide clinical,
radiographic, and epidemiologic consultation to medical
practitioners and public health agencies. A majority of aca-
demic institutions manage university-based hospitals, which
often serve populations at high risk. University hospitals
can become models for TB risk assessment of patients,
inpatient care, and infection-control practice, and they can
serve as tertiary care sites for an entire community or region.
Partnerships between academic institutions and public
health agencies are mutually beneficial (248). In certain
cases, health departments and public health TB clinics are
staffed or managed by faculty physicians from academic
institutions. This partnership facilitates use of these clinics
for graduate medical training for physicians in subspecialty
areas (e.g., pulmonary and infectious diseases), enhances
training for clinic staff, and provides opportunities for
clinical and operational research.
Roles and Responsibilities of Academic
Institutions
• Academic institutions (including schools of medicine,
public health, and nursing) should incorporate TB edu-
cation into their curricula. Training and teaching programs
should include the routine applications of TB risk assess-
ment. Students and trainees in all medical disciplines
should understand and appreciate the importance and
roles of the primary and specialty medical care providers
and public health, including the necessary collaboration
between academic institutions and local, state, and
federal public health agencies.
• Academic institutions should serve as repositories of
expertise in the treatment and management of TB and as
a resource for public health and community-based
clinicians and other HCWs.
• Academic institutions should partner with public health
agencies to improve TB control. Partnerships are mutu-
ally beneficial. For academic institutions, partnerships
provide additional sites for education and training,
opportunities for clinical research, and, for patients with
TB, a systematic transition from hospital to outpatient
care, including DOT. Public health agencies gain expo-
sure to students and trainees, a ready source of referral for
consultation and management of complex medical prob-
lems, and research opportunities.
• Academic institutions should provide leadership in con-
ducting research in diagnostics, drugs, and vaccines for TB.
Medical Professional Organizations
Because they are involved with medical practice, research,
education, advocacy, and public health, medical professional
organizations are critical partners in TB control efforts.
Greater participation of the nonpublic health medical sec-
tor is needed to maintain clinical expertise in the diagnosis
and management of TB in an era of declining incidence.
Organizations whose memberships include primary care
medical practitioners can make significant contributions
to the control, prevention, and elimination of TB by
including TB in their training and education agendas.
ATS and IDSA both support TB control efforts in the United
States. With a membership of approximately 14,000 health
professionals, including clinicians trained in pulmonary dis-
eases, ATS conducts research, education, patient care, and
advocacy to prevent respiratory diseases worldwide. IDSA
promotes and recognizes excellence in patient care, education,
research, public health, and the prevention of infectious
diseases. In recent years, IDSA has joined ATS in focusing
education and advocacy activities on TB through its annual
meetings, publications, and sponsorship of this series of state-
ments.
Other medical professional organizations also can support
TB control efforts. Medical professional organizations can 1)
provide TB education to their members through meetings,
symposia, statements, and web sites; 2) serve as venues for
better communication between the private medical and pub-
lic health sectors; 3) promote the TB research agenda locally
and nationally; and 4) advocate for resources for strong TB
control globally and in the United States.
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Roles and Responsibilities of Medical
Professional Organizations
• Medical professional organizations should train and
educate their members and other health professionals
(e.g., private medical practitioners, nurses, epidemi-
ologists, laboratory specialists, or program administra-
tors) regarding the clinical and public health aspects
of the risk assessment, diagnosis, treatment, control,
and prevention of TB. Training and education can be
provided in traditional venues, such as scientific meet-
ings and symposiums, and electronically through web
sites. As continuing medical and nursing education is
now a prerequisite to licensure, medical professional
organizations are a convenient education resource for
the private medical community.
• Medical professional organizations should provide pro-
fessional leadership on clinical practice and control of TB
by participating in the development or endorsement of
guidelines, influencing professional school curricula, and
establishing and supporting fellowship training programs
as applicable.
• Medical professional organizations should provide
advocacy for adequate funding for TB control and
research through public education campaigns.
• Medical professional organizations should advocate the
importance of greater U.S. involvement in global control
of TB by linking U.S. health professionals with those from
other parts of the world at meetings and symposia,
including information on global TB in statements and
education materials, providing their members with
opportunities to serve as technical consultants, and par-
ticipating in special projects to support or improve TB
control in other regions of the world.
Community-Based Organizations
Involvement of community groups in TB control has long
been encouraged (17). The critical importance of such
involvement is underscored by the trend in the United States
for TB to be limited to certain populations at high risk (e.g.,
contacts of persons with active cases, persons born outside the
United States, homeless persons, incarcerated persons, and
persons with HIV infection). Programs for education and tar-
geted testing and treatment of LTBI should be organized for
these populations.
The public health sector frequently experiences difficulty
in gaining access to persons in populations of high risk (51).
Such persons might be socially marginalized, as in the case of
new refugees, or they might be suspicious of persons repre-
senting government agencies, as in the case of undocumented
aliens. Furthermore, the target population’s own view of
its health-care priorities, often best articulated by
community-based organizations that represent them, should
be considered in the design of public health interventions
(249). Social, political, religious, and health-related orga-
nizations that have arisen from grassroots efforts to meet
community needs often can facilitate access to public health
programs (221).
Community-based organizations can be particularly
effective in providing information and education on TB to
their constituencies. As part of the communities they serve,
such organizations are often highly regarded in their com-
munities, and their messages might be accepted more posi-
tively than those delivered by the jurisdictional health
department.
Roles and Responsibilities of Community-
Based Organizations
• Community-based organizations should be aware of
their constituents’ health risks. Organizations provid-
ing services to populations at risk for TB should part-
ner with the jurisdictional public health TB program
and medical care providers from the community to
facilitate access to diagnostic, treatment, and preven-
tion services for the target population. As resources allow,
organizations should provide assistance for treatment
services to their constituency (e.g., DOT, incentives
and enablers, and other outreach services).
• When serving a population at risk for TB, community-
based organizations should become involved in advocacy
initiatives, such as state and local TB advisory commit-
tees and coalitions.
• Community organizations serving populations at high risk
should work with public health agencies and educational
institutions to develop education materials that are
tailored culturally and linguistically to their populations.
Correctional Facilities
Correctional facilities are common sites of TB transmission
and propagation (250,251). Incidence of TB and of LTBI are
substantially higher in prisons and jails than in the general
population (252,253). TB is believed to be the leading cause
of death for prisoners worldwide (254).
Targeted testing for and treatment of LTBI in correctional
facilities have been demonstrated to have a substantial public
health impact (124). Testing and treatment for LTBI is car-
ried out more easily in prisons (255) because the length of
stay is generally sufficient to permit completion of a course of
treatment. Jails have proved convenient sites for targeted
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testing, but subsequent treatment of LTBI has proved chal-
lenging (256). Innovative methods for assuring comple-
tion of treatment for LTBI in jail detainees have been
proposed (257).
Because of their communal living arrangements, correctional
facilities, like health-care facilities, have the responsibility to
limit the transmission of TB within the institution and to
protect their inhabitants and staff from exposure. This is a
particular challenge in jails because of the short lengths of
stay for the majority of detainees. Even in prison systems,
abrupt and unexpected transfers of detainees among institu-
tions might occur, with little consideration for health issues.
Prisons and jails frequently house HIV-infected persons in
separate facilities to ensure adequate health care. However,
recent publications describing outbreaks of TB in such set-
tings have emphasized the hazard of this strategy (35,126).
Roles and Responsibilities of Correctional
Facilities
• Correctional facilities should work with the jurisdictional
public health agency to develop and maintain an accu-
rate epidemiologic profile of the risk for TB in the inmate
population.
• On the basis of the local epidemiology of TB, correc-
tional facilities should develop written policies to estab-
lish effective programs to screen for active TB, respond
promptly when cases occur within the facility, provide
targeted testing and treatment programs for inhabitants
and detainees with LTBI, and provide ongoing,
competency-based education of all staff members.
• Correctional facilities should establish ongoing working
relations with public health agencies, hospitals, and other
community partners for policy development, consulta-
tion and referral.
• Correctional facilities should develop firm linkages for
referral of persons under treatment for TB disease and
LTBI.
• Correctional facilities, following requirements of the
Occupational Safety and Health Administration and other
regulatory agencies, should develop infection-control pro-
grams to protect inhabitants, detainees, staff, and visitors
from exposure to TB (258). Correctional facilities should
continually evaluate the effectiveness of the institutional




Because of their essential role in developing new diag-
nostics, drugs, and vaccines, the pharmaceutical and
biotechnology industries are partners in TB control.
Although development of new tools for diagnosis, treat-
ment, and prevention of TB has been deemed essential to
the effort to combat the disease globally and to continue to
make progress toward its elimination in the United States
and other developed countries (1,2,45,259), progress in
these fields has been slow. Slow progress in this field has
been attributed to private industry’s perception that such
products are not needed in developed countries and do not
offer profit opportunities in resource-poor countries
(246,260). However, new public-private partnerships are
emerging to facilitate the development of essential new tools
(261), including three partnerships established with
support from the Bill and Melinda Gates Foundation: the
Global Alliance for Tuberculosis Drug Development (http://
www.tballiance.org), the Aeras Global Tuberculosis Vaccine
Foundation (http://www.aeras.org), and the Foundation for
Innovative New Diagnostics (http://www.finddiagnostics.org).
These organizations have provided venues to identify and
address obstacles to developing new tools for TB among
private industry, public and academic researchers, and phil-
anthropic organizations. These organizations also receive
support from the private sector.
The pharmaceutical industry has also contributed to the
global TB control effort by assisting in making drugs for TB,
including second-line drugs for patients with multidrug-
resistant TB, more affordable (262,263). Such actions can
enable pharmaceutical companies to become leaders in efforts




• The pharmaceutical and biotechnology industries should
— understand the dimensions of the global TB epidemic
and realize their key role in developing the necessary
tools for diagnosis, treatment, and prevention of TB;
— respond to the current surge of interest in TB globally
by reexamining the costs of new product development
and by considering potential new public and private
funding and the markets for such products in devel-
oping countries;
— contribute their perspectives and become involved in
coalitions such as NCET, the Global Partnership to
Stop Tuberculosis, the Global Alliance for Tuberculo-
sis Drug Development, and the Foundation for
Innovative New Diagnostics; and
— work with other stakeholders to ensure access of
essential products to those whose lives are at stake.
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Essential Components
of TB Control in the United States
Case Detection and Management
Case detection and case management include the range
of activities that begin when a diagnosis of TB is first sus-
pected and end with the completion of a course of treat-
ment for the illness. TB case management describes the
activities undertaken by the jurisdictional public health
agency and its partners to ensure successful completion of
TB treatment and cure of the patient. The rationale and
methodology of TB case management have been described
previously (5). Organizational aspects of case management
from the viewpoint of the jurisdictional public health agency
are also discussed in this statement.
Case detection includes the processes that lead to the pre-
sentation, evaluation, receipt of diagnosis, and reporting of
persons with active TB. Case detection involves patients with
active TB who seek medical care for symptoms associated with
TB, their access to health care, their health-care providers, the
consultants and clinical laboratories used by those health-
care providers, and the responsible public health agency.
Although steadily increasing treatment completion rates
(14) indicate that progress has been made in the manage-
ment of TB patients, TB case detection is still problematic.
Delays in diagnosis and report of TB cases continue to be
common. Also, despite the 44% reduction in TB incidence
in the United States since 1992, the proportion of pulmo-
nary cases that are sputum smear-positive at diagnosis has
changed little, accounting for >60% of all reported cases
(14). The majority of pulmonary TB cases continue to be
diagnosed at an advanced stage. Earlier diagnosis would
result in less individual morbidity and death, greater suc-
cess in treatment, less transmission to contacts, and fewer
outbreaks of TB. Improvement in the detection of TB cases
is essential to progress toward elimination of TB in the
United States (Box 1).
The first step in improving TB case detection is to remove
barriers in access to medical services that are often encoun-
tered by persons in high-risk categories. Such barriers might
be patient-related, such as cultural stigmas associated with the
diagnosis of TB, which might lead foreign-born persons to
deny or hide symptoms (264,265), or fear of being reported
to immigration authorities if medical care is accessed (19).
Foreign-born persons, particularly recently arrived immi-
grants, refugees, and other persons of low SES might not
have access to primary health services because they do not
have health insurance or they are not familiar with the U.S.
medical care system (20,118,266).
Removing patient-related barriers to health care is par-
ticularly difficult. Improved patient education about TB is
needed (18). Continuing immigration from countries at
high risk, often including persons with strong cultural views
about TB, underscores the need for patient education. As
with other interventions to enhance TB control and pre-
vention, local public health action should be based on the
local pattern of disease. In developing education messages
and outreach strategies, public health authorities should
work with organizations that serve communities at high
risk to gain community input (203). This statement pro-
vides recommendations on working with community-based
organizations, key informants, and academic institutions
to gain ethnographic information, learn about the health
beliefs and values of populations at high risk within the
community, and develop targeted interventions that will
be most effective.
The majority of TB cases are detected during the medi-
cal evaluation of symptomatic illnesses (19,267). Persons
experiencing symptoms ultimately attributable to TB usu-
ally seek care not at a public health TB clinic but rather
from other medical practitioners and health-care settings.
In 18 California counties with the highest TB morbidity of
persons during 1996–1997, initial points of entry into the
health-care system for persons who received a diagnosis of
TB were hospital inpatient evaluations (45%), private out-
patient offices or clinic evaluations (32%), TB clinic evalu-
ations (12%), and other sites (11%), including a non-TB
clinic in a health department and correctional facilities (Cali-
fornia Tuberculosis Controllers Association, unpublished
data, 2003). A similar pattern was observed in Washington
state. In Seattle and its suburban areas in 1997, primary
care practitioners or clinics reported 48% of TB cases dur-
ing evaluations of outpatients with symptoms and 32%
during hospital evaluations; only 2% of cases were diag-
nosed during a public health TB clinic evaluation for a symp-
tomatic illness (Seattle-King County Department of Public
Health, unpublished data, 1998).
These data indicate that the professionals in the primary
health-care sector, including hospital and ED clinicians, should
be trained to recognize patients with symptoms consistent with
TB. Dramatic reductions in TB were recorded in NYC (13)
and Baltimore (195) in association with extensive education
campaigns for health-care providers in the community. These
studies indicate the need to maintain clinical expertise for
the diagnosis and treatment of TB (24,41).
Because pulmonary disease among adults is most fre-
quently associated with the spread of TB, the following
discussion and recommendations regarding TB case detec-
tion are limited to considerations of pulmonary TB among
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adults. A classic set of historic features, signs, symptoms,
and radiographic findings occurring among adults should
raise a suspicion of pulmonary TB and prompt a diagnostic
investigation (3,189,267–271). Historic features include
exposure to TB, a positive test result for M. tuberculosis
infection, and the presence of risk factors such as immigra-
tion from a high-prevalence area, HIV infection,
homelessness, or previous incarceration. Signs and symp-
toms typical of TB include prolonged coughing with pro-
duction of sputum that might be bloody, fever, night
sweats, and weight loss. On a chest radiograph, the classi-
cal findings of TB in immunocompetent patients are upper-
lobe infiltrates, frequently with evidence of contraction
fibrosis and cavitation (270). However, these features are
not specific for TB, and, for every person in whom pulmo-
nary TB is diagnosed, an estimated 10–100 persons are
suspected on the basis of clinical criteria and must be
evaluated (272,273).
The clinical presentation of TB varies considerably as a
result of the extent of disease and the host response. In addi-
tion, variation in clinical symptoms and signs of TB is associ-
ated with underlying illnesses (e.g., HIV infection, chronic
renal failure, alcoholism, drug abuse, and diabetes melli-
tus). The signs of TB are also associated with race and
ethnicity and are attributed to unknown factors
(3,267,270). The chest radiograph among persons with
advanced HIV infection and pulmonary TB, for example,
might have lower-lobe and lobar infiltrates, hilar adenopa-
thy, or interstitial infiltrates (274). TB should be suspected
in any patient who has persistent cough for >2–3 weeks or
other compatible signs and symptoms as noted previously
(10,267,275).
In the drive toward TB elimination in the United States,
effective TB case detection is essential, and medical practi-
tioners should recognize patients in their practice who are
at increased risk for TB and be aware of the possibility of
diagnosing TB if they observe compatible symptoms. Guide-
lines have been provided for the initial steps of TB case
detection in five clinical scenarios encountered by provid-
ers of primary health care, including those serving in medi-
cal EDs (Table 5). In these settings, evidence exists to
support proceeding with a diagnostic evaluation for pul-
monary TB. The subsequent management of suspected cases
in these scenarios depends on the judgment of the medical
practitioner, in consultation with specialists in internal
medicine, pulmonary diseases, or infectious diseases if nec-
essary (5). These recommendations do not cover the spec-
trum of clinical presentations of pulmonary TB in adults
and are not meant to substitute for sound clinical judgment.
Cases of pulmonary TB also are detected through directed
public health activities designed to detect TB disease among
certain persons who have not sought medical care. Compared
with persons whose cases were detected passively by medi-
cal practitioners among patients who have sought medical
care, persons whose cases are detected actively are usually
in a less advanced stage of pulmonary disease, as manifested
by the absence of symptoms and by negative sputum AFB
smear results. Although no supporting literature exists, cases
detected in that stage of disease might be less advanced and
easier to cure.
TABLE 5. Guidelines for the evaluation of pulmonary tuberculosis (TB) in adults in five clinical scenarios
Patient and setting
Any patient with a cough of >2–3 weeks’ duration, with at
least one additional symptom, including fever, night sweats,
weight loss, or hemoptysis
Any patient at high risk for TB† with an unexplained illness,
including respiratory symptoms, of >2–3 weeks’ duration
Any patient with HIV infection and unexplained cough and
fever
Any patient at high risk for TB with a diagnosis of
community-acquired pneumonia who has not improved
after 7 days of treatment
Any patient at high risk for TB with incidental findings on
chest radiograph suggestive of TB even if symptoms are
minimal or absent§
Recommended evaluation
Chest radiograph: if suggestive of TB*, collect three sputum
specimens for acid-fast bacilli (AFB) smear microscopy and
culture
Chest radiograph: if suggestive of TB, collect three sputum
specimens for AFB smear microscopy and culture
Chest radiograph, and collect three sputum specimens for
AFB smear microscopy and culture
Chest radiograph, and collect three sputum specimens for
AFB smear microscopy and culture
Review of previous chest radiographs if available, three
sputum specimens for AFB smear microscopy and culture
* Infiltrates with or without cavitation in the upper lobes or the superior segments of the lower lobes. SOURCE: Daley CL, Gotway MB, Jasmer RM.
Radiographic manifestations of tuberculosis: a primer for clinicians. San Francisco, CA: Francis J. Curry National Tuberculosis Center; 2003:1–30.
†Patients with one of the following characteristics: recent exposure to a person with a case of infectious TB; history of a positive test result for
Mycobacterium tuberculosis infection; HIV infection; injection or noninjection drug use; foreign birth and immigration in <5 years from a region in which
incidence is high; residents and employees of high-risk congregate settings; membership in a medically underserved, low-income population; or a
medical risk factor for TB (including diabetes mellitus, conditions requiring prolonged corticosteroid and other immunosuppressive therapy, chronic
renal failure, certain hematological malignancies and carcinomas, weight >10% below ideal body weight, silicosis, gastrectomy, or jejunoileal bypass).
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Active efforts to detect cases of TB among persons who
have not sought medical care are routinely made during
evaluation of contacts of patients with pulmonary TB
(30,31,276) and of other persons with newly diagnosed
infection with M. tuberculosis (4). Screening for TB also is
performed during evaluation of immigrants and refugees
with Class B1 or Class B2 TB notification status (277–
279), during evaluations of persons involved in TB out-
breaks (34,35,136,172,280,281), and occasionally in
working with populations with a known high incidence of
TB (167,185). Screening for TB disease is indicated when
the risk for TB in the population is high and when the
consequences of an undiagnosed case of TB are severe (282),
such as in jails and prisons (253,283).
Screening for TB disease (i.e., active case finding) might
contribute substantially to overall TB case detection. A popu-
lation-based study from Los Angeles indicated that 30% of
reported TB cases during the period of study were detected
through screening activities (267). During 1998–2001, of 356
TB cases reported by the Seattle-King County TB Program,
40 (11%) were detected through active case detection in
contact investigation and evaluations of immigrants and
refugees with Class B1 and B2 TB notification status.
The clinical settings in which TB has been effectively
detected among persons without symptoms, the method-
ology of testing, and outcomes of the screening process have
been described (Table 6). On the basis of its very high yield
of detecting TB cases, domestic follow-up evaluation of im-
migrants and refugees with Class B1 and B2 TB notifica-
tion status should be given highest priority by all
TB-control programs. The yield of detecting TB cases dur-
ing screening at homeless shelters increased sharply in an
outbreak setting (Table 6). Although prevalence data from
individual studies are not available, investigations under-
taken to control TB outbreaks that involved diverse
settings and groups of immunocompetent and
immunocompromised persons have consistently been pro-
ductive in detecting TB cases and high rates of LTBI among
exposed persons (34,35,136,173,280,281). Outbreak
investigations should be counted among the settings in
which screening for active TB is recommended.
Contact Investigation and Outbreak
Control
Contact investigation is an essential function of TB con-
trol in the United States (Box 4) (1,17). The investigation
TABLE 6. Settings, methodologies, and outcomes for detecting tuberculosis (TB) in persons without symptoms
Cases detected/
Setting Methodology* Persons screened (%)
Correctional facility intake screening 3 0.07, 0.17†
Shelter-based screening of homeless men (routine setting) 1,2 0.18, 0.36§
Inner-city residents seeking social services 1,2 0.52¶
Contact investigations 1,2 1.0–3.0**
Shelter-based screening of homeless men (outbreak setting) 1,2,4 3.1, 4.3††
U.S.-based screening of immigrants and refugees with Class B1 and B2-TB notification status¶¶ 1,2,3 3.0–14.0§§
* 1 = patients were screened with questionnaire for symptoms of TB; if present, a chest radiograph was obtained; if radiograph was suggestive of TB, sputum
specimens were obtained for acid-fast bacilli (AFB) microscopy and culture; 2 = patients were screened with tuberculin skin test; if positive, chest radiograph
was obtained; if radiograph was suggestive of TB, sputum specimens were obtained for AFB microscopy and culture; 3 = patients were screened with chest
radiography; if radiograph was suggestive of TB, sputum specimens were obtained for AFB microscopy culture; and 4 = patients were screened by obtaining
sputum specimens for AFB microscopy and culture.
† SOURCES: Puisis M, Feinglass J, Lidow E, Mansour M. Radiographic screening for tuberculosis in a large urban county jail. Public Health Rep 1996;111:330–4;
Jones TF, Schaffner W. Miniature chest radiograph screening for tuberculosis in jails: a cost-effectiveness analysis. Am J Respir Crit Care Med 2001;164:77–81.
§ SOURCES: Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless. A prospective study. Am J Respir Crit Care Med
2000;162(2 Pt 1):460–4; Kong PM, Tapy J, Calixto P, et al. Skin-test screening and tuberculosis transmission among the homeless. Emerg Infect Dis
2002;8:1280–4.
¶ SOURCES: Schluger NW, Huberman R, Holzman R, Rom WN, Cohen DI. Screening for infection and disease as a tuberculosis control measure among
indigents in New York City, 1994–1997. Int J Tuberc Lung Dis 1999;3:281–6.
** SOURCES: Reichler MR, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA
2002;287:991–5; Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tubercu-
losis patients. Am J Respir Crit Care Med 2000;162:2033–8; Dasgupta K, Schwartzman K, Marchand R, Tennenbaum TN, Brassard P, Menzies D. Compari-
son of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000;162:2079–86.
†† SOURCES: Nolan CM, Elarth AM, Barr H, Saeed AM, Risser DR. An outbreak of tuberculosis in a shelter for homeless men. A description of its evolution
and control. Am Rev Respir Dis 1991;143:257–61; Kimerling ME, Shakes CF, Carlisle R, Lok KH, Benjamin WH, Dunlap NE. Spot sputum screening:
evaluation of an intervention in two homeless shelters. Int J Tuberc Lung Dis 1999;3:613–9.
§§ SOURCES: Sciortino S, Mohle-Boetani J, Royce SE, Will D, Chin DP. B notifications and the detection of tuberculosis among foreign-born recent arrivals in
California. Int J Tuberc Lung Dis 1999;3:778–85; CDC. Recommendations for prevention and control of tuberculosis among foreign-born persons: report of
the Working Group on Tuberculosis Among Foreign-Born Persons. MMWR 1998;47(No. RR-16):1–29; Zuber PL, Knowles LS, Binkin NJ, Tipple MA,
Davidson PT. Tuberculosis among foreign-born persons in Los Angeles County, 1992–1994. Tubercle Lung Disease 1996;77:524–30.
¶¶ Persons with TB disease are classified as having suspected active noninfectious (Class B1) or inactive (Class B2) TB notification status.
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of a case of TB results in identifying approximately 10 con-
tacts (284). Among close contacts, approximately 30% have
LTBI, and 1%–3% have progressed to TB disease (30,284).
Without intervention, approximately 5% of contacts with
newly acquired LTBI progress to TB disease within 2 years
of the exposure (285). The prevalence of TB among close
contacts is approximately 1,000/100,000 population
(>100-fold higher than in the general population) (285).
Examination of contacts is therefore one of the most
important activities for identifying persons with disease and
those with LTBI who have a high risk for acquiring TB disease.
Transmission of M. tuberculosis has occurred in health-
care facilities (286,287), bars (134,288), doctors’ offices
(289), airplanes (290), crack houses (291), respite facili-
ties that provide care for HIV-infected persons (136), drug
rehabilitation methadone centers (36), navy ships (292),
homeless shelters (120), schools (173), church choirs (140),
and renal transplant units (141). The utility and impor-
tance of contact investigations in those settings and also for
populations at high risk (e.g., foreign-born persons [293],
children [294–297], and persons exposed to multidrug-
resistant TB cases [91,298]) has also been documented.
In the United States, state and local public health agen-
cies perform 90% of contact investigations as part of the
public health mandate for TB control (Box 5) (2). Public
health TB-control programs are responsible for ensuring
that contact investigations are conducted effectively and
that all exposed contacts are identified, provided with
access to adequate care, and followed to completion of
therapy. For health agencies to fully discharge this responsi-
bility, adequate funding and political commitment are required.
Health agencies use a general epidemiologic framework
for contact investigations (299). However, this approach
alone might have limited effectiveness because of factors
such as initial diagnostic delays and failure to ensure
completion of therapy for LTBI. Consequently, programs
have recognized the necessity of widening traditional con-
tact investigation sites to include nonhousehold locations
(e.g., homeless shelters, correctional facilities, nursing
homes, and hospices that serve HIV-infected persons) and
households. Genotyping studies have documented that tra-
ditional contact investigation methods have failed to iden-
tify contacts or detect transmission of M. tuberculosis
(28,33,34,151,172). As a result, IOM (2) and ACET (1)
have called for the development and implementation of
enhanced techniques for contact investigation.
The primary goal of a contact investigation is to identify
persons who were exposed to infectious M. tuberculosis and
ensure that they are tested for M. tuberculosis infection,
screened for TB disease, are followed up, and complete a
standard course of treatment, if indicated. Secondary goals
are to stop transmission of M. tuberculosis by identifying
undetected patients with infectious TB and to determine
whether a TB outbreak has occurred. In that case, an
expanded outbreak investigation should ensue.
Steps of a Contact Investigation
State and local public health agencies, often represented
by TB-control programs, are responsible for initiating and
conducting contact investigations and evaluating their out-
comes to ensure their effectiveness. A contact investigation
has 14 steps, as follows:
1. Setting priorities. A contact investigation is considered
once a suspected or confirmed case of TB comes to the
attention of the jurisdictional TB-control program. At
that time, a decision should be made about the priority
of that investigation among other TB-control activities.
Not all cases of TB require a contact investigation, and
certain investigations will have greater priority than
others. Priorities should be decided on the basis of
the characteristics of the source-case, of the
environment of the place(s) of exposure, and of the
contacts. The three most important categories of
information used to establish priorities for cases for
contact investigations are 1) the site of disease, 2)
the results of sputum AFB smears and NAA testing,
and 3) the findings on the chest radiograph. In
general, patients with pulmonary TB, positive
sputum AFB smear results, and cavitation noted on
a chest radiograph are more infectious and therefore
have a higher priority for contact investigation. The
use of an NAA test is helpful in rapidly differentiating
between pulmonary disease caused by M. tuberculosis
and nontuberculous mycobacteria, thus avoiding
unnecessary contact investigations. Persons with
pulmonary TB who have negative sputum AFB smear
results tend to be less infectious, and their contacts
should be investigated, but with lower priority.
Contacts of patients with extrapulmonary TB should
be evaluated if the patient has concurrent pulmonary
or laryngeal disease, the contacts are at increased risk
for acquiring TB disease (e.g., children aged <5 years
and HIV-infected persons), or the patient has pleural
TB (300). Pleural TB is a manifestation of primary TB
and often occurs among persons who have been
recently infected. In addition, persons with pleural
TB can have positive sputum AFB smear results.
Children aged <5 years with TB, regardless of the
site of disease, should have a contact investigation to
identify the source-case.
36 MMWR November 4, 2005
2. Defining the beginning and end of the period of
infectiousness. Before a contact investigation can be
started, the period of infectiousness of the index case
should be determined. This period sets the limits for
the investigation, allows for setting priorities for contacts
within the designated timeframe, and determines the
scheduling for follow-up tests. Exactly when a patient
becomes infectious is unknown; the usual assumption
is that the patient becomes infectious approximately
3 months before diagnosis; however, it might be longer,
depending on the history of signs and symptoms,
particularly cough and the extent of disease. The end of
the period is defined as the time when contact with the
index case is broken or when all of the criteria for
determining when during therapy a patient with
pulmonary TB has become noninfectious (Box 3) are
met. Patients with multidrug-resistant TB who are on
inadequate therapy or who have persistently positive
sputum AFB smear or culture results might remain
infectious for a prolonged period of time. Those
patients, if not in effective isolation, should be
reassessed for new contacts as long as they remain
infectious.
3. Medical record review. For potential transmission
risk and infectiousness of a case to be assessed, all
currently available information about the reported
case or suspect is obtained through case medical
record reviews, conversations with the health-care
provider or other reporting source, and laboratory
report reviews. This information can be disclosed by
covered entities for public health activities as provided
by the Privacy Rule of HIPAA (217).
4. Case interview and reinterview. The patient interview
may be conducted in the hospital, at the patient’s home,
or wherever convenient and conducive to establishing
trust and rapport. The ability to conduct an effective
interview might determine the success or failure of the
contact investigation. All persons with whom the patient
has been in close contact and the locations that the
patient commonly frequents should be identified. Good
interviewing skills can elicit vital information that
otherwise might not be forthcoming. For different
reasons (e.g., stigmatization, embarrassment, or
involvement in illegal activities), patients might be
reluctant to identify contacts or places they frequent.
Developing an ability to interview patients effectively
so as to elicit contacts requires training and periodic
review by supervisors, and only trained personnel should
interview patients. A patient should be interviewed
as soon as possible after notification and
reinterviewed 1–2 weeks later to clarify data or obtain
missing data. When possible, the second interview
should be conducted at the patient’s primary
residence. Also, all interviews should be conducted
in the patient’s primary language and with sensitivity
to the patient’s culture.
5. Field investigation. Field investigations enable
investigators to 1) interview or reinterview identified
contacts and obtain an adequate medical history to
evaluate previous exposure to TB, existence of prior
M. tuberculosis infection, existence of disease and
treatment, risk factors for acquiring TB, and symptoms;
2) obtain locator information; 3) apply a tuberculin
skin test to identified contacts (the role of QFT-G in
the assessment of contacts has not been determined);
4) observe contacts for any signs or symptoms suggestive
of TB; 5) schedule subsequent medical evaluations and
collect sputum samples from any contact who is
symptomatic; 6) identify sources of health care and make
referrals; 7) identify additional contacts who might also
need follow-up; 8) educate contacts about the purpose
of the investigation and the basics of TB pathogenesis
and transmission; 9) observe the contact’s
environment for possible transmission factors (e.g.,
crowding and poor ventilation); 10) assess contacts’
psychosocial needs and other factors that might
influence compliance with medical recommendations;
and 11) reinforce confidentiality. Visits to the
exposure site(s) should be conducted as soon as
possible. Contacts at higher risk for disease progression
and more severe disease (e.g., young children and
HIV-infected persons) require the most rapid follow-up.
Transmission sites might involve social networks not
customarily considered in traditional contact
investigations. For example, in certain TB cases reported
separately in different communities, participation in a
church choir was identified as a common factor (140).
The contact investigation failed to identify the source-
patient’s choir contacts, resulting in secondary cases of
TB. In an outbreak associated with a floating card game,
the outbreak was propagated because a network of
persons engaged in illegal activities was not identified
(172). These examples demonstrate the importance of
congregate activities beyond work and socially defined
high-risk contacts.
6. Clinical evaluation of contacts. All close contacts of
patients with pulmonary or laryngeal TB and a positive
culture result for M. tuberculosis or a positive sputum
AFB smear result should receive a tuberculin skin test
unless they have documentation of a previously
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positive test. Highest priority for tuberculin skin
testing and follow-up evaluation should be given to
1) contacts identified as being at highest risk for
recent infection on the basis of their history of
exposure to the case-patient and risk for transmission
and 2) those at high risk for progression from
M. tuberculosis infection to TB disease (e.g., infants,
young children, HIV-infected persons, and other
persons whose medical conditions predispose them
to progress from infection to disease). Among children
and infants, children aged <3 years are at greatest
risk for rapid progression and should receive the
highest priority for all preventive interventions for
contacts. For the greatest level of protection of
children exposed to TB to be ensured, all children
aged <5 years should be considered to be high-risk
contacts.
Regardless of where the tuberculin skin test is
performed (e.g., field visit, TB clinic, or referral site),
arrangements should be made to ensure that the skin
test is read within 48–72 hours. Contacts who have
tuberculin skin test reactions >5 mm and who have
no history of a prior positive result are considered at
risk for newly acquired M. tuberculosis infection. Those
persons should receive a chest radiograph and medical
evaluation for TB disease. Adults and children aged >5
years should receive a single posterior-anterior
radiograph (4); children aged <5 years should receive
both posterior-anterior and lateral TB radiographs (4).
The following contacts should have a chest radiograph
regardless of skin test result: 1) persons with symptoms
of TB; 2) persons who are immunosuppressed or who
have other risk factors for progression from
M. tuberculosis infection to TB disease; and 3) children
aged <5 years.
The presence of HIV coinfection might affect decisions
about subsequent management of contacts (e.g.,
prescribing prophylactic treatment and completing
treatment for LTBI regardless of results of a tuberculin
skin test). An HIV-infected contact also should be
effectively counseled about the substantial risk for
disease progression and the need to accept and adhere
to a course of treatment for LTBI. Although contacts
of HIV-infected persons with TB have substantial risk
for HIV infection themselves, contacts of TB cases
without HIV infection have low rates of HIV infection
(301), suggesting that offering HIV testing to all
contacts might not be cost-effective. The decision should
be based on local data demonstrating that contacts of
TB cases are at high risk for HIV infection (i.e., the
contacts have a prevalence of HIV infection of >1%
[302]). The local epidemiology of TB, HIV infection,
and TB/HIV coinfection also may be used as a basis for
the decision. If resources are limited, and if local data
indicate that HIV infection contributes only minimally
to the TB problem (i.e., the HIV seroprevalence of
contacts is likely to approach 0.1% of the general U.S.
population), then the highest priority for voluntary HIV
counseling and testing should be assigned to contacts
of HIV-infected persons with TB and those who have
identified risk factors for HIV (303).
Contacts who have a documented prior positive
tuberculin skin test and who are not known or likely to
be immunocompromised generally do not require
further evaluation unless they have symptoms suggestive
of TB disease. However, candidates for treatment of
LTBI on the basis of other criteria (4) should first receive
a medical evaluation, including a chest radiograph, to
exclude TB. Contacts with a negative tuberculin skin
test should be retested approximately 8–12 weeks after
the first test unless the initial skin test was performed
>8 weeks after the contact’s last exposure to the index
patient. Every 3 months, all contacts with negative skin
test results who remain in close contact with an
infectious patient should receive a repeat tuberculin skin
test and, if symptoms of TB disease are present, a chest
radiograph. A contact whose repeated test is positive
(>5mm) should receive a chest radiograph if one has
not been taken recently. If the radiograph is normal,
the contact should be evaluated for treatment of LTBI;
if it is abnormal, the patient should be evaluated for TB
disease or other cause of the abnormality.
TB-control programs should find and evaluate all
persons who have had sufficient contact with an
infectious TB patient to become infected. Contacts at
high risk (e.g., infants, young children, and HIV-
infected persons) should be identified and evaluated
rapidly to prevent the onset of serious, potentially life-
threatening complications (e.g., TB meningitis). In
certain jurisdictions, legal measures have been put in
place to ensure that contact evaluation and follow-up
occurs (304). The use of existing communicable disease
laws should be considered for contacts that fail to
comply with the examination requirements. All contacts
should be assessed routinely for obstacles to their
participation in the evaluation process. Any structural
barrier that impedes the ability of the patient to access
services (e.g., inconvenient clinic hours or location, work
or family obligations, and lack of transportation)
should be addressed.
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7. Treatment of contacts with LTBI. Contacts with
LTBI should be treated unless compelling
contraindications exist. For completion of therapy to
be ensured, contacts should be placed on DOT
whenever possible. If resources do not allow that all
infected contacts receive DOT, priority should be
assigned to 1) children aged <5 years; 2) contacts
with HIV infection; 3) other contacts with risk factors
for progression to TB disease (4); 4) contacts with
documented skin test conversion; and 5) contacts of
patients with positive sputum AFB smear results and
cavities on chest radiography. Contacts on self-
administered therapy should be monitored monthly
by personal interview for adverse effects and adherence
until treatment is completed.
8. Primary prophylaxis of high-risk contacts. Because
tuberculin skin test results might take 8–10 weeks to
become positive after infection with M. tuberculosis, a
contact’s initial skin test result might be negative even
if the person is infected. A second test should be placed
8–12 weeks after the contact’s last exposure to the
infectious patient, so the possibility of LTBI for those
persons can be better evaluated. During the 8–12
week window period between a first and second skin
test, the following contacts with initially negative
tuberculin skin test results should receive treatment
for LTBI after TB disease has been ruled out by clinical
examination and chest radiograph: 1) contacts aged
<5 years (with highest priority given to those aged
<3 years) and 2) contacts with HIV infection or who
are otherwise immunocompromised (4). If the second
skin test result is negative (<5 mm), the contact is
immunocompetent (including immunocompetent
young children) and no longer exposed to infectious
TB, treatment for LTBI may be discontinued, and
further follow-up is unnecessary. If the second skin
test is negative but the contact is
immunocompromised (e.g., with HIV infection), a
course of therapy for LTBI should be completed. If
the second skin test result is negative but the person
remains in close contact with an infectious patient,
treatment for LTBI should be continued if the contact
is 1) aged <5 years; 2) aged 5–15 years, at the
clinician’s discretion; or 3) HIV-seropositive or
otherwise immunocompromised.
9. Expanding the contact investigation. Defining the
extent of the contact investigation is the responsibility
of the investigating TB-control program. Once testing
of high-priority contacts is completed, the extent of
transmission of M. tuberculosis should be evaluated.
Consideration can then be given to expanding the
investigation to include contacts at lower risk for
infection. In general, the contact investigation need
be expanded only if excessive transmission is detected,
on the basis of the following criteria: 1) secondary
cases of TB are identified in contacts; 2) documented
skin test conversions exist; and 3) comparison of skin
test positivity among contacts with available data on
the baseline prevalence of skin test positivity in the
population indicates the probability of transmission.
When a contact investigation is expanded, resources
should continue to be directed to persons identified as
being at greatest risk. In any case, the total contact-
tracing process should be completed <3 months after
initiation of the investigation, unless evidence of
transmission requires further expansion of testing.
10. Data management and use in decision-making.
Maintenance of data is crucial to all aspects of the
contact investigation. Protocols should be developed to
maximize the efficiency of the process, given available
resources. Data should be collected for cases and contacts
by using standardized forms (paper or electronic) with
standard definitions and formats, according to national
guidelines (305). Data elements should mirror those
collected by the states and CDC, but individual
jurisdictions may elect to expand the data elements.
11. Evaluation. Contact investigation steps should be
adequately documented, so the process can be
monitored and evaluated. National performance
measures for TB control stipulate that programs should
complete treatment of LTBI among 61% of contacts of
infectious TB cases (Table 4). Additional parameters
should also be tracked and evaluated. Programs should
determine whether the indications given previously for
conducting a contact investigation are applied to all
reported cases. In addition, for each TB case that is
investigated, the number of contacts identified should
be recorded. For each contact identified, outcomes to
monitor include 1) whether the contact evaluation took
place (including placing and reading the first and second
tuberculin skin tests, if applicable) and was completed
and 2) whether the recommended protective
interventions (including screening for TB disease,
treatment for LTBI, and prophylaxis within the
window period) were offered, accepted, started, and
completed. Results of the evaluation should be
aggregated and recorded for stipulated intervals of
time, as follows: 1) among identified contacts, the
number and percentage that were referred for
evaluation; 2) among those referred, the number and
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percentage that completed evaluation; 3) among
those evaluated, the number and percentage eligible
for treatment of LTBI; and 4) among those eligible,
the number and percentage that started and
completed treatment.
Surveillance of individual contacts is not conducted
routinely in the United States. However, CDC collects
aggregate data on the outcomes of contact investigations
from state and local TB control programs through the
Aggregate Report for Program Evaluation. Routine
collection and review of these data can provide the basis
for evaluation of contact investigations for TB control
programs.
12. Education and training for contact investigations.
The education needs for all aspects of the investigation
process (including medical abstraction, patient
interviewing, cultural competency, maintaining patient
confidentiality, and how to perform tuberculin skin
testing) should be continuously assessed. All involved
staff should receive ongoing training. CDC-funded
regional training centers offer training courses in contact
investigation and interviewing skills.
13. Confidentiality. Maintaining confidentiality is a
critical component of the contact investigation
process. Guidelines for release of confidential
information related to conducting contact
investigations should be developed. An example of
appropriate release of confidential medical
information is the release of an index case patient’s
drug susceptibility test results to a clinician caring
for a contact with LTBI or one who has progressed to
active TB.
14. Contact investigations among special populations.
Contact investigations often are conducted among
special populations or locations (e.g., homeless shelters,
correctional facilities, HIV residential facilities, schools,
worksites, health-care facilities, active drug users, and
living along the U.S.–Mexico border). Guidelines
offering specific recommendations for contact
investigations under these circumstances have been
published (305).
Outbreak Investigations
Failure to recognize an increase in the occurrence of TB
(162) or to expand a contact investigation when needed can
result in continued transmission of TB. Missed epidemiologic
links among patients with TB can have severe consequences
as evidenced in an outbreak associated with a floating card
game in the rural south (172) and an outbreak in Kansas
among exotic dancers and their close contacts that occurred
during a 7-year period (38).
When TB occurs with high incidence, clusters of cases
that have epidemiologic links likely occur constantly but
tend to blend into the generally high morbidity (306). In
a low-incidence setting, however, clusters of linked TB cases
can be identified more readily. Three criteria have been
established to determine that a TB outbreak is occurring
(162): 1) an increase has occurred above the expected num-
ber of TB cases; 2) transmission is continuing despite
adequate control efforts by the TB-control program; and
3) contact investigations associated with the increased cases
require additional outside help.
TB outbreaks have occurred in low-incidence areas in which
expertise and experience in dealing with such outbreaks might
be lacking. Such outbreaks have occurred among different
populations and settings, including a young foreign-born child
in North Dakota (25); exotic dancers and their contacts in
Kansas (38), homeless persons in Syracuse, New York (120);
factory workers in Maine (188); and limited, seemingly unre-
lated clusters of cases that were the cause over time of
perpetuating transmission in Alabama (307).
For an increase in the expected number of TB cases (the
first criterion of an outbreak) to be identified, the local
epidemiology of TB should be understood. Detection of a
TB outbreak in an area in which prevalence is low might
depend on a combination of factors, including recognition
of sentinel events, routine genotype cluster analysis of sur-
veillance data, and analysis of M. tuberculosis drug-resistance
and genotyping patterns.
When an outbreak is identified, short-term investigation
activities should follow the same principles as those for the
epidemiologic part of the contact investigation (i.e., defining
the infectious period, settings, risk groups, mode of transmis-
sion, contact identification, and follow-up). However, long-
term activities require continued active surveillance,
M. tuberculosis genotyping, additional contact investigations
and related follow-up for additional cases, and continuing edu-
cation of providers, staff, and patients. Consequently, a plan
for long-term support should exist from the outset of the
investigation.
A written protocol should be developed. At a minimum,
the protocol should outline the outbreak response plan,
including indications for initiating the plan, notification pro-
cedures, composition of the response team, sources of staff-
ing, plan for follow-up and treatment of contacts, indications
for requesting CDC assistance, and a process for evaluation
of the outbreak response. The outbreak response plan should
also include information on how to work strategically with
the media during the public health emergency. CDC offers
training packages to assist public HCWs in media commu-
nications, including emergency and crisis communication.
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This training emphasizes prevent planning, event response
activities, and post-event follow-up. Information on public
health communication programs is available at http://
www.cdc.gov/communication/cdcynergy.htm.
Targeted Testing and Treatment
of LTBI
An estimated 9.5–14.7 million persons in the United States
have LTBI (39). Continued progress toward eliminating TB
in the United States and reducing TB among foreign-born
persons will be impossible without devising effective strate-
gies to meet this challenge. Guidelines on targeted testing and
treatment of LTBI have been published (4) and revised (308).
Those guidelines include recommendations for diagnosing LTBI
and treating infected persons, limiting the possibility of treat-
ment-associated hepatotoxicity, and identifying persons and
populations to target for testing. A new diagnostic test for LTBI,
QFT-G, has been approved by FDA, and guidelines for its use
will be published by CDC. This section outlines a recommended
approach to planning and implementing programs for tar-
geted testing and treatment of LTBI to create an effective
public health tool for communitywide prevention of TB.
Targeted testing and treatment of persons with LTBI is
not a new concept for the prevention of TB in the United
States (309). The effectiveness of treating LTBI among
populations at high risk has been established in clinical
trials (285), but this intervention has not been proven to
have an impact on the incidence of TB in the United States.
Theoretically, the epidemiologic impact would be consid-
erable if cases of TB in a population were largely the result
of progression of LTBI and if all persons at high risk with
latent infection could be identified and treated success-
fully. Practically, those circumstances rarely exist. In the
United States, the effectiveness of targeted testing and treat-
ment of LTBI as a public health measure has been limited
by concern for the side effects of treatment (notably
hepatotoxocity) (310), poor acceptance of the intervention
among health professionals (311), and poor adherence
among patients to the lengthy course of treatment (45,312).
Two approaches exist to increasing targeted testing and
treatment of LTBI. One is to promote clinic-based testing
of persons who are under a clinician’s care for a medical
condition (e.g., HIV infection or diabetes mellitus) that
also confers a risk for acquiring TB. This approach, which
depends on a person’s risk profile for TB and not on the
local epidemiology of the disease, requires education of
health-care providers and depends ultimately on their ini-
tiative. Although difficulties exist in quantifying and evalu-
ating its effectiveness, this approach could conceivably
become a useful tool to reduce the incidence of TB among
foreign-born and other persons at high risk because they
can be accessed conveniently where they receive primary
health-care services. The other approach is to establish spe-
cific programs that target a subpopulation of persons who
have a high prevalence of LTBI or who are at high risk for
acquiring TB disease if they have LTBI, or both. This
approach presumes that the jurisdictional TB-control agency
has identified the pockets of high TB risk within its juris-
diction through epidemiologic analysis and profiling (313–
316). Those high-risk pockets might consist of foreign-born,
homeless, or HIV-infected persons, or they might be geo-
graphic regions (e.g., a neighborhood within a city or town)
or specific sites (e.g., a homeless shelter or an HIV-housing
facility).
The epidemiologic profile should include an assessment
of the risk for TB in the population or at the site, the ease
of access to the population or site, and the likelihood of
acceptance of and adherence to targeted testing and treat-
ment. For this assessment to be facilitated, populations at
high risk may be separated into three tiers (Box 6). Assign-
ment of groups to these three tiers is based on six criteria:
1) incidence of TB; 2) prevalence of LTBI; 3) risk for
acquiring TB disease if the person is infected with
M. tuberculosis; 4) likelihood of accepting treatment for LTBI
BOX 6. Priority population subpopulations and sites for targeted
testing and treatment of latent tuberculosis (TB) infection
Tier 1
• Persons working in or served by clinics or community
health organizations providing care to HIV-infected
persons
• Prisoners
• Legal immigrants and refugees with Class B1 and B2
TB notification status
• Recently-arrived refugees
• Other well-defined groups in congregate living facilities
• Persons enrolled in substance abuse treatment programs*
Tier 2
• Jail detainees
• Persons working or living in homeless shelters
• Immigrants reporting for adjustment of status
Tier 3
• Other foreign-born persons at high risk (i.e., those that
immigrated <5 years from countries with a high inci-
dence of TB)
* Persons enrolled in substance abuse treatment programs should be
considered a transition group between Tier 1 and Tier 2, depending on
the local epidemiology of tuberculosis.
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and adhering to it; 5) ease of access to the population; and
6) in a congregate setting, the consequence of transmission
of M. tuberculosis.
Tier 1 is made up of well-defined populations at high
risk that can also be conveniently accessed and followed,
either in locations such as clinics or community health cen-
ters, prisons, or other congregate living sites or through
mandatory registration. Persons in this tier often have a
high prevalence of TB and LTBI (immigrants and refugees
with Class B TB notification status), an increased risk for
TB disease if infected with M. tuberculosis (persons with
HIV infection), or both (certain homeless and detained
populations). The consequences of the spread of TB in con-
gregate settings increase the necessity of preventive action.
Location-based, high-risk communities in Tier 1 are, for
the most part, readily identifiable and easily accessible;
often have their own resources; and generally include the
probability of access for a long enough period to permit
completion of treatment for LTBI. These populations should
be the first priority for targeted testing programs.
Persons enrolled in substance-abuse treatment centers
may be considered transitional between Tier 1 and Tier 2,
depending on local epidemiologic and demographic fac-
tors. Substance abusers might have a high prevalence of
LTBI. Injection drug users also might have an increased
risk for acquiring TB if they are infected with M. tuberculosis
and at increased risk for HIV infection (317). Access and
factors related to acceptance and completion of therapy also
might vary by location. Typically, substance abuse treat-
ment centers that include long-term inpatient treatment
or regularly scheduled appointments (e.g., methadone
treatment centers) are the best choices for intervention
because ease of ongoing access allows sufficient time for
completion of therapy. Voluntary HIV counseling and test-
ing should be offered routinely as part of any targeted testing
program among this population.
Populations in Tier 2 also include identifiable and acces-
sible populations made up of persons at high risk, but the
distinguishing characteristic is that obtaining satisfactory rates
of completion of treatment for LTBI might be difficult
because of dispersal of the population throughout a larger
community or a brief duration of residency in congregate
settings. For example, in Atlanta, Georgia, after local epi-
demiology of TB was analyzed, community sites for tar-
geted testing and treatment of LTBI of residents of high-risk
inner-city areas were identified (184). Sites of access in-
cluded outpatient areas of the public hospital, the city jail,
clinics serving homeless persons, and neighborhoods fre-
quented by substance abusers. Although 65% of the tar-
geted population that had a tuberculin skin test placed
returned to have the skin test read, only 20% of those with
an indication for treatment of LTBI completed a course of
therapy; this represented 1% of persons who underwent
targeted testing.
Tier 3 consists of persons born in countries with a high
incidence of TB or U.S.-born persons in racial/ethnic minor-
ity populations with high prevalence of LTBI who do not nec-
essarily have an increased risk for progressing to TB disease.
Eventually, the control of TB among foreign-born persons and
progress toward elimination of TB in the United States
depends on achieving greater success in preventing TB among
populations at high risk by widespread targeted testing and
treatment of LTBI in the public and private medical sectors.
However, establishing successful targeted testing and treat-
ment programs for foreign-born persons who are not found
in Tier 1 or Tier 2 settings is challenging. Obstacles include
the limitations of the tuberculin skin test to differentiate
between reactions attributable to BCG or infection with
M. tuberculosis, the prevalent belief among a substantial num-
ber of foreign-born persons that BCG vaccination is the cause
of a positive test for M. tuberculosis infection and is also pro-
tective against TB disease, language and cultural barriers, bar-
riers in access to medical care, and difficulties in providing
outreach and education.
Typical Tier 3 populations are new refugee and immigrant
groups that are not yet assimilated into U.S. society. Such
populations might be ignorant of their TB risk, usually lack
ready access to health-care services, and might have strong
cultural understandings about TB that are at variance with
those that guide TB-control activities in the United States.
TB-prevention activities in this kind of community are highly
cost-intensive (221). Engaging such communities is a
challenging task.
Community-based TB prevention for Tier 3 populations
requires a partnership between the jurisdictional health
department and the affected community. The community
should gain an understanding of the TB problem as it relates
to them and should participate in the design of the interven-
tion. Community education is essential for this approach to
succeed. The target population should be involved in the
design and implementation phases of the intervention, inter-
ventions should be developed within the cultural context
of the targeted population, and intermediate goals or bench-
marks should show the population that program activities
are achieving success. For example, in Los Angeles, Califor-
nia, the public health TB program contracted with com-
munity-based organizations to screen and provide treatment
for LTBI to persons at risk in Latino and Asian neighbor-
hoods and at schools teaching English as a second language
(249). In Cambridge, Massachusetts, a coalition of
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Haitian community groups identified TB education as an
issue for their community; strategies to achieve this goal
included development of a videotape written and produced
for viewing in Haitian barbershops and beauty salons in
the community, a lottery, and measures for evaluation in
terms of knowledge and future access to care (S. Etkind,
Massachusetts Department of Health, personal communi-
cation, 2002).
For communities in Tier 3, TB is only one (and often not
the most important) of multiple medical and public health
needs. A broad approach should be adopted that includes TB
prevention with other activities to improve health status. Cer-
tain Tier 3 populations have achieved sufficient self-identity
and development to establish access to health care through a
community health center, individual medical providers, or
clinics. Those communities that have an already established
route of access to health care have an infrastructure in place to
establish programs for targeted testing and treatment of LTBI.
Obstacles to overcome often include lack of medications and
chest radiographs, the need for a system to track patients who
do not return for monthly appointments, and the capacity to
evaluate the program.
Programs for population-based targeted testing and treat-
ment for LTBI often have been conducted by public health
agencies through TB-control programs. However, recent
studies have also described the establishment of such pro-
grams in nonpublic health venues. Promising results, in
terms of access to persons at high risk and completion of
treatment of LTBI, have been achieved from nontraditional
sites, including syringe exchanges (318), jails (256), neigh-
borhood health clinics (319), homeless shelters (320), and
schools (321,322). This trend indicates a widening inter-
est in this means of preventing TB and is possibly influ-
enced by the emergence of community-oriented primary
care (241,323), which places primacy on interventions for
specific patients that help prevent disease and preserve the
health of the entire population from which these patients
are drawn.
As programs move from Tier 1 to Tier 2 and Tier 3 popula-
tions, the complexity of the effort and the cost of the program
will increase. Also, because persons in Tier 3 populations gen-
erally have a lower risk for progression from LTBI to TB
disease, the effectiveness and impact of a program will be
less than efforts directed to Tier 1 and Tier 2 populations.
Whatever population is selected or strategy is employed
for the targeted testing project, programs should system-
atically evaluate the activity to ensure the efficient use of
resources. Process, outcome, and impact indicators should
be selected and routinely monitored by the program.
For purposes of monitoring and evaluation, activities
associated with targeted testing and treatment for
M. tuberculosis infection can be divided into three phases:
the testing itself, the medical evaluation of persons with
positive test results, and the treatment of those persons
with LTBI. Performance indicators should be selected for
each phase. For the testing phase, indicators include the
number of persons at high risk identified and the number
and proportion of those that were actually tested. Among
those tested, the number and proportion that had a posi-
tive result for M. tuberculosis infection should be tracked.
Useful indicators for the medical evaluation phase include
the proportion of persons with a positive test result who
completed a medical evaluation and the number and pro-
portion that were determined to have TB disease. Indica-
tors for the treatment phase include the proportion of
eligible persons starting treatment for LTBI and the num-
ber and proportion that completed treatment. Reasons for
failure to complete treatment (e.g., adverse drug effects,
loss of interest, and loss to follow-up) should be monitored.
Costs should be measured for each phase of the project.
The cost per person with LTBI completing treatment pro-
vides a measure of the relative efficiency of the program.
Finally, the impact of the program can be estimated by
estimating the number of cases of TB prevented, which is
dependent on the number of persons completing treatment
and the estimated risk for progressing to TB disease.
Surveillance of persons with LTBI does not routinely
occur in the United States. However, CDC has recently
developed a national surveillance system to record serious
adverse events (i.e., hospitalization or death) associated with
treatment of LTBI. Surveillance of these events will provide
data to evaluate the safety of treatment regimens recom-
mended in current guidelines (4,324).
Control of TB Among
Populations at Risk
This section contains recommendations for measures to
control and prevent TB in five populations (children, foreign-
born persons, HIV-infected persons, homeless persons, and
detainees and prisoners in correctional facilities). Each of these
populations occupies an important niche in the epidemiol-
ogy of TB in the United States. Individual members of each
population have been demonstrated, on the basis of their
membership in the population, to be at higher risk for expo-
sure to M. tuberculosis or for progression from exposure to
disease, or both. Furthermore, nationwide surveillance and
surveys (27,118–120,127,136,139,150,198,295,315,325,326)
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indicate that the epidemiology of TB in these populations
is similar from community to community, which suggests
that the recommended control measures are subject to gen-
eralization and can be applied more or less uniformly
throughout the United States.
Children, foreign-born persons, HIV-infected persons,
homeless persons, and detainees and prisoners should not
be assumed to be the only populations at high risk for TB,
nor are homeless shelters and detention facilities the only
settings in need of enhanced TB-control strategies. Local
surveillance and surveys frequently have identified popula-
tions and settings of high TB risk and transmission that
required the formulation of specific control measures
(122,137,152,313,315,316,327,328). This is the primary
reason why state and local surveillance should be conducted
to develop a clear understanding of the epidemiology of
TB at the jurisdictional level.
Most important, the concept of identifying and target-
ing populations and settings at high risk should be viewed
as a dynamic rather than as a static process. Such popula-
tions emerge and recede in importance at the local, state,
and national levels. For example, foreign-born persons
received little attention in the 1992 edition of this state-
ment (6). A population whose risk for TB is now being
recognized and delineated is U.S.-born non-Hispanic blacks,
who account for approximately 25% of TB morbidity in
the United States and who have TB rates approximately
eight times those of whites (329,330) (Table 2). CDC and
collaborating public health agencies in Chicago, Illinois
and the states of Georgia and South Carolina are exploring
new strategies to address this problem (331).
Control of TB Among Children
and Adolescents
The occurrence of TB among infants and young children
indicates recent transmission of M. tuberculosis and often the
presence in the community of an unidentified adult with
infectious TB. Thus, a case of TB in a child is a sentinel
health event that signals a public health breakdown (197).
Also, certain features of TB among children mandate spe-
cial considerations in case detection and case management,
contact investigations, and targeted testing and treatment
of LTBI. For example, if LTBI results from exposure to TB
in infancy and early childhood, a substantial risk exists for
rapid progression to TB disease, including the development
of potentially lethal forms of TB (198,294,325). The rec-
ommendations in this statement for control of TB among
children and adolescents should receive high priority in all
state and community TB-control plans.
Basis for Recommendations for TB Control
Among Children and Adolescents
Case detection and primary prevention strategy:
contact investigation of adults with pulmonary TB. The
majority of infants and children who acquire TB disease do
so within 3–12 months of contracting M. tuberculosis
infection. Infants and toddlers aged <3 years are especially
prone to the rapid progression from infection to disease,
and they often acquire severe forms of TB, including men-
ingitis and disseminated disease. The most important step
to detect and prevent TB among children is the timely iden-
tification and effective treatment of adults with active TB.
The cornerstone of TB prevention among children is high-
quality contact investigations of suspected cases of pulmo-
nary TB in adults, because 20%–40% of pediatric cases of
TB could have been prevented if contact investigation had
been more timely and thorough (198,293,325).
Contact investigation of adult pulmonary TB cases is cru-
cial to the detection, control, and prevention of pediatric TB
and its complications (332,333). The yield of detection of TB
and LTBI is high, with an average of 50% of childhood house-
hold contacts having LTBI or TB disease (31,60). Because
<50% of cases of TB among children are asymptomatic
despite abnormal radiographic findings, contact investigation
leads to earlier discovery of TB among children, better treat-
ment outcomes, and fewer complications (326). Also, chil-
dren with LTBI or TB disease identified through contact
investigation are more likely to receive DOT at the same time
as the source-case, which increases adherence to therapy.
Another benefit of contact investigations is the ability to
identify and treat infants and young children who have been
exposed to a person with a contagious case of TB and who
might be infected but nevertheless have a negative tuberculin
skin test (the role of QFT-G for diagnosis of LTBI in children
aged <17 years has not been determined). A tuberculin skin
test might take 2–3 months after infection to become positive
in an infant or toddler. However, the incubation period for
severe TB, including meningitis and disseminated disease,
might be only 4–6 weeks. Failure to give empiric treat-
ment for LTBI to exposed infants and young children with
negative tuberculin skin test results, particularly those aged
<3 years, might therefore result in rapid acquisition of
disease (295,325).
Case management. The record for adherence to treat-
ment for TB is no better for children than it is for adults
(333). Children with TB might live in socially disorga-
nized or disadvantaged homes and receive care from mul-
tiple adults. A chaotic environment can lead to a poor
understanding of TB and its treatment and decreased
adherence. DOT is effective in TB treatment for children
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and adolescents. However, almost 10% of children receiv-
ing DOT experience gaps in treatment that require exten-
sions of therapy (326). Intensive-case management,
including use of incentives and enablers, is a crucial ele-
ment of a TB-treatment plan for children.
Contact investigation of cases of TB among children
and adolescents. Contact investigations for children with
suspected TB are generally conducted to identify the adult
source-case. Identifying a source-case serves to establish the
diagnosis of TB in the majority of children and, if the source-
case is culture-positive for M. tuberculosis, to determine the
likely drug susceptibility pattern of the infecting strain of
M. tuberculosis in the child.
Even with optimal medical evaluation, M. tuberculosis can
be isolated from <50% of children with clinically suspected
TB. While microbiologic testing determines the diagnosis of
TB for the majority of adults, positive culture results often are
lacking for children. In the majority of cases, the diagnosis of
pediatric TB is established by the triad of 1) a positive tuber-
culin skin test result, 2) either an abnormal chest radiograph
or physical examination or both, and 3) discovery of a link to
a known or suspected case of contagious pulmonary TB.
Because culture yields from children with TB are low, deter-
mining the drug susceptibility pattern from the source-case
isolate often is the only way to determine optimal treatment
for children with either LTBI or TB disease (334,335).
Because TB among infants and young children usually
occurs within weeks to months of contracting infection with
M. tuberculosis, having a child with disease is a marker of
recent transmission from someone in the child’s environment.
The source-case, often a parent or other caregiver (336–338),
might not have been identified as having TB by the time the
child becomes ill. Consequently, parents and other adults who
are close contacts of children hospitalized with TB should be
evaluated themselves for TB disease as soon as possible to serve
as a case-detection tool and to prevent nosocomial transmis-
sion of M. tuberculosis (339). A chest radiograph should be
performed on these family members to exclude pulmonary
TB; certain centers have implemented this recommendation
by requiring that adults who accompany a child have a chest
radiograph performed and interpreted immediately while
at the health-care facility (339). Other adult family mem-
bers or friends also should be required to show evidence of
a normal chest radiograph, performed by the health
department or other provider, before being allowed to visit
the child. Because TB in the child, not LTBI, is the reliable
marker of recent infection, chest radiograph screening of
accompanying adults is not necessary if the child has LTBI
without TB disease.
Associate investigations (i.e., efforts to identify and evalu-
ate household contacts of a child with LTBI to identify the
infectious person responsible for the child’s infection) are
often performed as part of the evaluation of a child with LTBI
(5,17,340–343). The usefulness of this approach depends on
the criteria for placing skin tests on children. If testing of chil-
dren at low risk is undertaken, associate investigations will
be costly, have a low yield, and divert TB-control resources
from more important activities. Associate investigations of
children at high risk, however, usually detect a limited
number of persons with TB but do identify substantial
numbers of other persons with LTBI who are candidates for
treatment (341–343).
Targeted testing and treatment of LTBI. In the 1950s
and 1960s, child-centered TB control activities were based on
periodic testing of all children for LTBI (344). However, as
the number of TB cases dropped, the disease became concen-
trated among persons at high risk in particular subpopula-
tions. Consequently, the majority of U.S. children have
negligible risk for acquiring LTBI. Among children at low
risk, the majority of positive tuberculin skin test results are
false positives caused by nonspecific reactivity or exposure to
nontuberculous mycobacteria in the environment (344). False-
positive results lead to unnecessary health-care expenditures
and anxiety for the child, family, school, and HCWs (345).
Thus, while the testing of children with an expected high preva-
lence of LTBI is desirable, mass testing of children with a low
prevalence of LTBI is counterproductive and should not be
undertaken.
The optimal approach is to perform tuberculin skin test-
ing only on those children with specific risk factors for LTBI.
A questionnaire that assesses risk factors for TB can be used
successfully in clinics and private offices to identify chil-
dren at risk for LTBI (237,346–348); this approach can
also be used to identify at-risk college students (349). The
screening tool is the questionnaire; only those children
whose answers indicate that they are at risk for LTBI should
receive a tuberculin skin test. Use of a questionnaire can
also address issues related to discrimination; all children in
a setting such as a school or child-care center can be screened
easily, but only those with identified risk factors for LTBI
should receive a tuberculin skin test, thereby diminishing
the number of false-positive results.
No single questionnaire has been validated for use in all
settings and for all ages of children. Factors that have corre-
lated highly with risk for LTBI among children in more than
one study include 1) previous positive tuberculin skin test
result; 2) birth in a foreign country with high prevalence;
3) nontourist travel to a high-prevalence country for >1 week;
4) contact with person with TB; and 5) presence in the
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household of another person with LTBI. Questions per-
taining to a locally identified population with a high rate
of TB should be included in a questionnaire, but valida-
tion of these questions is difficult.
In certain treatment programs for LTBI among children
in the United States, the completion rate associated with
6–9 months of self-supervised isoniazid therapy is only
30%–50%. As LTBI among young children might progress
rapidly to TB disease, DOT is recommended. Children
with LTBI, who are most likely to benefit from DOT
because of their high risk for rapid progression of infection
to disease, include contacts of persons with recently diag-
nosed cases of pulmonary TB, infants and young children,
and children with immunologic deficiencies, especially HIV
infection.
Control of TB Among Foreign-Born
Persons
TB among foreign-born persons is of increasing impor-
tance. During 1992–2003, the number of TB cases
decreased 64% among U.S.-born persons but increased 8%
among persons born outside the United States (14,15).
During 1992–2003, the percentage of TB cases in the
United States that occurred among foreign-born persons
increased from 27% in 1992 to 53.3% in 2003 (15), and
the number of states in which >50% of reported cases of
TB occurred among foreign-born persons increased from
four (8%) in 1992 to 25 (50%) in 2003 (15). In 2003,
eight states (California, Florida, Illinois, Massachusetts,
New Jersey, New York, Texas, and Virginia) accounted for
71% of cases among foreign-born persons. Foreign-born
persons with TB have been more likely than U.S.-born per-
sons to harbor drug-resistant strains of M. tuberculosis; in
2003, 10.6% of foreign-born persons with TB had TB with
primary isoniazid resistance, compared with 4.6% of U.S.-
born persons with TB (14).
The increase in cases of TB among foreign-born persons
has been attributed to at least three factors (350). First, the
number of persons entering the United States from other coun-
tries in which TB occurs with high incidence (44) now
accounts for >75% of the immigrant flow (116,278); during
1994–2003, an estimated 80%–86% of immigrants
admitted to the United States came from high-incidence
countries (351). Second, foreign-born persons are subject
to cultural and linguistic barriers that might affect health-
seeking behavior and access to medical care, resulting in
delays in diagnosis and difficulty in understanding and
completing treatment (18,19,194,325). Third, these bar-
riers, which have implications for the treatment, control,
and prevention of TB among foreign-born persons, have
not been sufficiently appreciated and addressed in TB-
control program planning in the United States.
Precise information is lacking to assist in the identifica-
tion of foreign-born persons who have an elevated risk for
acquiring TB during residence in the United States. Immi-
grants entering either Canada or the United States have a
risk for TB during their early years of residence that
approximates that of residents of the country of birth
(115,352,353). Over time, the risk declines and approaches
that of residents of the host country. Consequently, recent
guidelines have designated immigrants from countries with
a high prevalence of TB who have resided in the United
States <5 years as foreign-born persons at high risk (4).
Criteria for characterizing countries as having a high preva-
lence of TB have not been developed, and no consensus exists
on which countries should be designated as having a high
prevalence of TB. In rank order, the 14 countries listed
most frequently as country of origin of foreign-born per-
sons with reported TB in the United States are Mexico, the
Philippines, Vietnam, India, China, Haiti, South Korea,
Somalia, Guatemala, Ecuador, Ethiopia, Peru, El Salvador,
and Honduras), and these 14 countries accounted for 76%
of cases among foreign-born persons during 1999–2002
(14). Estimated incidence rates of TB in these countries in
2002 ranged from 33/100,000 population (Mexico) to
406/100,000 population (Somalia) (354). However, the
country of origin of foreign-born persons with TB can vary
substantially among localities within a state and between
states and regions across the United States.
State and local TB control programs should develop their
own profiles of risk for TB among foreign-born persons as
part of the jurisdiction’s overall epidemiologic analysis of TB
and then define which immigrant and foreign-born popula-
tions in their areas should be considered as being at high risk
for TB. Data sources for TB programs to use in making this
determination include 1) WHO data on the estimated inci-
dence of TB in countries of origin (354); 2) local epidemio-
logic and surveillance data (151,152,313–316,355); 3)
published guidelines (4,279), and other sources of data
(115,116); 4) qualitative information on refugee and
immigrant movement into the jurisdiction; and 5) avail-
ability of resources to establish control and prevention mea-
sures targeted toward the foreign-born population. The
principles and priorities of TB control among foreign-born
persons at high risk are not different from those for control
of TB among U.S.-born persons (Box 4). However, for the
reasons given previously, TB control among foreign-born
persons at high risk might present challenges requiring tar-
geted strategies specific to that population (152,356).
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How Foreign-Born Persons Enter the United
States
Foreign-born persons enter the United States legally
through different official channels (Table 7). As a condi-
tion of entry, persons migrating as immigrants, refugees,
and asylees are required to be screened for diseases of pub-
lic health significance, including TB. Persons entering in
the nonimmigrant category do not require preentry screen-
ing. Persons who enter the country without legal docu-
mentation are referred to as unauthorized aliens.
During 1992–2002, an estimated 380,000–536,000 per-
sons entered the United States annually as immigrants, refu-
gees, or asylees (Table 8). In 2002, among the estimated
516,000 persons in those categories, 86.6% were from coun-
tries with high incidence of TB. Immigrants, refugees, and
asylees constitute only a fraction of foreign-born persons who
enter the United States each year; the majority (20–35 mil-
lion persons) enter in one of the nonimmigrant subcatego-
ries (Table 8). The majority of entering nonimmigrants
are tourists or business travelers who spend only a short
time in the United States. However, an estimated 850,000–
1.9 million workers, students, and other visitors and their
families might reside in the United States for multiple years
(Table 8).
A nonimmigrant, refugee, or asylee residing in the United
States who meets the eligibility requirements and applies for a
change in visa status to that of a lawful permanent resident
should undergo required health screening assessment by a civil
surgeon. During 2002, of the 679,305 persons who adjusted
their immigration status under this program, 536,995
(79%) were from countries with high incidence of TB
(238). In addition, an estimated 7 million unauthorized
aliens resided in the United States in January 2000, and
during 1990–1999, the unauthorized alien population
increased annually by approximately 350,000 persons
(357).
Current Requirements for TB Screening
of Immigrants
U.S. immigration law mandates screening outside the
United States for applicants designated as immigrants who
are applying for permanent residence status and for appli-
cants designated as refugees or asylees (Table 7). The pur-
pose of mandated screening is to deny entry to persons
who have either communicable diseases of public health
import or physical or mental disorders associated with harm-
ful behavior, abuse drugs or are addicted to drugs, or are
likely to become wards of the state. The current list of
infectious diseases of public health significance that are
grounds for exclusion include infectious TB, HIV infec-
tion, leprosy, and certain sexually transmitted diseases
(358). Worldwide, approximately 400 licensed local phy-
sicians, designated as “panel physicians,” perform these
medical examinations. Panel physicians are appointed by
U.S. embassies and consulates that issue visas. CDC is
responsible for monitoring the quality of these examina-
tions and for providing technical guidance and consulta-
tion for TB diagnosis and treatment.
The TB screening process is a program for active TB case
detection designed to deny entry to persons with infectious
TABLE 7. U.S. Citizenship and Immigration Services immigration




Category Definition of entry
Immigrant An alien* admitted to the United Yes
States as a lawful permanent
resident
Refugee/Asylee A person outside his or her country Yes
of nationality (refugee) or at a
point of entry to the United States
(asylee) who is unable or unwilling
to return because of a well-founded
fear or persecution
Nonimmigrant An alien granted temporary entry No
to the United States for a specific
purpose (most common visa
classifications for nonimmigrants
are visitors for pleasure, visitors
for business, temporary workers,
students, and visitors)
Unauthorized alien An alien residing in the United NA†
States in an unlawful status
SOURCE: US Citizenship and Immigration Service. Glossary & acronyms.
Washington, DC: US Citizenship and Immigration Service; 2004. Available
at http://uscis.gov/graphics/glossary.htm.
* A persons who is not a U.S. citizen.
†Not applicable.
TABLE 8. Numbers of foreign-born persons who entered the
United States, by immigration category — United States, 2002




Temporary visa: pleasure 19,967 (16,441–24,104)
Temporary visa: business 4,377 (2,788–4,593)
Temporary visa: worker 723 (216–755)
Students§ 687 (400–740)
Visitors§ 370 (230–388)
SOURCE: US Citizenship and Immigration Services. Statistical yearbook.
Available at http://uscis.gov/graphics/shared/aboutus/statistics/ybpage.htm.
* Numbers in parentheses are the 1992–2002 range.
† Includes parolees (i.e., persons allowed to enter the U.S. for urgent
humanitarian reasons).
§ Includes family members.
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pulmonary TB (identified by positive sputum AFB smear
results). For persons aged >15 years, a brief medical history
and a chest radiograph are obtained (Figure 4). If the chest
radiograph is considered compatible with pulmonary TB, three
sputum specimens are obtained and examined for AFB.
Although procedures vary from site to site, smears are usually
performed by Ziehl-Neelsen staining and examined with light
microscopy. Cultures for M. tuberculosis are not required and
are not routinely performed. Persons aged <15 years are evalu-
ated only if they have symptoms that are consistent with
TB or are a contact of person with infectious TB. A test for
M. tuberculosis infection is performed, and a chest radiograph
is obtained if the test is positive or if the child is suspected
to have TB.
Persons with abnormal chest radiographs suggestive of
TB and with AFB-positive sputum smear results are classi-
fied as having Class A TB, which is an excludable condi-
tion for entry into the United States (358). Persons so
designated have two options: 1) to complete a course of
treatment for TB, including documented negative sputum
AFB smears at the end of treatment, at which point they
are classified according to their chest radiograph results and
may enter the United States; or 2) to receive TB treatment
until sputum smear results for AFB convert from positive
to negative and then apply for an immigration waiver. A
U.S. health-care provider who agrees to assume responsi-
bility for the completion of TB treatment after a person’s
arrival in the United States should sign the waiver. The
waiver is countersigned by a representative of the jurisdic-
tional public health agency of the person’s intended U.S.
destination. An applicant whose chest radiograph is com-
patible with active TB but whose sputum AFB smear
results are negative is classified as having Class B1 status
and may enter the United States. If the chest radiograph is
compatible with inactive TB, no sputum specimens are
required, and the applicant enters the country with Class
B2 status (358).
Immigrants with a Class A waiver or with Class B1 or B2
status are identified at ports of entry to the United States
by CIS on entry to the United States and reported to CDC’s
Division of Global Migration and Quarantine (DGMQ).
DGMQ notifies state and local health departments of refu-
gees and immigrants with TB classifications who are moving
to their jurisdiction and need follow-up evaluations. Persons
with a Class A waiver are required to report to the jurisdic-
tional public health agency for evaluation or risk deportation.
For persons with Class B1 and B2 status, however, the stipu-
lated evaluation visits to the health agency are voluntary.
Persons Seeking Adjustment of Status
After Arrival
Persons seeking to adjust their immigration status after
residing in the United States with nonimmigrant visa status
should undergo a medical evaluation by one of the approxi-
mately 3,000 U.S. medical practitioners designated by DGMQ
as civil surgeons. TB screening by civil surgeons is based on
tuberculin skin testing; QFT-G is also approved for
detecting LTBI. If an applicant seeking adjustment of sta-
tus has a tuberculin skin test reading of >5 mm, a chest
radiograph is required. If the radiograph is compatible with
active TB, the person is referred to the jurisdictional pub-
lic health agency for further evaluation (358). Civil sur-
geons are also advised that persons with a positive
tuberculin test result and no signs or symptoms of TB dis-
ease should be referred to public health agencies for evalu-
ation for treatment of LTBI, following ATS/CDC/IDSA
guidelines (4,324).
Because data on the outcomes of TB screening of persons
seeking to adjust their immigration status are not aggre-
gated or analyzed, only limited information is available. In
an evaluation of the screening practices in five U.S. Immi-
gration and Naturalization Service jurisdictions, among
5,739 applicants eligible for screening through tuberculin
skin testing, 4,290 (75%) were considered to have been
screened appropriately (240). In Denver, Colorado, where
health department physicians serve as civil surgeons, 7,573
persons were evaluated for adjustment of status during May
1987–December 1988 (239). Applicants were screened
with tuberculin skin testing, chest radiographs, or both.
Among 4,840 applicants that had a tuberculin skin test
FIGURE 4. Tuberculosis (TB) screening process for immigrants
and refugees conducted outside the United States
* Acid-fast bacilli.
Chest radiograph for
persons aged >15 years
If radiograph is normal,
no follow up
Consistent with inactive
TB (Class B2 TB)




(Class A TB [Infectious])
AFB positive
(Class B1 TB [Noninfectious])
Consistent with active TB
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placed, 2,039 (42%) had a reaction >10 mm. Sixteen per-
sons (0.7%) were sputum culture-positive for M. tuberculosis.
Therapy with isoniazid was recommended for 1,029
applicants, of whom 716 (70%) completed 6 months of
treatment.
Immigration Status of Foreign-Born Persons
with TB
Studies have sought to identify the initial immigration
status of foreign-born persons with reported TB. During
1992–1993 in Hawaii, 78% of TB cases occurred among
immigrants, 4% among student nonimmigrants, and 4%
among nonimmigrant tourists (350); in 14% of cases, the
immigration status could not be determined. During 1992–
1994 in Seattle, Washington, 58% of TB cases among
foreign-born persons who had resided in the United States
for <1 year occurred among immigrants or refugees
(293); immigration status was not determined among the
remaining foreign-born persons. During 1998–2000, a
total of 59% of foreign-born persons with TB in Tarrant
County, Texas, were immigrants or refugees, 24% were
unauthorized immigrants, and 17% were nonimmigrant
students and workers (316).
Assessment of TB Screening Requirements
for Immigrants
The priority for immigration screening efforts is to detect
cases of pulmonary TB among persons applying for perma-
nent residence in the United States and to prevent the most
infectious persons from entering the United States. However,
requirements for screening outside the United States do not
apply to the majority of foreign-born persons entering the
United States because those classified as nonimmigrants and
unauthorized immigrants do not undergo screening (Table 7)
(277).
Furthermore, a significant proportion of immigrants with
Class B1 (4%–14%) and B2 (0.4%–4%) status allowed to
enter the United States with abnormal chest radiographs
because of having AFB-negative sputum smears on screening
outside the United States are later discovered (on the basis of
follow-up evaluations by U.S. public health agencies) to
have active TB at the time of entry (350). This finding has
great importance for TB-control activities in certain U.S.
jurisdictions.
IOM, NTCA, and CDC have suggested changes in the
screening procedures for immigrants, as follows:
• IOM has recommended that testing for M. tuberculosis
infection be added as a requirement to the medical evalu-
ation for immigrant visa applicants from countries with
high incidence of TB (2).
• IOM has recommended that 1) a Class B4 TB designa-
tion be created for persons with normal chest radiographs
and positive tuberculin skin tests and that 2) immigrants
with B4 status be required to undergo an evaluation for
TB and, when indicated, complete an approved course
of treatment for LTBI before receiving a permanent
residency card.
• CDC has proposed enhancing training and oversight of
panel physicians outside the United States and of civil sur-
geons in the United States to improve the quality of immi-
gration screening (359). CDC is also working to develop
an electronic system for notifying jurisdictional public
health agencies about the arrival of Class B immigrants.
• NTCA has called for 1) clarification of legal and fiscal
issues associated with domestic evaluation and treatment
of immigrants; 2) efforts to educate immigrants with Class
B1 and B2 status about their responsibilities for follow-
up; and 3) operational research to address the cost
effectiveness of screening additional categories of
immigrants.
• Consideration also should be given to broadening the
scope of medical evaluations for immigrants. The costs
and benefits of extending the requirement for screening
to all visa applicants planning to reside in the United States
for >6 months should be examined. Consideration is
being given to adding sputum cultures to the sputum AFB
smear evaluation of visa applicants who, on the basis of
an abnormal chest radiograph, are suspected to have
pulmonary TB or who, at least for persons with smear-
positive TB cases, are from countries with known high
rates of drug resistance.
TB Control at the U.S.-Mexican Border
The U.S.-Mexican border presents specific challenges to
TB control. Four U.S. states (California, Arizona, New
Mexico, and Texas) and six Mexican states (Baja California
Norte, Sonora, Chihuahua, Coahuila, Nuevo León, and
Tamaulipas) comprise the U.S.-Mexican border, and an
estimated 1 million persons cross the border daily. In the
six Mexican border states, estimated annual TB incidence
is 27.1 cases/100,000 population, compared with 5.1
cases/100,000 population in the United States (359). In
1999, Mexico was the country of origin for 23% of foreign-
born persons in the United States with reported TB, and
75% of those cases were reported from the four U.S. bor-
der states. In 1996, those same states reported 83% of TB
cases among foreign-born Hispanics (360). The high rate
of TB at the border, the substantial number of border cross-
ings, the substantial geographic area involved, and the
prevalent cultural and linguistic barriers make TB control
a challenge in this region.
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Recommendations to improve TB control at the U.S.-
Mexican border have been published (361). These recom-
mendations include use of a binational case definition and
development of a binational registry of TB cases, improve-
ments in clinical care of binational TB patients and close con-
tacts by cross-border case-management strategies,
development of performance indicators for these activities,
and setting research priorities (361).
Basis for Recommendations on TB Control
Among Foreign-Born Persons
Surveillance. The inability to distinguish imported TB
present at the time of entry of foreign-born persons into the
United States from domestically occurring disease obscures
the progress that certain states and cities have made in TB
control. Standardized reporting of new TB cases does not
allow separating TB among foreign-born persons that is
present at the time of entry from cases that arise during
residence in the United States. This is more than a seman-
tic distinction because cases of TB that occur among short-
term visitors and workers, students, and unauthorized aliens
are counted as U.S. incident cases even though a substan-
tial number are imported (115). Surveys using sputum
cultures indicate that 4%–13% of immigrants and refu-
gees with Class B1 status have TB disease at the time of
entry (279). TB present at the time of entry is likely to
contribute to the higher incidence rates of TB noted among
foreign-born persons in the first 2 years after arrival (115).
The importance of imported cases and the need to distin-
guish them from domestic cases has also been demonstrated
in the smallpox, polio, and measles eradication efforts in
North America.
Case detection. Multiple factors common to the experi-
ence of foreign-born persons in the United States might lead
to delays in the detection of TB. Preexisting culturally derived
beliefs about TB might serve as a disincentive to seek health
care when symptoms of TB are experienced (18,279). Also,
foreign-born persons wishing to receive a medical evaluation
might encounter financial, linguistic, or other barriers to
access (19). Once medical services are sought, foreign-born
persons are likely to receive their evaluation from certain kinds
of health-care providers (e.g., foreign-born physicians or those
working in community health centers or hospital EDs) rather
than from TB clinics conducted by public health agencies.
These challenges to optimal case detection among foreign-
born persons will require 1) targeted public education for
foreign-born populations at high risk to explain that TB is
a treatable, curable disease; 2) better access to medical ser-
vices, especially for recently arrived immigrants and refu-
gees; and 3) maintenance of clinical expertise in the
diagnosis and management of TB among medical practi-
tioners (Box 1).
The TB-screening process for visa applicants (i.e., iden-
tification of persons with abnormal chest radiographs) has
provided opportunities for active case detection in follow-
up evaluations in the United States. Data derived from pro-
grams that have sought to identify active TB cases on the
basis of positive sputum cultures for M. tuberculosis among
immigrants with Class B notification status indicate that
3%–14% of the approximately 6,000 immigrants with
Class B1 status who enter the United States each year and
0.4%–4.5% of the 12,000 immigrants with Class B2 sta-
tus have TB at the time of entry (279). In San Francisco,
California, during July 1992–December 1993, of 182
immigrants with Class B1 status who received follow-up
evaluations, 27 (14.8%) had active TB, and 134 (73.3%)
had inactive TB (362). Among 547 immigrants with Class
B2 status, 24 (4.3%) had active TB, and 301 (54.5%) had
inactive TB. In California, 3.5% of all persons with a Class
B notification status who arrived during January 1992–
September 1995 were reported to have active TB <1 year
of arrival (277). Recent arrivals with Class B notification
status accounted for 38% of all foreign-born persons with
TB reported <1 year of arrival. Among 124 immigrants
and refugees in Hawaii who were reported during 1992–1993
to have TB <1 year of arrival, 78 (63%) had been classified as
having Class B1 status and 17 (14%) as having Class B2
status (350). However, a study from Los Angeles suggested
that the visa application process was more effective in iden-
tifying cases among persons recently arrived from South-
east Asia than among those from Mexico and Central
America (363).
An active Class B1/B2 follow-up program can be relatively
cost effective. During October 1995–June 1996, in Santa Clara
County, California, 87% of immigrants with Class B status
responded to letters inviting them to receive a follow-up
evaluation, resulting in a cost of $9.90 to locate one immi-
grant with Class B1/B2 status and $175.88 to locate one
person with TB (364).
Case management. As with case detection, cultural and
linguistic differences might impede successful treatment out-
comes among foreign-born persons. Case management of
persons whose primary language is not English depends on
reliable and competent medical translation. Providers and agen-
cies that work with foreign-born patients at high risk should
ensure that adequate translation and interpretation services
are available. In jurisdictions in which the majority of the cases
occur among foreign-born person, providing these services
can be costly. For example, in 2000, the Tarrant County
Health Department TB Program (Fort Worth, Texas), spent
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approximately $24,000 on professional translation services
(365). Ideally, professional services should be used for trans-
lation rather than relatives or family friends (365).
Culturally derived attitudes and beliefs about TB and its
treatment can also be impediments to the management of
TB among foreign-born persons. Each culture has its own
knowledge, attitudes, and beliefs about TB and how it
should be treated. For example, in a study that used focus
groups to evaluate attitudes regarding TB among Filipino
immigrants, participants expressed a belief that TB was
extremely contagious (264) and mentioned the associated
social stigma and isolation. Although all participants agreed
that medical therapy was necessary, participants also trusted
the effectiveness of traditional treatments. As more of the
burden of TB in the United States is borne by foreign-born
persons, the need for health-care providers to understand
cultural attitudes toward TB will increase.
Case management is particularly difficult at the U.S.-Mexico
border where, until recently, tracking systems for persons who
migrated between the two countries were not in place. A new
binational system has been established to ensure continu-
ity of care and completion of TB treatment for patients
who migrate between the United States and Mexico and to
coordinate the referral of patients between the health sys-
tems of both countries. The project is now being tested in
four U.S.-Mexican jurisdictions (San Diego, California, and
Tijuana, Baja California; El Paso, Texas–Las Cruces, New
Mexico, and Ciudad Juarez, Chihuahua; Webb and
Cameron Counties, Texas, and Matamoros, Tamaulipas; and
Arizona and Sonora). If the pilot project proves successful,
this binational TB patient referral and information system
will likely be expanded to other parts of the United States
and Mexico.
Contact investigation. Contact investigations have a par-
ticularly high yield when conducted on foreign-born patients.
In Seattle, for example, contacts of foreign-born persons
with TB were more numerous (6.0 versus 3.4 per case) and
substantially more likely to be have positive tuberculin skin
test results (50% versus 18%) and to be started on treat-
ment for LTBI (40% versus 23%) than were contacts of
U.S.-born persons with TB (293). A multicenter survey
from around the United States demonstrated that the
tuberculin skin test was positive among 71% of foreign-
born contacts compared with 32% of all close contacts (31).
Although not all foreign-born contacts identified during a
contact investigation are recently infected, the majority
would nevertheless be considered candidates for treatment
of LTBI under current guidelines (4). In addition, a Cana-
dian study indicated that contact investigations were more
cost effective than preimmigration screening and postarrival
surveillance (276).
Targeted testing and treatment of LTBI. Surveys using
molecular epidemiologic methods have consistently demon-
strated that less clustering of M. tuberculosis isolates occurs
from foreign-born patients than from U.S.-born patients; this
has been interpreted as evidence that less person-to-person
spread of TB occurs among foreign-born persons in the United
States and that the majority of cases of TB among foreign-
born persons occur as a result of activation of a latent
infection (150–152,356). In fact, one reason for the lack of
progress in reducing TB among foreign-born persons might
be that insufficient attention has been given to targeted
testing and treatment (152), which should be the most
applicable prevention strategy for this population, in which
TB disease occurs mainly by progression from LTBI.
The success of programs for targeted testing and treatment
of LTBI among populations at high risk in the United States
has been thwarted by poor interest in the intervention on the
part of medical practitioners and poor adherence by patients
(51). Among foreign-born persons, these problems are mag-
nified by the lack of access to care and by cultural and linguis-
tic obstacles. Successful models for administering targeted
testing and treatment of LTBI among refugees have been pub-
lished; these models are resource-intensive and require a com-
mitment to working within the population’s cultural contexts
(202,221). In addition, the use of DOT increases treatment
completion rates (366).
Other opportunities to conveniently access foreign-born
persons for targeted testing programs include school-based
testing of foreign-born students. The majority of persons
residing as students in the United States remain long enough
to receive targeted testing for LTBI and, if TB is diagnosed, to
complete a course of treatment. Screening for TB is required
by 61% of colleges and universities: for all students in 26%,
for all international students in 8%, and for students in
specific academic programs in 47% (367). School-based
screening also has been evaluated among younger students
(150,322,345). In California, widespread TB screening of kin-
dergarten and high school students yielded a low prevalence
of skin test reactors and a limited number of cases of TB, but
foreign-born students were >30 times more likely than U.S.-
born students to have the infection (345). In a cost-benefit
analysis, screening all students would be expected to prevent
14.9 cases/10,000 children screened, whereas targeted testing
would prevent 84.9 cases/10,000 screened and would be less
costly (345).
Control of TB Among Persons with HIV
Infection
HIV and M. tuberculosis interact in ways that tend to
worsen both diseases among coinfected persons (368).
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When a person with HIV infection is exposed to a patient
with infectious TB, the risk for acquiring TB disease soon
after that exposure is markedly increased (369). In out-
breaks in which the start of exposure could be determined,
HIV-infected persons acquired active TB in as little as a
month after exposure to a person with infectious TB (136).
HIV coinfection is also a highly potent risk factor for pro-
gression from LTBI to TB (44,46,370). Persons with LTBI
and HIV coinfection have a risk for progressing to TB dis-
ease of approximately 10%/year (317,371,372), which is
113–170 times greater than the risk for a person with LTBI
who is HIV-seronegative and has no other risk factors (4,44).
On a global level, HIV infection has had a substantial
effect on the epidemiology of TB. Areas of the world most
heavily affected by the global epidemic of HIV/AIDS (e.g.,
sub-Saharan Africa) have also sustained increases in the
incidence of TB (44,46,373). TB is the most common
infectious complication and the most common cause of
death among persons with HIV/AIDS in places where the
incidence of both diseases is high (374). In the United
States, HIV infection has been associated with TB outbreaks
in institutional settings, including health-care facilities (53),
correctional facilities (37), and homeless shelters (33).
Before the advent of highly active antiretroviral therapy
(HAART) in the early 1990s, HIV infection caused a pro-
gressive decline in immune competence and death. However,
the use of HAART using combination therapy plus protease
inhibitors has prolonged the survival among persons with HIV
infection (375–377). The introduction of HAART has also
decreased the incidence of TB among HIV-infected persons:
an 80% decrease in risk for TB has been demonstrated among
HIV-infected persons receiving HAART (378).
With the declining incidence of TB in the United States
since 1992, the incidence of HIV infection among persons
with TB also has decreased. This is likely attributable to
increased understanding of the biologic interactions between
the two pathogens, leading to more targeted TB-control
efforts and to the introduction of HAART. Another factor is
improved TB infection control in health-care facilities,
because HIV- infected persons were particularly affected by
health-care–associated transmission of M. tuberculosis (53).
HIV infection was a prominent cause of the 1985–1992
TB resurgence in the United States, especially the incursion
of health-care–associated TB (including multidrug-resistant
disease). That fact, along with the knowledge that the global
epidemics of HIV infection and TB are continuing unabated
(44), dictates a high degree of respect and vigilance for the
adverse consequences that HIV infection could impose on
the epidemiology of TB in the United States.
Basis for Recommendations of Control
of TB Among Persons with HIV Infection
HIV counseling and testing. Knowledge of the presence
of HIV infection among patients with TB is useful for sur-
veillance purposes to ensure that an optimal drug regimen is
chosen for treatment (5), refer persons for HIV primary care
if the case is newly detected, and guide decisions about
contact investigations. TB is frequently the first illness that
brings a person who has not previously received a diagnosis
of HIV infection into the health-care system.
Voluntary counseling and testing for HIV is recommended
for all patients with TB (5), but this recommendation has not
been fully implemented, and reporting of HIV among per-
sons with TB is incomplete (14). In 2003, HIV testing was
performed for <50% of patients reported with TB in the
United States, and only 63% of persons in the age group at
greatest risk (persons aged 25–44 years) were tested (14). HIV
counseling and testing has also been recommended for con-
tacts of persons with TB (302). However, recent data
indicate that contacts of HIV-infected persons with TB have
a high rate of HIV infection but that contacts of persons with
TB without HIV infection do not (301). HIV testing for other
persons with LTBI should be limited to those who have clini-
cal or behavioral risk factors for HIV infection.
Case detection. HIV coinfection affects the clinical and
radiographic manifestations of TB. HIV-infected patients are
more likely than persons without HIV infection to have
extrapulmonary and miliary TB (379,380), and those who
have pulmonary TB tend to have atypical findings (e.g., they
are less likely to have apical cavities and are more likely to
have lower lobe or instititial infiltrates and mediastinal or
paratracheal lymphadenopathy). These atypical features are
heavily dependent on the patient’s CD4 cell count; those
with CD4 cell counts >300 cells/µL usually have manifes-
tations, such as upper lobe cavitary infiltrates (274). Per-
sons with HIV infection might also have pulmonary TB
despite a normal chest radiograph (274,379).
HIV-infected patients are also vulnerable to other pulmo-
nary and systemic infections such as Pneumocystis carinii and
pneumococcal pneumonias and disseminated M. avium com-
plex disease. Although the symptoms and signs of TB are
usually different to the trained clinician from those caused
by other prevalent invasive pathogens (273,381), HIV
co-infection often results in delay in the diagnosis of TB as
a result of altered clinical and radiographic manifestations
(23).
Undetected transmission of M. tuberculosis to HIV-infected
persons can have serious sequelae (136). A substantial
outbreak of TB in a prison in South Carolina in 1999
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demonstrated the widespread consequences of an unrecog-
nized TB case in a congregate setting with a substantial
number of HIV-infected persons (37). In that outbreak,
32 TB cases and 96 tuberculin skin test conversions
resulted from a single unrecognized case. Similar outbreaks
have occurred in hospitals (53,244), HIV-living facilities
and day-treatment programs (136), and homeless shelters
(33). Such outbreaks underscore the importance of aggres-
sive TB screening and treatment in settings in which HIV-
infected persons congregate. Screening for TB in those
settings has been successfully conducted by using symp-
tom checklists, tuberculin skin testing, and chest radio-
graphs (37,118,136).
Case management. Management of TB among persons
with HIV infection is complex. Drugs used to treat TB
and those employed in combination antiretroviral therapy
have overlapping toxicities and potentially dangerous drug
interactions (382). Paradoxical responses to TB therapy are
more common among HIV-infected persons (383). Use of
multiple potentially toxic medications also provides fur-
ther challenge to adherence with TB treatment. Therefore,
integration of management of both HIV infection and TB
is critical to the success of management of both. Compre-
hensive case management, including DOT, is particularly
important (5). Among HIV-infected TB patients, more
favorable outcomes and survival have been associated with
DOT than with self-administered therapy (384). ATS/
CDC/IDSA guidelines should be consulted for recommen-
dations on length and mode of treatment and selection of
drug regimens (5). Finally, patients with HIV and TB bear
the brunt of two conditions that are associated with clini-
cal and social complexities that can be personally over-
whelming. Both HIV infection and TB are associated with
stigmatization, and patients with these concomitant
conditions often suffer from isolation and a lack of social
support.
Contact investigation. Despite controversy as to whether
HIV-coinfected patients with TB are more or less infectious
than HIV-seronegative patients (385,386), they are clearly
capable of transmitting M. tuberculosis; contacts of the two
populations of patients have comparable rates of LTBI
(369,387). The higher risk for progressing rapidly from expo-
sure to M. tuberculosis to TB disease means that all of the
medical and public health interventions (case detection and
reporting, initiation of an effective drug regimen, and identi-
fication and evaluation of contacts) are more urgent when
working to control HIV-associated TB (388).
Although offering HIV counseling and testing to all con-
tacts of persons with infectious TB has been recommended
(302), this undertaking would be resource-intensive. Whereas
prevalence of HIV infection among contacts of HIV-infected
persons is high, prevalence among contacts of persons with
TB without HIV infection or with undetermined status is
negligible (301).
Targeted testing and treatment of LTBI. HIV coinfection
is the most important known risk factor for persons with LTBI
acquiring active TB (317,371,372). Treatment of LTBI is
effective in reducing the risk for progression to TB disease
among HIV coinfected persons (372,389). Thus, all possible
efforts should be made to ensure that HIV-infected persons
are tested for M. tuberculosis infection and that those found
to have latent infection receive and complete a course of
treatment. In addition, knowledge of the HIV status of
persons being evaluated for LTBI is desirable 1) in inter-
preting the tuberculin skin test result (e.g., >5 mm of
induration is considered a positive test among persons with
HIV infection [4]) and 2) in counseling persons with posi-
tive skin test results about the risks and benefits of treat-
ment for LTBI (the role of QFT-G for testing persons with
HIV infection for LTBI has not been determined). Accord-
ing to current guidelines (302), persons being evaluated
for LTBI should also be screened for HIV infection by
using self-reported clinical and behavioral risk factors.
Institutional infection control. Infection-control measures
recommended to prevent transmission of M. tuberculosis have
been effective in limiting exposure of HIV-infected persons,
including patients, visitors, and staff members, to
M. tuberculosis in hospitals, extended care facilities, and cor-
rectional facilities (9,244). Nevertheless, the risk for rapid
progression from exposure to TB disease means that HIV-
infected persons should continue to be advised of any poten-
tial sites of institutional exposure so an informed choice
regarding employment or volunteering can be made.
Control of TB Among Homeless Persons
The persistence of TB among homeless persons in the
United States is a major public health problem. The home-
less population is not insubstantial; in 1995, an estimated
5 million persons (2.5% of adult U.S. residents) either were
or had recently been homeless, living in streets or shelters,
or marginally housed (e.g., living on public support in resi-
dential hotels) (390). TB incidence is high among home-
less persons, and evidence exists of considerable transmission
of M. tuberculosis. Among 2,774 homeless persons enrolled
during 1990–1994 in San Francisco, California, 25 inci-
dent cases were identified for 1992–1996, for an annual
rate of 270 cases/100,00 population (118). Among 20
M. tuberculosis isolates from incident cases that were sub-
jected to genotyping study, 15 (75%) were clustered,
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indicating chains of transmission in the population. Other
molecular epidemiology studies also have identified
homelessness as an important risk factor for clustering of
M. tuberculosis isolates (33,119,391,392).
Shelters are key sites of TB transmission among homeless
persons throughout the United States (27,33,118–120,166,
391–393). In Los Angeles, California during March 1994–
May 1997, three homeless shelters were sites of TB transmis-
sion for 55 (70%) of 79 homeless patients (33). In Fort Worth,
Texas during 1995–1996, clusters of cases among homeless
persons occurred simultaneously in four homeless shelters
(27). In Alabama, genotyping of isolates from TB cases
reported in 1994-98 revealed an undetected statewide out-
break of TB that was traced to transmission in a correc-
tional facility and in two homeless shelters (166). In an
outbreak in a shelter in Syracuse, New York, during 1997–
1998, a shelter resident was probably infectious for 10
months before receiving a diagnosis; ventilation in the shelter
was poor, and the population included vulnerable persons
with risk factors that included HIV infection, substance
abuse, and malnutrition (120).
Multiple barriers to the control of TB among homeless per-
sons have been identified. Delays in detection of infectious
cases have been reported (20); in a computer simulation study
that modeled multiple strategies for TB control among home-
less persons, a 10% improvement in access to treatment led to
greater declines in disease and death after 10 years than com-
parable improvements in treatment programs (394). Tradi-
tional methods of conducting contact investigations often fail
to identify contacts of homeless persons with TB (30,119,120).
Difficulties also have been encountered in completing treat-
ment for homeless patients with active TB (395) and LTBI
(167,184).
Basis for Recommendations for Control
of TB Among Homeless Persons
Surveillance and case detection. Delays in diagnosis and
treatment of TB among homeless persons might occur as a
result of delays in seeking medical care (181) and to the fail-
ure of medical providers to detect TB among those seeking
care (20). Homeless persons with TB are disproportionately
likely to receive care in hospital EDs and other urgent care
clinics (232). For example, during 1994–1996, homeless per-
sons in Atlanta, Georgia, were more likely than other patients
to receive a diagnosis in a hospital ED (184). On the basis of
sputum AFB smear results and radiologic findings, homeless
persons had more advanced disease at the time of diagnosis,
another indication that they received diagnoses later in the
course of their disease (184).
Shelters have proved to be effective sites for case detec-
tion by use of screening procedures among homeless per-
sons. During May 1996–February 1997, among 127
homeless persons in Alabama for whom shelter-based
screening was conducted by using symptom evaluation,
sputum culture, and chest radiographs as the screening
package, four (3.1%) persons had TB disease (281). Symptom
evaluation alone was not proven to be useful. In a similar study
from London, United Kingdom, that employed symptom evalu-
ation, tuberculin skin testing, and chest radiography, 1.5% of
homeless persons were determined to have TB (396).
On the basis of findings of a high prevalence of TB in
shelter-using homeless populations, certain communities
have implemented compulsory screening of shelter residents
based on symptom evaluation or tuberculin skin testing
with radiographs for those with positive tests. One such
program in Portland, Oregon, initiated in 1985, was asso-
ciated with an 89% reduction in TB morbidity in the geo-
graphic area served by participating shelters during
1980–1995 (397). The implementation of a similar screen-
ing program in shelters in Denver, Colorado, in 1995 led
to lower rates of active TB and reduced transmission of TB
disease, as demonstrated by less genotype clustering by
DNA fingerprinting (167). Both screening programs were
based on symptom evaluation, tuberculin skin testing, and
chest radiography. The decrease in TB morbidity in both
these studies was attributed to shelter-based case
detection through screening activities.
Case management. Completion of treatment for active TB
is more difficult for homeless persons, particularly those who
report substance abuse, including alcohol abuse (395). Home-
less persons with active TB are at high risk for poor adherence
even with enhanced DOT and are more likely to default and
move from the area of initial diagnosis. They are also more
likely to have legal action taken in the form of court-ordered
treatment or detention. Comprehensive case management that
includes a variety of incentives and enablers, including food,
temporary housing, transportation vouchers, and treatment
for substance abuse and mental illness has improved rates of
treatment completion in this population.
Costs for homeless persons who are hospitalized for ini-
tial treatment of active TB have been $2,000 more than
costs for persons who were not homeless (398). Excess hos-
pital utilization could be attributable to social consider-
ations, clinical indications (especially the need to render a
patient noninfectious before discharge to a congregate liv-
ing setting), or concerns about adherence to the plan of
treatment. In San Diego, California, a novel housing pro-
gram that used hostels facilitated the completion of treat-
ment of TB in homeless persons (399). Completion rates
of 84%–100% were achieved for persons housed at a des-
ignated hostel in 1995. Certain TB-control programs in
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cities with substantial homeless populations routinely pro-
vide temporary or longer-term housing in attempts to
improve completion of treatment. The California Depart-
ment of Health allots funds for temporary housing of per-
sons with TB to each of its county and local jurisdictions.
The U.S. Department of Housing and Urban Development
also provides funding for housing patients with TB.
The beneficial impact on treatment outcomes of an inte-
grated approach to managing homeless patients with TB has
been emphasized (394). For example, a social care and health
follow-up program among homeless patients in Spain was
associated with a decrease in TB rates from 32.4/100,000
in 1987 to 19.8 cases/100,000 in 1992, and better comple-
tion rates and reduced costs for hospitalizations were also
documented (400). In Massachusetts, 58 (34.5%) of 214
persons hospitalized in a dedicated inpatient unit for diffi-
cult TB patients during 1990–1995 were homeless (401).
Regardless of the case-management plan that is chosen, all
such interventions should take into consideration the
importance of addressing major gaps in knowledge, atti-
tudes, and beliefs about TB among homeless persons (181).
Contact investigation. Contact investigations for cases
of TB among homeless persons are particularly challeng-
ing. Homeless patients with TB often fail to identify con-
tacts during routine investigation (30). Completing a
contact evaluation in identified contacts and completing
treatment for LTBI among contacts that are homeless are
often difficult (320,391,402). Interpretation of the results
of tuberculin skin testing of contacts of homeless cases is
problematic because the background prevalence of positive
tuberculin skin tests in the population is usually higher
than that of the general population. As with contact inves-
tigations among other populations at high risk, discerning
when a contact investigation has become a targeted testing
program is often difficult. A proposed alternative approach
to conducting contact investigations of homeless persons is
to focus on possible sites or locations of exposure, such as
shelters (391,393).
Targeted testing for and treatment of LTBI. When home-
less persons are identified as a population at high risk on the
basis of the local epidemiology of TB, targeted testing and
treatment protocols tailored to local circumstances should be
developed. However, low rates of completion of therapy for
LTBI are commonly observed (167,184,402). For example,
among 7,232 inner city residents (including homeless persons)
screened for LTBI during 1994–1996 in Atlanta, Georgia,
4,701 (65%) completed tuberculin skin testing; of 809 (17%)
who had a positive test, 409 (50%) were candidates for
isoniazid therapy, and 84 (20%) completed treatment
(184). In another study conducted in San Francisco, Cali-
fornia, during 1991–1994 that was designed to improve
adherence, two novel interventions (biweekly preventive
DOT with either a $5 incentive or a peer health adviser)
were compared with the usual method of self-supervised
treatment (402). Even though completion of treatment was
not high for any of the three groups, multivariate analysis
indicated that independent predictors of completion were
being offered the monetary incentive and residence in a
hotel or other stable housing at entry into the study. That
report confirmed an earlier finding that advocated offering
monetary incentives (320).
Institutional and environmental controls. Efforts have
been made to reduce transmission of TB in shelters for home-
less persons by enhancing institutional control measures.
These efforts have included reducing shelter size (13),
improving ventilation systems, and using germicidal ultra-
violet light (280).
Control of TB Among Detainees
and Prisoners
Correctional facilities in the United States include jails and
prisons, which serve different but complementary functions.
Jails serve as pretrial detention centers and house persons
(detainees) awaiting trial and those sentenced to <1 year of
incarceration. Local and county governments operate the
majority of jails. Jails are characterized by rapid turnover of
detainees with short lengths of stay. Prisons serve as sites of
detention for persons (prisoners) who have been sentenced
and will be incarcerated for a known length of time, generally
>1 year. State governments, the federal government, and the
military all operate prison systems. On any given day, approxi-
mately 2 million persons in the United States are incarcer-
ated; 1.4 million of those are imprisoned, and the remainder
are detained in jails. Approximately 6 million persons are
incarcerated in jails or prisons each year for variable lengths
of time (124,125).
Detainees and prisoners represent the poorest and most
medically underserved segments of the U.S. population, the
same population segments at risk for LTBI and TB disease
(124,252,253). Persons entering prisons have usually spent
time in jail, and detainees and prisoners eventually reenter the
community. Consequently, TB outbreaks among detainees,
prisoners, and the general population of a geographic area are
interrelated (127,403), and close coordination of TB-control
activities is needed between health programs in correctional
facilities and jurisdictional public health agencies.
Prisons have long been identified as sites of transmission
of M. tuberculosis to other inmates and workers
(38,139,404–408), including those with HIV infection
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(38,139,405,408). In addition, time spent in jail is a risk
factor for subsequent acquisition of TB (127,250,256), an
indication that jails often are also sites of transmission. Cor-
rectional facilities are among the most important sites of trans-
mission of M. tuberculosis in the United States.
Failure to detect TB in correctional facilities results in TB
outbreaks, which have been well documented (37,139,404–
408). Outbreaks of multidrug-resistant TB involving inmates
and staff, including HIV-infected persons, were a prominent
component of the 1985–1992 TB resurgence in the United
States (404,405,409–411). However, outbreaks have contin-
ued to occur (37,139), even though TB control, including
control of M. tuberculosis transmission, in the United States
has improved.
Basis for Recommendations on Control
of TB Among Detainees and Prisoners
Case detection and case management. Despite the
importance of jails and prisons in sustaining and amplifying
the reservoir of TB in the United States (127,405,407),
little is known about the optimal means of case detection
of TB among detainees and prisoners. The majority of pris-
ons have adopted a case-detection strategy that is based on
a survey of TB symptoms obtained on admission, in which
all entrants are tested for M. tuberculosis infection <14 days
of admission; universal chest radiographs of all entrants are
rarely offered (410). No data have been published sup-
porting the effectiveness of symptom surveys and testing
for M. tuberculosis infection for detecting cases of TB and
preventing transmission within jail systems, although screen-
ing by tuberculin skin testing was effective in controlling
TB in one prison system (411). Certain substantial urban
jails perform chest radiographs on all persons entering the
institution in an attempt to minimize transmission of TB
(283,412), and data indicate that this approach is cost
effective (412). Because nearly all prison entrants have first
been detained in a jail system, effective TB case-detection
programs in jails will substantially decrease the probability
that persons with undetected active TB will be admitted
to prison.
Once cases are detected, strategies similar to those used
in the community have led to high rates of successful treat-
ment completion (413). A particular problem for case man-
agement in a jail setting is the unanticipated release of
detainees, which often precludes the development of an
effective discharge plan. Strategies to better coordinate dis-
charges with public health authorities should be promoted.
Contact investigation. Continuing outbreaks of TB in
correctional facilities (37,139) underscore the importance
of prompt and thorough contact investigations in jails and
prisons. Contact investigations in correctional facilities
involve two steps: 1) identifying and evaluating persons
exposed before the source-case was incarcerated, and 2) iden-
tifying and evaluating persons exposed during incarceration
of the source-case. Effective case detection is important to
limit the size of the latter group. Contact investigations
often need to be conducted broadly, among more than one
facility, because of the movement of detainees within the
correctional system (414).
Conducting contact investigations based on the concen-
tric circle method is difficult in correctional institutions.
Frequently, a single infected person can expose up to sev-
eral hundred persons both before and after incarceration.
Cases involving persons who were exposed before incarcera-
tion should be managed by the jurisdictional public health
agency for the community in which the person lived before
arrest. For the jurisdictional public health agency to carry
out those contact investigations effectively, prompt notifi-
cation and case reporting by the detention facility is neces-
sary. Guidelines for conducting contact investigations in
jails have been published (258).
Targeted testing and treatment of LTBI. Targeted test-
ing and treatment of latent TB among detainees and pris-
oners has been described in detail (415–417). Because of
the high risk for transmission of M. tuberculosis in correc-
tional facilities, inmates incarcerated for >14 days usually
receive a test for M. tuberculosis infection as part of TB case
detection. Detainees and prisoners with LTBI often are con-
sidered to be candidates for treatment of latent TB
(124,252,253). Prisons often are an ideal setting for effec-
tive treatment of LTBI because of known location of the
patient, length of stay, prohibition of illicit drugs and
alcohol, and a predictable diet. Nevertheless, achieving high
rates of completion of treatment for LTBI in prisons or jails
has been difficult (257,416,417).
The majority of jail detainees are released in <14 days of
entry. If treatment for LTBI is started in the jail setting,
community follow-up after release from jail is essential.
Without specific interventions to assure such follow-up,
the probability of completion of treatment might be <10%
(256,257,418). Recent developments in short-course treat-
ment of latent TB with a combination of rifampin and
pyrazinamide for 2 months offered promise in improving
treatment completion rates (419). However, the toxicity of
this regimen precludes its routine use (324), and this com-
bination should generally not be used for the treatment of
LTBI in correctional settings because the rates of toxicity
have been similar to those observed in the wider commu-
nity. In addition, detainees and prisoners have high rates
of hepatitis C infection, making them especially prone to
serious hepatotoxicity.
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Institutional infection control. Correctional institutions
have been sites of virulent outbreaks of TB, including
multidrug-resistant TB, that have involved HIV-infected
inmates and staff (37,139,405,408). Common findings in
these outbreaks have included the failure to isolate persons
with active TB quickly. Another common finding has been
disease associated with rapid transmission of M. tuberculosis
when immunosuppressed detainees and prisoners are
housed together. An effective infection-control program can
decrease the likelihood of TB transmission in correctional
institutions (420). Guidelines to assist correctional insti-
tutions in developing effective infection-control programs
have been published (258).
Control of TB in Health-Care
Facilities and Other High-Risk
Environments
During the 1985–1992 TB resurgence in the United
States, TB cases resulted from transmission of M. tuberculosis
in settings where patients with infectious TB congregated
closely with susceptible persons (52–54,170,421). This
epidemiologic disease pattern had not been recognized in
the United States since the development of effective drugs
against TB starting in the 1950s. Hospitals and other
health-care facilities were the primary, but not the only,
sites of transmission (405,406,408), and HIV-infected
persons were prominent among those who contracted
M. tuberculosis infection and rapidly acquired TB disease
(52–54,170,406,408). Although incidence of TB in
health-care facilities has been markedly reduced because of
the development and deployment of effective infection-
control measures (56,422–424) and decreasing incidence
of TB in different communities, TB disease attributable to
recent transmission of M. tuberculosis in other settings has
not only persisted but has been recognized in a wide vari-
ety of sites and settings and become an established epide-
miologic pattern.
As a consequence of the changed epidemiology of TB in
the United States, the primary strategies now required to
control the disease include measures for its prevention in
settings in which a risk for transmission of M. tuberculosis
exists (Box 4). Recommendations for infection-control
measures in high-risk settings are provided in this state-
ment. The approach to control of TB and other airborne
infections that was developed for health-care facilities (10)
is the most successful model and is outlined in detail in
this statement. Recommendations are also provided for
control of transmission of M. tuberculosis in extended care
facilities, correctional facilities, homeless shelters and other
high-risk settings.
Control of TB in Health-Care Facilities
Strategies for control of TB in health-care facilities, which
also are applicable for other settings in which high-risk per-
sons congregate, are based on comprehensive guidelines
issued by CDC in 1994 (10). New CDC guidelines for pre-
venting transmission of M. tuberculosis in health-care facili-
ties will be published in 2005. A draft† of these guidelines
has been published in the Federal Register. In the assess-
ment of institutional risk for TB, three levels of risk (low,
medium, and potential ongoing transmission) are recom-
mended, based on the recent experience with TB in the
institution and in the community it serves. The recom-
mended frequency of testing of employees for M. tuberculosis
infection varies, depending on the institution’s level of risk.
The tuberculin skin test is recommended for testing HCWs
and other employees with a risk for exposure to
M. tuberculosis. QFT-G is also approved for detecting LTBI;
guidelines for the use of QFT-G will be published in the
MMWR.
The risk for TB associated with health-care facilities is related
to the incidence of TB in the community served by the facility
and to the efficacy of infection-control measures (422). Imple-
mentation of infection-control guidelines (10) has markedly
reduced risk for exposure to TB in health-care facilities during
the past decade (56,422–424) and has also contributed to the
decreasing numbers of TB cases. Implementation of effective
infection-control measures in the medical workplace is thus an
important element of broader national and international
strategies to prevent transmission of TB (244).
Epidemiologic investigations of the early outbreaks of TB
in health-care facilities, including those involving multidrug-
resistant cases, indicated that transmission usually occurred
because of failure to identify and isolate patients with infec-
tious forms of TB. In certain instances, diagnosis of TB was
delayed as a result of the atypical presentation of TB among
patients with HIV infection, especially those with low CD4
counts. Transmission was also facilitated by 1) the intermin-
gling of patients with undiagnosed TB with patients who were
highly susceptible; 2) inadequate laboratory facilities or
delayed laboratory reporting; and 3) delayed institution of
effective therapy. Other factors facilitating transmission
included a lack of negative pressure respiratory isolation
rooms, recirculation of air from respiratory isolation rooms
† Draft Guidelines for Preventing the Transmission of Mycobacterium
tuberculosis in Health-Care Settings. Federal Register 2004;69:70457–8.
Vol. 54 / RR-12 Recommendations and Reports 57
to other parts of the hospital, failure to isolate patients until
they were no longer infectious, allowing isolated patients
to leave their rooms without wearing a mask, and leaving
respiratory isolation room doors open (52–54,170,421,425,426).
CDC guidelines recommend a hierarchy of TB infection-
control measures (10). In order of importance, these mea-
sures are administrative controls, engineering controls, and
personal respiratory protection (PRP) (Box 7). Administra-
tive controls consist of measures to reduce the risk for expo-
sure to persons with infectious TB, including screening of
patients for symptoms and signs of TB at the time of admis-
sion, isolating those with suspected disease, establishing a
diagnosis, and promptly initiating standard therapy (5).
Engineering control measures are designed to reduce dis-
semination of droplet nuclei containing M. tuberculosis
from infectious patients and include the use of airborne
infection isolation rooms. The third level (and the lowest
on the hierarchy of controls) is the use of PRP devices such
as N-95 respirators. Respirator usage for the prevention of
TB is regulated by the Occupational and Health Safety
Administration under the general industry standard for res-
piratory protection§.
In implementing a comprehensive infection control pro-
gram for TB, institutions should first conduct a risk assess-
ment to determine what measures are applicable. Risk for
transmission of M. tuberculosis varies widely, and procedures
that are appropriate for an institution in an area of high TB
incidence (e.g., an inner-city hospital or homeless shelter
in a metropolitan high-incidence area) differ from those
applicable to an institution located in a low incidence area
that is rarely used by patients with TB. The jurisdictional
public health TB-control program should assist in the
development of the assessment, which should include data
on the epidemiology of TB in the community served by
the institution and the number of TB patients receiving
evaluation and care.
The institutional risk for TB can be stratified according
to the size of the institution and the number of patients
with TB as low risk, medium risk, or potential ongoing
transmission. Hospitals with >200 beds that provided care
for fewer than six patients with TB during the previous
year are categorized as low risk whereas those that cared for
six or more patients are categorized as medium risk. For
hospitals with <200 beds, those with fewer than three TB
patients in the previous year are considered low risk, and
those with three or more cases are considered medium risk.
Outpatient clinics, outreach programs, or home health
§ Personal Protective Equipment, 29 C.F.R. Sect. 1910.134 (2003).
BOX 7. Principles of control and prevention of tuberculosis
(TB) in health-care facilities, by strength of recommendation
and quality of evidence*
• A TB infection control program should be established in
all health-care settings (sites that provide care to patients
with TB and sites that refer such patients to other facili-
ties) to prevent transmission of Mycobacterium tuberculosis.
A hierarchy of controls (i.e., administrative, engineering,
respiratory protection) should be implemented (AII).
• A risk assessment should be implemented to determine
the appropriate level of controls to implement. The risk
assessment will also determine the frequency of testing
of health-care workers for latent TB infection (AIII).
• Administrative controls, designed to ensure the prompt
recognition, isolation, diagnosis, and treatment of
patients with infectious TB, are the most important
elements of an infection control program (AII).
• A high index of suspicion for TB should be main-
tained by health-care providers. Airborne infection
isolation should be implemented for patients as soon
as TB is suspected, whether during emergency care,
during hospital evaluation, or in a clinic setting (AIII).
• When indicated, standard therapy for TB should be
promptly initiated, and the diagnosis confirmed or
excluded as soon as possible (AII).
• Surveillance should be conducted to ensure that rooms
for airborne infection isolation are functioning properly.
A risk assessment should determine the number of rooms
for airborne infection isolation that are needed (AIII).
• Institutions that do not provide care to persons with
TB should have a plan for isolation and prompt trans-
fer of suspected patients to other facilities (AIII).
• Patients with infectious TB should be discharged from
hospital only when arrangements have been made to
prevent contact with susceptible persons† (AIII).
• Health-care facilities should cooperate closely with pub-
lic health agencies to ensure that patients with TB
receive adequate planning for outpatient management
to ensure that treatment is continued until a complete
course of curative therapy has been administered (AIII).
• All health-care workers should undergo baseline testing
for latent TB infection. The frequency of subsequent test-
ing should be based on results of the risk assessment. Em-
ployees with latent TB infection should be encouraged to
start and complete treatment, if indicated. Surveillance
and analysis of results of serial testing of employees for
M. tuberculosis infection should be conducted (AIII).
• Employees should regularly receive education on TB (AIII).
SOURCE: CDC. Guidelines for preventing the transmission of
Mycobacterium tuberculosis in health-care facilities, 1994. MMWR 1994;43(No.
RR-13):1–132.
* See Table 1.
† See Box 3.
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settings that provide care for fewer than three patients with
TB per year are considered low risk, and those that care for
three or more patients are considered medium risk. TB clin-
ics, outreach programs, and other settings in which HCWs
are responsible for the care of persons with TB are classified
as medium risk. Any institution, clinic, or setting with evi-
dence of recent patient-to-patient or patient-to-employee
transmission of M. tuberculosis or of ongoing or unresolved
transmission should be classified as having potential ongo-
ing transmission until effective control measures have been
implemented and transmission is interrupted. Potential
ongoing transmission is a temporary classification.
When transmission of M. tuberculosis is suspected at a facil-
ity, an immediate investigation should be undertaken that
includes consultation with public health officials or experts in
hospital epidemiology and infection control. Evidence of
potential transmission of M. tuberculosis includes clusters
of conversions of tests for M. tuberculosis infection among
employees from negative to positive, increased rates of posi-
tive tests for M. tuberculosis infection among employees, an
employee with potentially infectious TB, unrecognized TB
among patients or employees, and recognition of identical
strains on genotyping of M. tuberculosis isolates from patients
or employees.
How often employees at health-care facilities and other
at-risk sites for M. tuberculosis infection are tested depends on
the risk assessment. The positive predictive value of the tuber-
culin skin test is low when populations with a low prevalence
of infection with M. tuberculosis are tested (424,427). Conse-
quently, frequent testing by using that method in low-
incidence, low-risk settings is discouraged. In addition,
false-positive tests have been reported when institutions
changed brands of Purified Protein Derivative (PPD)
reagent, for example from Tubersol® to Aplisol® (427).
At the time of employment, all HCWs should undergo
baseline testing (with two-step testing if the tuberculin skin
test is used and no testing was performed during the preced-
ing year) (10). Those in medium-risk settings should be tested
annually. Follow-up testing is recommended for workers in
low-risk settings only if exposure to a patient with infectious
TB (i.e., a patient not initially isolated but later found to have
laryngeal or pulmonary TB) has occurred. Institutions in which
ongoing transmission of M. tuberculosis is documented should
carry out testing for M. tuberculosis infection of HCWs at
risk every 3 months until transmission has been terminated.
Employees testing positive for M. tuberculosis infection
should receive a chest radiograph to exclude TB disease and
should be evaluated for the treatment of LTBI based on cur-
rent recommendations (4,324). Compliance with therapy
for LTBI among HCWs, including clinicians, has histori-
cally been poor (428–430). Employee health clinics and
infection-control departments should emphasize to HCWs
the importance of completion of therapy for LTBI. In a
comprehensive infection-control program that encourages
HCWs to complete treatment for LTBI, higher comple-
tion rates have been reported (431,432).
Control of Transmission of M. tuberculosis
in Other High-Risk Settings
Extended Care facilities. Elderly persons residing in a
nursing home are almost twice as likely to acquire TB as
those living in the community (252,433,434). Certain con-
siderations for control of TB in hospitals apply also to
extended care facilities, including 1) maintaining a high
index of suspicion for the disease; 2) promptly detecting
cases and diagnosing disease; 3) isolating infectious per-
sons and initiating standard therapy; 4) identifying and
evaluating contacts; and 5) conducting contact investiga-
tions when indicated. The value of treating LTBI in elderly
residents of nursing homes so as to prevent future outbreaks
has been documented (435).
In 1990, CDC published recommendations for TB control
in extended care facilities (433). Those long-term care facili-
ties that do not have airborne-infection-isolation rooms should
transfer patients suspected to have infectious TB to other
facilities (including acute-care hospitals) until the disease is
ruled in or out and treatment is started if indicated and con-
tinued until the patient is noninfectious (10). The risk assess-
ment and frequency of testing for LTBI for employees at
long-term care facilities are similar to those described previ-
ously. Residents should be tested on admission to the facility
and should provide a history and undergo physical exami-
nation to identify symptoms and signs of TB. Residents
with LTBI should be offered treatment according to cur-
rent recommendations (4,324), with careful monitoring
for drug toxicity.
Correctional facilities. Common findings in outbreaks
of TB in correctional facilities were the failure to recognize
and isolate patients with TB and rapid progression of out-
breaks when immunosuppressed detainees were housed
together (405,406,408). Because of the substantial num-
bers of cases of TB infection and disease that might result
from outbreaks at correctional facilities and the natural
movement of inmates from incarceration to the general
population, correctional facilities should be viewed as
being among the most important sites of transmission of
M. tuberculosis in the United States (128,436).
Guidelines for control of TB transmission in correctional
facilities (123) have emphasized that the infection-control
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principles developed for health-care facilities (10) are also
applicable to correctional facilities. In prisons and jails, the
most important activity in TB infection control is efficient
detection of infectious TB cases, including those that are preva-
lent among persons entering the facility and those that arise
during detention. A prompt diagnostic evaluation, respira-
tory isolation (including transfer out of the facility if airborne-
infection-isolation rooms are not available), and institution
of a standard treatment regimen are urgent priorities when
suspected cases are encountered. If this process is delayed, a
substantial number of persons might be exposed as a result of
the congregate living arrangements that characterize correc-
tional facilities.
Because of crowded conditions that favor the spread of
M. tuberculosis (420) and the high prevalence of HIV
infection among prisoners (255), contact investigations
should be undertaken immediately once a case of TB has
occurred at a facility. In a study conducted in the Mary-
land state correctional system, prisons that conducted pro-
grams for targeted testing and treatment of LTBI among
inmates experienced lower rates of tuberculin skin test con-
versions, an indication that this measure can contribute to
successful infection control (420). A template is now avail-
able to assist jails in instituting an effective infection-
control program (258).
Shelters for homeless persons. As with correctional facili-
ties, homeless shelters are important sites of transmission of
M. tuberculosis and an important cause of the continuing high
incidence of TB among the homeless population (33,118).
Effective infection-control strategies in those venues are use
of M. tuberculosis genotyping for rapid identification of clus-
tered cases and sites of transmission (27,33), screening shelter
users for TB disease, wide-ranging contact investigations,
and engineering controls, including ultraviolet germicidal
irradiation (437). A systematic shelter-based program for
targeted testing and treatment of LTBI in Denver was also
demonstrated to decrease incidence of TB in the homeless
population (167).
Because crowding and poor ventilation are often preva-
lent in shelters, infection-control efforts should also include
engineering modifications to decrease exposure to
M. tuberculosis. A guide to assist shelters in improving the
safety of their environment through modifications in ven-
tilation, air filtration, and the introduction of ultraviolet
germicidal irradiation has been published (438).
Other high-risk settings. As the incidence of TB has
receded in recent years, new patterns of transmission have
become evident. Epidemiologic investigations prompted by
an increase in the incidence in TB in a community or state
or by the identification of clusters of cases with identical
M. tuberculosis genotype patterns have detected transmis-
sion in such venues as crack houses (137) and bars (27). In
addition, transmission has been identified in association
with certain social activities that are not typically consid-
ered in routine contact investigations; a church choir (140),
a floating card game (172), exotic dancers and their con-
tacts (38), a transgender social network (34), and persons
who drink together in multiple drinking establishments
(439).
Although special techniques have been developed for
exploring chains of transmission of M. tuberculosis in com-
plex social networks (439), transmission of M. tuberculosis in
such settings is not amenable to prevention by available
infection-control strategies. These newly identified patterns
of transmission of M. tuberculosis might be too complex to
be detected and controlled by traditional approaches, and
real-time M. tuberculosis genotyping capable of identify-
ing unsuspected linkages among incident cases might be
increasingly useful (131).
This new TB threat, transmission in previously unknown
settings, has emerged at a time when local TB-control pro-
grams often are not prepared to respond. As TB morbidity
decreases in the United States and TB-control programs nec-
essarily contract, new approaches will emerge, particularly in
low-incidence areas. One model envisions that local public
HCWs who do not work exclusively on TB are served by
regional TB supervisors, who in turn are supported by state-
wide consultants and CDC specialists (172).
Research Needs
to Enhance TB Control
Implementation of the recommendations contained in
this statement will likely improve TB control and allow
progress to be made toward eliminating TB in the United
States. However, achieving TB elimination as defined by
ACET (i.e., one annual case of TB per one million popula-
tion [11]) will require substantial advancements in the tech-
nology of diagnosis, treatment, and prevention of the
disease. IOM has estimated that at the current rate of
decline, approximately 6% annually, eliminating TB in the
United States would take >70 years (2). New tools are
needed for the diagnosis, treatment, and prevention of TB
to accelerate the decline in TB incidence and reach the elimi-
nation threshold sooner (1,2,45). In addition, improved
tests for the diagnosis of TB and LTBI and more effective
drugs to treat them are needed to reduce the substantial
worldwide burden of disease and death resulting from TB
(44).
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AFB smear microscopy and the tuberculin skin test, the
most commonly used tests for the diagnosis of TB and
latent infection respectively, derive from technology devel-
oped in the 19th Century; the only available vaccine against
TB, BCG, dates from the early 20th Century; and rifampin,
the most recent novel compound for treatment of TB, was
introduced in 1963. In the long term, the development of
a new and effective vaccine would have the greatest impact
on the global epidemic of TB, and the United States should
lead the research and advocacy efforts to develop such a
vaccine (180,440). However, other advances in TB diagno-
sis and treatment might substantially improve the control
of TB in the United States. Better means to diagnose and
treat LTBI are needed immediately. Breakthrough diagnos-
tics and drugs that would facilitate the more effective
usage of this therapeutic intervention to prevent TB would
have an immediate and lasting effect on the incidence of
the disease in the United States by affecting at least three
of the major challenges to TB control in the United States:
the substantial pool of persons with LTBI, TB among
foreign-born persons, and TB among contacts of persons
with infectious TB (Box 1).
Public health interventions to control TB should be based
on practices that have been demonstrated to be effective.
Because an established scientific basis is lacking for certain
fundamental principles of TB control, including certain rec-
ommendations contained in this statement, logic, experience,
and expert opinion have been used to guide clinical and pub-
lic health practice to control TB. In the preparation of these
recommendations for TB control, deficiencies in evidence were
frequently noted. Better understanding is needed of which
persons among the millions of foreign-born persons that
enter the United States each year (Table 8) are at sufficient
additional risk for TB to warrant public health intervention.
The approaches recommended for the development of pro-
grams for targeted testing of LTBI need additional verifica-
tion. The new concepts of identifying contacts of infectious
TB cases (439) require refinement. The optimal method of
reducing the concentration of M. tuberculosis in ambient air
in venues such as homeless shelters is not yet defined (438).
Methods to monitor and evaluate TB control programs, and
in particular, new activities such outbreak surveillance and
response (441), should be delineated and standardized.
The epidemiology of TB in the United States is constantly
changing. Recent examples, as noted throughout this state-
ment, are the increase in TB among foreign-born persons, the
upsurge in reports of TB outbreaks, and the persistent high
incidence of the disease among U.S.-born non-Hispanic
blacks. Epidemiologic studies, including economic analy-
ses, are needed to augment surveillance data and facilitate
decisions about allocation of effort and resources to address
newly identified facets of the epidemiology of TB.
As new diagnostics are introduced to TB control, opera-
tional, economic, and behavioral studies will be needed to
determine their most effective use. For example, QFT, a new
diagnostic test for LTBI, was licensed in 2001, and early
research indicated that this new test might have advan-
tages over the tuberculin skin test in distinguishing
between latent M. tuberculosis infection and infection with
nontuberculous mycobacteria or vaccination with BCG
(102). However, guidelines on testing for LTBI recom-
mended that QFT should not be used in the evaluation of
contacts of infectious cases of TB, for children aged <17
years, for pregnant women, or for patients with
immunocompromising conditions, including HIV infec-
tion, because of a lack of data from studies in those popu-
lations (103). A newer version of the test, QFT-G, was
licensed in 2004. The role of this new test in these popula-
tions has not been determined Thus, considerable research
remains to be done to delineate the advantages this new
test can bring to TB control.
Despite the best efforts of national, state, and local TB pro-
grams, nonadherence to prescribed treatment for TB and
latent infection remains a major barrier to TB elimination. As
evidence of the importance of that intervention, completion
of a course of treatment is the first national performance stan-
dard for TB (Table 4). For the outcome of TB treatment to be
improved, both patient and health-care provider behaviors
related to adherence to TB treatment must be understood,
and that understanding should be used to design and
implement methods for improving adherence. Although
considerable research has been conducted in this field, no
comprehensive effort has been undertaken to examine and
compile the results and identify best practices. Gaps in knowl-
edge remain, and the need exists to develop and implement a
comprehensive behavioral and social science research agenda
to address these deficiencies.
Graded Recommendations
for the Control and Prevention
of Tuberculosis (TB)
Recommendations for TB Laboratory
Services
• Laboratorians, clinicians, and public health officials should
work together to develop an integrated system that
ensures timely laboratory testing and flow of informa-
tion among laboratorians, clinicians, and TB control-
lers (AIII).
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• Public health laboratorians should take a leadership role
to develop the laboratory system and assure that essential
laboratory tests for TB control are available, accessible,
standardized, reproducible, and with high sensitivity and
specificity (AII).
• Public health laboratories should educate laboratory staffs,
health-care providers, and public health officials about
the most effective uses of clinical microbiologic labora-
tory services. Such activities might include education pro-
grams, development of web-based or written materials,
or direct consultation (standard practice [SP]).
• All microbiology laboratories should subscribe to speci-
fied turnaround times (Box 2) from date of specimen col-
lection to date when the following results are reported:
— acid-fast microscopy: <24 hours;
— growth detection of mycobacteria in culture: <14 days;
— identification of M. tuberculosis complex: <21 days; and
— drug susceptibility testing: <30 days (AII).
• The following laboratory results should be reported
immediately (preferably by electronic or fax transmission)
by the testing laboratory to the responsible clinician and
to the jurisdictional TB control program:
— a positive smear for AFB and the subsequent growth
detection (culture) result of that specimen;
— identification of M. tuberculosis complex in any
specimen; and
— drug susceptibility test results, especially when isolates
are drug resistant (AII); and
• Clinical microbiologic laboratories should include, as
part of quality improvement, a plan for identification
and review of possible false-positive results. Any false-
positive result should trigger an inquiry and a plan of
correction (155) (SP).
Recommendations for TB Case Detection
• Steps recommended by IOM (2) to improve public
knowledge and awareness about the risk factors for TB,
symptoms of TB, and the implications of the diagnosis
of latent infection should be undertaken by TB-
control programs, community-based organizations rep-
resenting populations at high risk, and academic health
sciences institutions. Targeted education of populations
at high risk might be particularly effective in neutraliz-
ing the stigma associated with TB among foreign-born
populations on the basis of cultural beliefs in their coun-
try of origin. Programs for patient education should
always be designed with input from the targeted
community (AII).
• Because nonpublic health medical practitioners most
often conduct the initial evaluation on persons who have
symptoms related to TB, health departments, academic
institutions, and medical professional organizations should
provide continuing education about TB to their constitu-
ent health-care providers. These efforts should be focused
on clinicians serving populations at high risk for TB on the
basis of local or regional trends in TB epidemiology (AIII).
• Jurisdictional public health agencies should ensure that cli-
nicians who evaluate persons with suspected TB have
access to current, accurate, and timely diagnostic services (SP).
• Guidelines for detection of TB cases in clinical settings
should be followed by primary care, ED, and hospital-
based practitioners (Table 5).
• Screening for TB cases during contact and outbreak
investigations and during the evaluation of immigrants
and refugees with Class A/B1/B2 TB notification status
has a high yield of finding cases (Table 6) and should
be given high priority as a method for TB case detec-
tion (AII).
• Public health programs should identify other opportuni-
ties for screening for TB disease on the basis of the local
epidemiology of TB, such as in congregate settings, home-
less shelters, and correctional facilities in which the con-
sequences of an undiagnosed case are severe. All case
detection activities should be evaluated periodically to
determine their usefulness (AII).
Recommendations for Contact
Investigations and for Outbreak
Prevention and Response
• Contact investigations are a critical component of TB
control, following only TB case detection and treatment
in priority (AIII).
• State and local health departments should establish a com-
prehensive contact investigation program to ensure that
contacts of infectious TB cases are identified, access to
adequate care is provided, and therapy is completed (AIII).
• TB-control programs should develop a protocol for con-
ducting contact investigations that identifies persons
responsible for each step of the investigation and out-
line processes to maximize the efficiency of the process
within the framework of available resources (AIII).
• TB-control programs should have procedures for volun-
tary HIV counseling and testing of contacts. Those pro-
cedures should set priorities for HIV counseling and testing
of contacts on the basis of locally derived data on the risk
for HIV infection among contacts or, alternatively, on the
local epidemiology of TB and HIV infection (BIII).
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• Tuberculin skin testing of contacts should establish as
first priorities those contacts who are at highest risk for
progressing from LTBI to TB disease on the basis of
transmission risk assessment and the presence in con-
tacts of risk factors for progression (e.g., age <5 years,
HIV infection, and other immunocompromising
conditions (4) (AII).
• DOT for LTBI should be considered for all contacts. High
risk contacts should receive highest priority for directly
observed treatment (AIII).
• TB-control programs should apply existing communi-
cable disease laws that protect the health of the com-
munity to contacts who fail to comply with the
examination requirements (BIII).
• TB-control programs should develop guidelines, in con-
junction with the program legal office and in compliance
with HIPAA rule, for release of confidential information
related to conducting contact investigations (BIII).
• TB-control programs should evaluate the effectiveness and
impact of contact investigations and develop interven-
tions to improve performance when indicated (BIII).
• TB-control programs should develop outbreak response
plans for their jurisdictions. These plans should include
indications for initiating the plan, notification procedures,
composition of the response team, source of staffing, plan
for follow-up and treatment of contacts, indications for
requesting assistance from CDC, and a plan for evalu-
ating the outbreak response (BIII).
Recommendations for the Public Health
Aspects of Targeted Testing
and Treatment of LTBI
• When a TB-control program is prepared to develop strat-
egies for targeted testing and treatment of LTBI (i.e., the
program satisfies national objectives for management of
TB cases and contacts [Table 4]), it should begin by iden-
tifying populations and communities at high risk for LTBI
within its jurisdiction and establish priorities for inter-
vention (AIII).
• Populations and communities should be categorized
on the basis of the expected impact and efficacy of tar-
geted testing in the setting. Tier 1 groups (Box 6) should
receive the highest priority, followed by groups in Tier 2
and Tier 3 (AII).
• Once the targeted population or community has been
identified, strategic and operational decisions should be
made on how best to establish the targeted testing and
treatment program. Questions to decide include where
to locate the program, how to identify and allocate
resources, what training is needed for practitioners and
patients, and what data-management needs exist. Focus
groups, influential community leaders, associations and
community action agencies, religious organizations, coa-
litions, block organizations, and informal community
groups all can contribute to these decisions (AII).
• Public health agencies that establish targeted testing
and treatment programs should maximize patient con-
venience and acceptance through strategies such as
employing, when possible, staff members from the
populations being served, medical translation, cultural
awareness and sensitivity, flexible clinic hours, outreach
services for patient transport, and the use of incentives
and enablers. All services should be free of cost to
patients (AII).
• Targeted testing programs established in the community
(e.g., at community health centers, schools, prisons, jails,
substance abuse centers, and homeless shelters) should
receive full support from the jurisdictional public health
agency. Such support might be decisive in the success of
nonpublic health targeted testing and treatment programs.
Types of support should include training and education
of providers, patient education materials, provisions of
medication, radiographs and other laboratory services,
clinical consultation, and design of tracking and data
management systems (AII).
• Targeted testing programs should be routinely and sys-
tematically evaluated for their effectiveness, efficiency and
impact. Programs that are not effective should be improved
or discontinued (AIII).
Recommendations for TB Control
Among Children and Adolescents
Case Detection and Primary Prevention
Strategy
• Timely reporting of suspected cases of infectious TB is
crucial to the prevention of TB among children (AII).
• Contact investigation of adults with infectious TB is the
most important activity for early detection of TB among
children, identification of children with LTBI who are
at high risk for progressing to primary TB and its
sequellae, and determination of the drug susceptibility
pattern of the M. tuberculosis isolate causing TB disease
or LTBI in a child. Contact investigations should be
timely and thorough, and adequate resources for them
should be made available. This should be one of the
highest priority goals of any TB-control program (AII).
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• Children aged <5 years who have been identified as
contacts of persons with infectious TB should receive a
clinical evaluation, including a tuberculin skin test and
chest radiograph, to rule out active TB. Once active
TB has been ruled out, children with positive tubercu-
lin skin test results should receive a full course of treat-
ment for LTBI. Those who have negative skin test results
should also receive treatment for presumed LTBI. This
intervention is especially critical for infants and tod-
dlers aged <3 years but is recommended for all chil-
dren aged <5 years. A second tuberculin test is then
placed at least 3 months after exposure to infectious
TB has ended. If the second test result is positive, treat-
ment should be continued for a full course of treat-
ment for LTBI. If the second test result is negative,
treatment may be stopped (AII).
Case Management
• DOT should be the standard of care for treatment of
TB disease among children and adolescents (AII).
• As adherence to treatment is no better for children than
for adults, all efforts should be made to support children
and families through treatment of TB through compre-
hensive case management (AIII).
Contact Investigation
• Infants and younger children with primary TB disease
are rarely if ever contagious. They do not need to be
excluded from activities or isolated in health-care settings (AII).
• Children and adolescents of any age with characteris-
tics of adult-type TB (i.e., productive cough and cavi-
tary or extensive upper lobe lesions on chest radiograph)
should be considered potentially contagious at the time
of diagnosis (AII).
• Infants with suspected or proven congenital pulmo-
nary TB should be considered contagious and effec-
tive infection-control measures should be undertaken
(AII).
• Adults who accompany and visit children with TB in
health-care settings should be evaluated for TB disease as
soon as possible to exclude the possibility that they are
the source case for the child. These adults should have a
chest radiograph to rule out pulmonary TB and to pre-
vent the possibility of transmission within the health-
care setting (AII).
• Testing of the contacts of children aged <4 years with
LTBI is recommended for persons sharing a residence with
the child or those with equally close contact. Such inves-
tigations may be performed by public health agencies or
primary health-care providers (BII).
Targeted Testing and Treatment of LTBI
• Contact investigations of adults with TB and targeted
tuberculin skin testing of foreign-born children from
countries with a high incidence of TB are the best and
most efficient methods for finding children with LTBI
(AII).
• Because foreign birth in a country with a high prevalence
of TB is the greatest attributable risk factor for LTBI, chil-
dren born in or with extensive travel to such countries
should be targeted for testing for LTBI. This includes
foreign-born adopted children. Testing for LTBI among
children with low risk for infection should be avoided
(AII).
• A risk assessment questionnaire can be used to identify
children with risk factors for LTBI who should undergo a
tuberculin skin test (AI).
• A decision to place a tuberculin skin test is a commit-
ment to arrange evaluation and treatment for LTBI (SP).
• A tuberculin skin test should always be placed, read, and
interpreted by specifically trained persons (SP).
• In general, foreign-born children with LTBI should be
treated with isoniazid unless information exists linking
them to a specific case of isoniazid-resistant TB (AIII).
• DOT should be considered strongly as the means of treat-
ment for newborns and infants, contacts of persons with
recent cases, and immune-compromised children and
adolescents with LTBI because they are at greatest risk for
progression to TB disease (AIII).
Recommendations for TB Control
Among Foreign-Born Persons
Surveillance
• Public health agencies in states and communities with
a substantial number of TB cases among foreign-born
persons should develop enhanced surveillance meth-
ods in order to gain a detailed understanding of the
local epidemiology of TB among foreign-born persons.
This is important for program planning and to ensure
that recently arrived immigrants, refugees, and other
foreign-born persons at high risk have access to medi-
cal and public health services (AIII).
• Imported cases of TB present at the time of entry should
be distinguished from incident cases, i.e., those that arise
during residence in the United States (AIII).
• Cases of TB among persons granted temporary entry to
the United States as visitors, students, and temporary
workers and unauthorized aliens (Table 7) should be
distinguished from those among foreign-born perma-
nent residents (AIII).
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• Cases identified as a result of targeted testing activities
should be distinguished from those identified by noting
symptoms of active TB (AIII).
• For TB control along the U.S.-Mexico border to be facili-
tated, a binational TB case definition and TB registry
system should be adopted and evaluated (AIII).
Case Detection
• Jurisdictional public health agencies responsible for TB
control should undertake or engage community groups
to undertake education campaigns for foreign-born per-
sons at high risk. These campaigns should communicate
the importance of TB as a personal and public health
threat, the symptoms to look for, how to access diag-
nostic and targeted testing services in the community,
and the concept of LTBI. The purpose of this educa-
tion is to destigmatize the infection, acquaint the popu-
lation with available medical and public health services,
and explain the approaches used to treat, prevent, and
control TB (AIII).
• Public health agencies conducting TB-control programs
should establish liaisons with primary care physicians,
community health centers, hospital EDs, and other orga-
nizations that provide health care for foreign-born popu-
lations at high risk to provide TB publications and
guidelines and education about the local epidemiology of
TB (AIII).
• Public health agencies conducting TB-control programs
should establish liaisons with civil surgeons within their
jurisdictions. They should also ensure that civil surgeons
have access to recent TB publications and guidelines and
that they promptly report all suspected cases of TB (AIII).
• CDC should provide standardized education and train-
ing programs with a formal certification process for panel
physicians and civil surgeons. As part of the certification,
continuing education programs should be required (AIII).
• Federal, state and local public health agencies should
assign high priority to the follow-up of immigrants with
a Class A TB waiver and Class B1 and B2 TB notification
status (AII).
Case Management
• Culturally appropriate case management should be
instituted, including readily available professional trans-
lation and interpretation services, for all foreign-born
persons. If possible, outreach workers should be from
the patient’s own cultural background (AII).
Contact Investigation
• Local and state jurisdictions should assign high prior-
ity to contact investigations of foreign-born persons with
TB because of the high likelihood of identifying per-
sons with LTBI as well as secondary TB cases (AII).
• Culturally sensitive and appropriate contact investigation
protocols should be established (AIII).
Targeted Testing and Treatment of LTBI
• In jurisdictions where foreign-born persons constitute a
major proportion of the TB burden, targeted testing and
treatment of LTBI for foreign-born persons at high risk
(4) should be implemented as a primary means of pre-
venting TB in the community. The tiered approach
(Box 6), which is based on access to the target popula-
tions and likelihood of implementing a successful
program, should be employed (AII).
• In developing the plan for targeted testing and treatment
of LTBI among foreign-born persons at high risk, TB-
control programs should collaborate with health-care pro-
viders, neighborhood health centers, and community
advocacy groups that serve and work with the target popu-
lations (AII).
• The testing of immigrants and refugees with a Class A
TB waiver and Class B1 and B2 TB notification status
for LTBI as well as for active TB should always be priori-
tized (AII).
• Targeted testing and treatment of foreign-born children
at high risk aged <15 years should be a priority (SP).
• When resources permit, DOT for LTBI should be used
to ensure high completion rates (BII).
• Jurisdictional public health agencies should work with
local colleges and universities to develop targeted testing
protocols for foreign-born students at high risk and assist
with treatment of LTBI (BIII).
Recommendations for TB Control
Among HIV-Infected Persons
HIV Counseling and Testing
• Voluntary HIV counseling and testing is recommended for
all patients with TB and should be considered the standard
of care. In extreme circumstances, if establishing priorities
is necessary as a result of resource constraints, patients
aged 25–44 years should receive highest priority (SP).
• Clinic staff members at sites where patients with TB are
followed should receive up-to-date education and training
on the most current concepts and methodology of volun-
tary HIV counseling, testing, and referral. If on-site HIV
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testing is not feasible, TB facilities should have well-
established arrangements for referral to other testing sites
(SP).
• Voluntary HIV counseling and testing should be offered
routinely to contacts of HIV-infected TB cases (AII).
• Voluntary HIV counseling and testing should be offered
to all contacts that are members of populations with a
prevalence of HIV infection >1% (302). In other com-
munities and settings, the decision of whether to routinely
offer voluntary HIV counseling and testing to contacts of
persons with infectious TB should be based on the local
epidemiology of HIV infection and TB. In communities
or settings where populations at risk for TB are also known
to have high rates of HIV infection (e.g., injection drug
users (IDUs) in inner cities [317]), all contacts should be
routinely offered voluntary HIV counseling and testing.
In communities and settings in which the HIV
seroprevalence likely approaches that of the general U.S.
population (<0.1%), a risk-factor assessment for HIV
infection should be included in the evaluation of con-
tacts of infectious cases, and contacts with clinical or
behavioral risk factors for HIV infection (302) should
receive voluntary HIV counseling and testing (AII).
• Persons with LTBI who are members of populations
with a prevalence of HIV infection >1% should be rou-
tinely offered voluntary HIV counseling and testing
(302). Otherwise the decision of whether to routinely
offer HIV counseling and testing to persons with LTBI
should based on the local epidemiology of HIV infec-
tion and TB. In communities or settings where popu-
lations at risk for TB are also known to have high rates
of HIV infection (e.g., IDUs in inner cities [317]), rou-
tine counseling and testing among patients with LTBI
is indicated. In other communities and settings the HIV
seroprevalence is likely to approach that of the general
U.S. population (<0.1%), a risk-factor assessment for
HIV infection should be included as a standard part of
the initial evaluation for all persons diagnosed with
LTBI. Persons with clinical or behavioral risk factors
(302) should receive HIV counseling and testing (AII).
• Routine periodic cross-matches of jurisdictional HIV and
TB case registries should be conducted to ensure
completeness of reporting of both diseases (SP).
Case Detection
• Physicians who provide primary care to persons with
HIV infection or populations at increased risk for HIV
infection should maintain a high index of suspicion for
TB. Every patient in whom HIV infection has been
newly diagnosed should be assessed for the presence of
TB or LTBI. This should include a history for symp-
toms compatible with TB (e.g., cough of >2–3 weeks’
duration, fever, night sweats, weight loss, or hemopty-
sis, or unexplained cough and fever [Table 5]) and of
exposure to persons with TB. Physical examination
should include examination of extrapulmonary sites
such as lymph nodes, and a chest radiograph should
be taken to check for findings of current or previous
TB. Testing for M. tuberculosis infection by using the
tuberculin skin test should be conducted, and patients
with >5 mm of induration be considered to have a posi-
tive test and should receive, in addition to chest radi-
ography, a clinical evaluation to rule out TB (4) (SP).
• Public health agencies conducting TB-control activi-
ties should maintain close contact with HIV control
programs, medical practitioners and clinics,
community-based organizations, homeless shelters, cor-
rectional facilities, and housing facilities that serve per-
sons with HIV infection to ensure that a high index of
awareness of TB is maintained by persons who provide
services at those sites and by their HIV-infected
patients (AIII).
• Health-care facilities, social service agencies, and work sites
that serve patients with HIV infection should establish
firm lines of referral for patients with respiratory
symptoms (AIII).
Case Management
• Public health agencies conducting TB-control activities
should have access to consultants with expertise in
managing HIV related TB (SP).
• Management of TB and HIV infection should be effec-
tively integrated and should include a multidisciplinary
team of providers and supportive care (AIII).
• Comprehensive case management, including DOT, is
strongly recommended for persons with HIV infection
who have TB (AII).
• HIV-infected patients with TB and a CD4 count <100 cells/
µL should receive DOT daily or three times per week (A1).
Contact Investigation
• Contact investigations of persons with TB and known or
suspected HIV infection and those conducted in any cir-
cumstance in which HIV-infected persons could have been
exposed to a person with infectious TB should have the
highest priority and be completed without delay (AII).
• Persons with known or suspected HIV infection who
have contact with a patient with infectious pulmonary
TB should be offered a full course of treatment for
LTBI regardless of the initial result of tuberculin skin
testing once active TB has been ruled out (AII).
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Targeted Testing and Treatment of LTBI
• Targeted testing and treatment for LTBI are strongly
recommended at the time the diagnosis of HIV infec-
tion is established (AII).
• For HIV-infected persons whose initial tuberculin skin
test is negative, repetitive testing is recommended (at least
yearly) if the local epidemiologic setting indicates an
ongoing risk for exposure to TB (AII).
• An HIV-infected patient who is severely immuno-
compromised and whose initial tuberculin skin test result
is negative should be retested after the initiation of
antiretroviral therapy and immune reconstitution, when
CD4 cell counts are greater than 200 cells/µL) (AII).
• HIV-infected persons who receive a diagnosis of LTBI
should receive high priority for DOT (BIII).
Institutional Infection Control
• HIV-infected persons should be advised that certain
occupations and activities increase the likelihood of
exposure to TB. These include employment and vol-
unteer work in certain health-care facilities, correctional
institutions, and shelters for the homeless, as well as in
other high-risk settings identified by jurisdictional
health authorities. The decision about continuing
employment or volunteer activities in a high-risk set-
ting should be made in consultation with a health-care
professional and be based on factors such as the person’s
specific duties in the workplace, prevalence of TB in
the community, and the degree to which precautions
are taken to prevent TB transmission in the workplace
(AIII).
Recommendations for TB Control
Among Homeless Persons
Surveillance and Case Detection
• Information on whether the person is homeless should be
included for each reported TB case to determine the
importance of homelessness in the TB morbidity in the
state or community. This is particularly important for com-
munities that provide shelters or other congregate living
facilities that are conducive to the transmission of TB (AII).
• In designing programs for control and prevention of TB
in homeless persons, public health agencies should work
closely with providers of shelter, housing, primary
health care, treatment for alcoholism or substance
abuse, and social services to ensure a comprehensive
approach to improving the health and welfare of this
population (AIII).
• Public health agencies should closely monitor the
location, mode (i.e., screening or symptomatic presen-
tation), and timeliness of diagnosis of TB in homeless
persons in their community and use such data to
develop more effective control strategies (AIII).
• Public health agencies should identify providers of medical
care for homeless persons and facilities that serve homeless
persons (e.g., hospital EDs and correctional institutions)
to ensure that practices and procedures are implemented
to readily detect and report suspected cases of TB (AIII).
• Providers of primary health care for homeless persons
should be knowledgeable about how to diagnose (Table 5),
isolate, and report suspected cases of TB (AIII).
• Public health agencies should have ready access to an
inpatient facility for the isolation and induction phase of
therapy of homeless patients with infectious TB (AII).
• Public health agencies should be prepared to conduct
activities to detect TB among persons without symp-
toms and enhance TB case detection as part of a plan
for TB control among homeless persons (Table 6).
Indications for screening for TB disease include 1) a
documented outbreak, 2) an increase in incidence of
TB in the homeless population, and 3) evidence of
current transmission of TB in the population. Shelters
should always be suspected as sites of transmission (AII).
Case Management
• Case management for homeless persons with TB should
be structured to encourage adherence to treatment regi-
mens by making TB treatment a major priority for the
patient. It should include provision of housing, at least
on a temporary basis; an increasing number of models
have demonstrated the importance of a housing incen-
tive in successful treatment of TB in homeless persons.
Case management should also include establishing link-
ages with providers of alcohol and substance treatment
services, mental health services, and social services (AII).
Contact Investigation
• Health departments should regularly evaluate their meth-
ods for contact investigation for cases of TB among home-
less persons to identify barriers and develop alternative
strategies, such as shelter- or other location-based contact
investigations oriented to possible sites of transmission.
Factors to evaluate should include timeliness of complet-
ing contact investigations, number of contacts identi-
fied and evaluated per case, proportion of evaluated
contacts with LTBI and TB disease, and completion of
treatment of LTBI among contacts (AII).
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Targeted Testing and Treatment of LTBI
• Targeted testing and treatment of LTBI should be a
priority for homeless populations because studies from
throughout the United States have demonstrated high rates
of transmission of M. tuberculosis in this group. This epi-
demiologic situation, causing a high ongoing risk for
acquiring LTBI and TB disease, might necessitate repeti-
tive testing for M. tuberculosis infection among homeless
persons (AII).
• When high rates of transmission of M. tuberculosis are docu-
mented among homeless persons, those with a positive test
for M. tuberculosis infection should be presumed to be
recently infected and treated for LTBI (AIII).
Institutional and Environmental Controls
• Organizations that provide shelter and other types of
emergency housing for homeless persons should develop
institutional TB-control plans. Guidelines to facilitate this
process are available from CDC (9) and the Francis J.
Curry National TB Center (403) (AII).
Recommendations for TB Control
Among Detainees and Prisoners
Case Detection and Case Management
• All jails and prisons should conduct a TB case detection
program for detainees and prisoners entering the facility
as well as for those who become ill during incarceration
to ensure prompt isolation of contagious cases of TB (AII).
• Strategies for case detection for incoming detainees and pris-
oners include symptom surveys (BIII), testing for
M. tuberculosis infection followed by chest radiography (BIII)
for those with a positive test, and universal chest radiogra-
phy in jails (BII). In each setting, the adopted strategy
should receive ongoing evaluation.
• Each correctional facility’s health-care program for
inmates and staff should ensure that training in the
clinical and public health aspects of TB and other dis-
eases of public health significance is provided in an
ongoing manner (SP).
• Detainees and prisoners with signs and symptoms of TB
should be placed in respiratory isolation on-site or off-
site until infectious TB is ruled out (SP).
• Case-management strategies including DOT and
incentives should be used to assure completion of
therapy of detainees and prisoners with TB (BII).
• When detainees and prisoners receiving therapy for TB
are transferred to another facility or released from deten-
tion, responsibility for continuation of the treatment plan
should be transferred to the appropriate facility or
agency, and the jurisdictional TB-control program
should be notified (SP).
Contact Investigation
• Contact investigations of infectious TB cases in correc-
tions facilities should receive equal priority as effective
case detection as the primary means of aborting TB out-
breaks. Facilities should have written procedures for con-
tact investigations and have adequate staff to ensure
prompt and thorough contact investigations. They should
also consult with the jurisdictional public health TB-
control program (AII).
Targeted Testing and Treatment of LTBI
• Prisons should implement a treatment program for prison-
ers with LTBI as part of the effort to prevent the transmis-
sion of M. tuberculosis within their walls and to contribute
to the overall goal of TB elimination (AII).
• Treatment programs for LTBI in jail detainees should
be undertaken only if it is possible to develop a suc-
cessful plan for community follow-up of released per-
sons on treatment (AII).
• Reducing the length of treatment for LTBI is more likely
to lead to completion of treatment in correctional facili-
ties; 4 months of rifampin is recommended as an alterna-
tive for the treatment of LTBI (4,324). Correctional health
providers need to consider the costs and benefits of this
regimen compared with the standard 9-month course of
isoniazid in each individual case (BIII).
Institutional Infection Control
• Jails and prisons should implement effective infection-
control programs including risk assessment, staff training,
screening and treatment of LTBI, isolation of inmates
with infectious forms of TB, treatment and discharge
planning, and contact investigation (AII).
• HIV-infected detainees and prisoners should not be
housed together in a separate facility unless institutional
control programs following current guidelines have been
established and proved to be effective in preventing the
transmission of M. tuberculosis (AIII).
Recommendations for TB Control
in Health-Care Facilities and Other
High-Risk Settings
• All health-care institutions and other sites at high risk
for transmission of M. tuberculosis should have in place
a TB infection control program; they should imple-
ment and enforce procedures to promptly identify,
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isolate, and either manage or refer persons with sus-
pected and confirmed infectious TB (AII).
• All health-care institutions that care for persons with
TB and other sites that are at risk for transmission
should implement TB infection-control measures based
on a hierarchy of administrative controls, engineering
controls, and respiratory protection. Administrative
controls and early recognition of persons with TB are
the most important parts of an airborne infection con-
trol program for TB (AII).
• Employees who have first contact with patients in set-
tings that serve populations at high risk for TB should be
trained to detect persons who could have infectious TB.
Patients should be routinely asked about exposure to
M. tuberculosis, previous TB infection or disease, current
symptoms suggestive of TB, and medical conditions that
increase the risk for TB. The medical evaluation should
include an interview conducted in the patient’s primary
language, with the assistance of a medical interpreter if
necessary (AIII).
• The index of suspicion for TB should be very high in
health-care settings located in geographic areas where TB
is prevalent and those serving patients at high risk for TB.
Guidelines exist for conducting an evaluation for suspected
pulmonary TB in adults at high risk (Table 5) (AIII).
• Among persons suspected of having TB, arrangements
should be available for the diagnosis to be promptly
established and standard therapy initiated (AII).
• HCWs and employees in other high-risk settings should be
tested for M. tuberculosis infection upon employment. Sub-
sequent testing should be based on risk assessment (AIII).
• Health-care facilities and other high-risk institutions
should conduct a risk assessment to determine the fre-
quency of testing for M. tuberculosis infection among
employees, as a component of the proper level of TB
infection control measures (AIII).
• For HCWs and employees in other high-risk settings
with no other risk factors for TB, a cut-off of 15 mm of
induration (rather than 10 mm) on the tuberculin skin
test should be used to define a positive baseline test at
the time of initial employment. An increase of >10 mm
in reaction size is generally accepted as a positive test
result on subsequent testing unless the worker is a con-
tact of a TB case or has HIV infection or is otherwise
immunocompromised, in which case a result of >5 mm
is considered positive (AIII).
• Employees with M. tuberculosis infection should have a
chest radiograph performed to exclude TB disease and
should be evaluated for treatment of LTBI, based on
current recommendations (AII).
• HCWs and employees in other high risk settings with
an indication for treatment of LTBI should be encour-
aged to initiate and complete treatment (AII).
• Residents admitted to long-term care facilities should be
tested for M. tuberculosis infection upon admission (with
a two-step test if using tuberculin skin testing) and should
receive a history and physical examination to detect symp-
toms and signs of TB. Residents with M. tuberculosis
infection should be offered treatment if indicated (4,324),
with careful monitoring for drug toxicity (BII).
• Jails and prisons should develop and implement effective
infection-control programs including risk assessment, staff
training, screening for TB among incoming detainees and
prisoners, isolation of inmates with infectious forms of
TB, treatment and discharge planning and prompt and
thorough contact investigations (AII).
• In jails and prisons, HIV-infected inmates should not be
housed together in a separate housing unit unless institu-
tional control programs following current guidelines
have been established and proved to be effective in pre-
venting the transmission of M. tuberculosis (AII).
• Organizations that provide shelter and other types of
emergency housing for homeless persons should develop
institutional TB-control plans. Guidelines to facilitate this
process are available from the Francis J. Curry National
TB Center (403) (AII).
• TB-control programs should remain aware of the possi-
bility of TB disease as a result of current transmission
when conducting epidemiologic surveillance and contact
investigations. M. tuberculosis genotyping should be
immediately available to any program that is investigat-
ing possible transmission of M. tuberculosis (AII).
• In an era of declining rates of TB in the United States,
expertise in the recognition, diagnosis and treatment of
TB is likely to decline, especially in areas in which inci-
dence is low (48). Because the risk for spread of
M. tuberculosis increases when the diagnosis is not
promptly made, institutional education programs for
HCWs, including physicians in training, should be made
a continuing priority (AIII).
Recommendations on Research for
Progress Toward Elimination of TB
• A comprehensive TB research plan for the United States
should be developed that identifies the major areas of need
and the most effective research approaches to meet those
needs. CDC and NIH should convene a broadly-based
group of experts and stakeholders to develop this plan
(AIII).
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• The availability of improved diagnostic tests and thera-
pies for LTBI would have an immediate and lasting
impact on the incidence of TB in the United States, and
research in those fields should be a priority (AIII).
• Research leading to a new and effective TB vaccine is one
of the most important contributions that the United States
can make to the global TB epidemic and should be a
priority (AIII).
• The CDC-funded Tuberculosis Epidemiological Studies
Consortium and Tuberculosis Trials Consortium repre-
sent excellent new models for bringing resources from the
Federal government, public health agencies, and academia
together to plan and implement research for the assess-
ment of new diagnostics and drugs and epidemiologic
and operational research on TB. These initiatives should
be a priority (AIII).
• Because a substantial number of recommendations for
TB control are based on logic, anecdotal experience, and
expert opinion, additional research, including clinical,
operational, behavioral, and economic research should
focus on unanswered questions relating to the basic
elements of TB control (AIII).
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